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GUIDELINES 
The purpose of the UWO Medical Journal is to provide a single forum for original articles ba ed on clinical or re earch medicine of topical or historical 
interest. Since readership of the Journal is 
interdisciplinary, articles published will attempt to reflect 
a wide range of medical interests. In this regard, 
submission should be directed toward the general 
medical reader. Article which do not pertain to the 
feature topic will be given lower priority as will those with 
exce ive technical jargon. Plea e re trict submission to 
under 2,000 word . 
Informal peer review is required, i.e., non- peciali t 
authors are encouraged to collaborate with, or at 
minimum, have their work reviewed for content by a 
specialist in the field. This individual, if not a co-author, is 
to be acknowledged at the end of the paper. In addition, it 
is recommended that all submissions be proof-read for 
significant stylistic or grammatical error . The editors will 
not a sume responsibility for corrections of this nature 
and article requiring such revi ions will be returned to 
the author. 
Submi sions are to include a cover letter, two double 
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the form of a photograph. Two copies of figures or tables 
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number a well as the fir t author. Legends, which are to 
be included at the end of the text, should start on a 
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figures and tables. 
Submis ion and disks become the property of the 
Journal. The Journal reserves the right to correct errors of 
punctuation and spelling. Short biographical notes on the 
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The U. W.O. Medical Journal is an interdisciplinary 
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Journal is published twice each academic year: Fall, & 
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Journal i copywright protected-no section of the 
U. W.O. Medical Journal may be reproduced without the 
expre sed written permi sion of the Editor. 
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Technology has always been a driving force in history. In the Bronze Age, according to one theory, barbarian tribes of the steppe were able to overrun 
much of Europe and Asia because they had chariots while 
their victims were still running around on foot. As a 
result, half the world today speaks one or another of the 
Indo-European languages, descended from the speech of 
the charioteers. Around 1500 AD, European navies began 
to dominate the world's oceans, in part because their 
shipyards turned out wide-bottomed boats that could fire 
a cannon without tipping over. In World War II, Alan 
Turing and others at Bletchley Park, Britain's secret 
cryptanalysis centre, helped change the course of the war 
when they used a rudimentary version of a computer to 
crack Nazi Germany's Enigma cipher. 
These examples are military, but the role of 
technology is equally clear in the history of medicine. 
Today's physicians are better healers than their leech-
wielding predecessors thanks mainly to applied science. 
Major advances in medicine, like those in warfare, are 
often achieved by scientists and technicians working far 
from the front line, far from the clinics and the hospital 
wards. 
Medical imaging, for example, is largely an 
achievement of physicists. It was a physicist, Wilhelm 
Rontgen, who discovered Xrays in the first place, and it is 
his successors from physics faculties who have more 
recently provided us with PET and MRI. In this issue, 
Sean Dukelow and Joseph DeSouza describe the latest 
variant, functional MRI, which is a fast-growing field and 
a new focus of research here at Western. Another imaging 
tool, discussed by Jamie Mangin in these pages, is 
ultrasound, which is used by bats and dolphins, followed 
again by physicists and finally obstetricians. 
Mathematicians, too, have driven medical progress. 
Around 1917, Johann Radon was working out how to 
reconstruct surfaces based on certain mathematical 
"shadows" of them. He can scarcely have guessed the 
extreme clinical importance of what he was doing. As a 
mathematician, he was presumably motivated by the 
sheer intellectual beauty of such concepts as integrals, 
manifolds, and tenure. But his formulae, dusted off and 
adapted by Godfrey Hounsfield and others in the 1970s, 
are the basis for the algorithms behind computerized 
tomography. 
Computer scientists have given us, or are trying hard 
to give us, Virtual Reality, which may be part of the OR of 
the future, as Erik Viirre points out in this issue. And the 
list continues: chemists, statisticians, evolution theorists, 
basic medical scientists, all have driven clinical advances. 
Of course clinicians themselves have played a crucial part 
as well, but in the struggle against disease, clinical 
medicine is just the thin front line of a huge, scientific war 
effort. 
We at the UWO Medical Journal are also keeping 
pace with technology. We no longer employ roomfuls of 
tonsured clerks to copy the journal onto scrolls of 
parchment. We now desktop publish on a Pentium 
Computer. 
What will the future bring? Forecasters, particularly 
when they are technophiles, often overestimate the rate of 
progress to come. As a child, I read several old books that 
tried to predict the state of the world in the year 2000. By 
now, we were supposed to be wearing silver body suits 
and flying around in hovercars. We'd have names like 
"Citizen XZ1A9" and would call to each other in buzzing, 
metallic voices. 
Sadly, we've not yet come so far, but technology's 
progress is impressive all the same. The Pentium 133 I'm 
typing on is obsolescing so fast I can see the moss 
growing up the sides. So one safe prediction is that 
computers will play an ever-greater role in medicine. 
Soon it may be commonplace for physicians to seek 
advice from medical expert systems, which are computer 
programs that take in data about a patient's history and 
physical exam, and suggest diagnoses and further tests. 
Already there are pleasing stories of prominent human 
consultants who have scoffed at some Robo-Doc's 
surprising diagnosis and later had to eat their words. 
We can expect more of this. Recently IBM's chess-
playing computer, Deep Blue, defeated the world's best 
human player, Garry Kasparov, in a six-game match. If 
IBM put their resources behind the project, they could 
likely build a digital diagnostician, Deep Clerk, that could 
similarly surpass any human specialist. 
This sort of thing troubles some observers. They fret 
and make excuses whenever a computer program beats 
us at something we had regarded as our own game. But 
in medicine, surely the sane attitude is that we need all 
the help we can get. 
Besides, there are other medical skills on which to 
hang our human pride. Running through a differential 
diagnosis is just the sort of thing that computers excel at: 
it is largely a matter of memorizing a huge database and 
applying some fairly simple logic, essentially a branching 
chain of "if-thens". But other aspects of medicine, for 
example the sensory-motor skills like physical 
examination and surgery, are much harder to reduce to a 
program, and will likely remain a human province for 
decades or centuries to come. But the rate of progress is 
unequal in different areas of technology. Cars, for 
instance, are not improving as fast as computers are. If 
they were, then my ten-year-old K-car would weigh as 
much as a tank and would have a top speed of 5 km/h, 
whereas in reality it can do 20 on long downhills. 
Medicine may be the field where technology' s 
progress has been most disappointing. One reason is that 
the task is so difficult. "They can put people on the moon 
but they can't cure the common cold" largely because 
lunar voyages are child's play compared with selectively 
deactivating viruses. On the scale of complexity, the 
human body is off the high end of the range that usually 
interes ts technophiles . A malfunctioning car will 
magnetically attract a crowd of amateur mechanics 
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around its open hood, whereas simpler or more complex 
cases, like a bent spoon or a person with diabetes, will not 
excite the same analytic interest. 
The sick per on, however, can sometimes excite a 
stronger emotional response, and this is the second 
reason that medicine's progress is disappointing: our 
hopes are so high and o intense. In medicine, the gap is 
unusually large between what we would like to achieve 
and what we can actually manage. For example, with 
more advanced cranes and building materials, we could 
presumably build skyscraper ten times higher than what 
we have now, and do it ten times as fast. But no one is 
fervently wishing for a breakthrough here the way many 
of us are hoping for breakthroughs in therapy for cancer 
or strokes. 
One reliable forecast is that our personal taste for new 
technology will decline with age. Right now, I love new 
gadgets, but when I'm 70 my grandchildren will urge me 
to use the teleporter, and I'll resist, saying I prefer to get 
around the old-fashioned way, in the hovercar. Q 
Cintfy :J-fawf(jns, 
t£tfitor-in-Ciiief 
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family practice opportunities with good 
specialists backup and reasonable on-call 
responsibilities. Obstetric interest an asset. 
This is a friendly and supportive medical 
community and the position offers a 
generous relocation cash allowance as well 
as above-average family practice 
remuneration. 
WRITE: 
Sydenham District Hospital 
Wallaceburg, NBA 2A7 
OR CALL 
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(519) 627-3531 (Bus) 
(519) 627-8443 (Res) after 5 p.m. 
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Interview With Dr 
New Assistant 
Undergraduate 
John 
D 
Howard, 
of ean 
Medicine 
D r. John Howard is a ga troenterologist at the London Health Sciences Centre who e practice is largely comprised of pediatric patients. He is a 
husband, and the father of three children, and enjoys a 
spectrum of activities ranging from his involvement in 
their hockey games to cottaging, theatre and travel, tennis 
and golf. 
Dr. Howard is the newly appointed Assistant Dean 
for Undergraduate Medicine. This office is most 
appropriate for the clinician and teacher, who has, until 
recently, been integrally involved in the organization and 
execution of Clinical Methods, one of the most critical 
course that is taught to undergraduate medical students; 
moreover, he continues to travail as Director of 
Undergraduate Curriculum and Evaluation. This latter 
post has been an ongoing and arduous task as Dr . 
Howard has collaborated with a multitude of dedicated 
contributors to create, and ultimately to implement, a 
new paradigm for medical education at the University of 
Western Ontario. 
ABOUT THE AUTHOR 
Jordan Solmon is a third-year medical student at UWO 
with a BSc from the University of Toronto. He is interested in 
paediatric surgery and has participated in the curriculum 
renewal process. 
by Jordan B Solmon 
Medicine is unique, and for some, enrapturing, in 
that it is an ever-evolving multidisciplinary profession 
based on clinical and laboratory practices, and includes as 
es entia! components the ability to be both humane and 
an excellent communicator. Underlying the myriad 
constituents of the art and science of medicine is the 
system which educates and empowers physicians-to-be. 
The new and innovative curriculum that will be in place 
for the class of 2001 may be described a ystems ba ed, 
but not in the traditional sense. It is student driven, and 
community responsive, and most importantly it is patient 
centred. Dr. Howard explains that being patient-centred 
is recognizing the unique experience a patient ha when 
he has a disease," We will focus not just on identifying 
and 'fixing' the disea e, but we will equally focus on 
understanding the unique experience a patient ha as he 
experiences a disease. To achieve this focus we need to 
have a full understanding of the 'context' of that patient-
the cultural, spiritual, and community needs to name a 
few "Indeed, this is the frontier of medicine." 
For as long as many students are able to recall, you 
have been involved in some capacity in our medical 
education why the recent change in your focus? 
"I have been rather heavily involved in hospital 
administration over the Ia t couple of years, and I have 
been interested in leadership". I have taken some courses 
in leadership and I was contemplating getting out of 
education because I saw some opportunities in the 
hospital management sector. But then there was the 
merger, and when you merge two things together, the 
opportunities are halved. Shortly thereafter, the Dean 
approached me about taking on the task of renewing the 
curriculum, and it seemed like a great leadership thing 
for me, and so that's what I did." 
And here you are today 
"Well, I'm basically someone who wants to change 
the world a little bit, and if you can effect the lives of a 
thousand medical students that's kind of neat!" 
Often, we ask our patients why they are presenting 
now, why not yesterday, or wait until tomorrow. I would 
ask the same of you regarding changing the curriculum: 
why now? 
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"There are a couple of thing to say about that. The 
deci ion to change the curriculum was made four years 
ago when there wa a process put in place called the 
Green Paper. It wa authored by a task force tha t was 
chaired by Michael Clarke. The Green Paper it elf was 
based on recommendations, and was an exce llent 
document, but it came out at a time when faculty were 
quite reactive. Interestingly, I think everyone agreed with 
seventy or eighty percent of the Green Paper, but it was a 
different seventy or eighty percent for each individual. 
And o, we are actually in the fourth year of 'curriculum 
changing', but the pre ent structure has only been around 
for about twelve months. The Green Paper had a number 
of conclu ions, and tho e conclusions were to et up a 
curriculum coordinating team, and that there would be 
subject development groups, and that it would be a case 
based curriculum. When I came onto the cene, I think 
there was orne concern because it wa at a time when 
people were reacting rather than creating, o an initial 
part of the process for me wa building bridge . and 
creating a consensus curriculum finding out what we as a 
group need to be doing. So, the decision to change the 
curriculum came about four or fi e years ago, but when I 
came to the project, I needed to discover for my elf w hy it 
needed changing, and it became clear after a while that 
there were two things. One was that the curriculum was 
locked ina much as it wa exceedingly difficult to make 
any modifications, to add a course, or to subtract a 
cour e; there were new things coming up and we were 
unable to addre s them, partly becau e it was difficult to 
make time in the existing curriculum. The econd thing 
was readily apparent, and that was that over the Ia t ten 
or fifteen years, the cour es had each become excellent, 
but these courses do not necessarily fit together well. The 
analogy whlch I have been using is that of a chair. The 
curriculum i like building a chair, and what we had done 
was taken each part of the chair and given them to the 
course committees, and they have, over the course of ten 
or more years, honed their piece so that they are near 
perfect. So, we have a curriculum that ha perfect pieces, 
but each piece i a different size, style, and de ign and 
when you put them all together, they just don't fit as well 
a they should . You lo e the perspective of the overall 
curriculum at the expen e of perfection of the cour e , 
and o the drive right now i the integration o f the 
content of the cour e , and the other theme of the r newal 
is to create a curriculum that can continue to change. 
Hopefully, we will never have another curriculum 
renewal per se; rather, the curriculum will always be 
renewing itself. I would gue that 50 percent of the 
change will occur in the fir t year, then I hope we will 
ee 25 percent of the change for many year thereafter!!" 
There have been rumors of the imminent closure of 
one of the medical schools in Ontario, how much did this 
influence the current effort? 
"There is nothing to that component. But, I think you 
have to look at the environment around us, and I think 
we have to recognize that we are in a competitive 
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environment, and we have to po ition ourselves. We need 
to consider the possibility, although there i nothlng to it 
right now, that the Ontario Government could uggest 
the clo ure of a medical school, which would save money 
-we are eeing the closure of ho pitals, the do u re of 
chool boards, why not con ider the closure of secondary 
institutions or medical chools? The best thing we can do 
is to take We tern and to make it the leading medical 
chool in Canada and as uch, it would be very hard to 
do e. Essentially, the best defen e is a good offense." 
Many students who have been drawn to Western up 
to tww have recognized that it was a traditional school 
witlz a largely didactic curriculum. What do you say to 
new and prospective students who saw that as a 
distinguishing feature of Westem? 
"I would reiterate that this is a renewal and not an 
overhaul. Our trength ha been our cour e, and part of 
our future is to maintain the quality of the cour e . o, in 
orne respects, our curriculum will be traditional, but in 
the context of omething which is more holistically 
radical. We have listened to the students as a mandatory 
part of thi process, and they will continue to have a 
trong voice in the proces of change." 
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What repercussions will the new tenets of the 
curriculum have on the admissions and selections 
process? 
"We want to have a curriculum that respects all of the 
EFPO values. Thu far, there has been a tendency to 
emphasize the medical expert. Independently, but 
coincident to the renewal process there have been some 
changes to admissions criteria. These include an emphasis 
being placed on communication skill , and the 
introduction of the community into the election process." 
In the effort to include the communihJ in this process, 
communihJ representatives have been asked what they 
expect in a physician. Predictably, they respond with 
wishes for an expert who is accessible and available, but 
a doctor on even} block who is open for business twenty-
four hours a day is au impossibility. Also, skeptics have 
remarked that we do not expect social workers to be 
medical scientists, and that we should be teaching basics 
and not everyone else's business. How do you answer 
these remarks? 
"We have to remember who the boss is in all 
this; the taxpayer. The EFPO organization came 
to their conclusion ba ed on interviews they 
conducted with all aspects of ociety. We are not 
ignoring the medical expert in this; it i the 
number one EFPO expectation. But I think its 
very clear that you have to have omeone who 
can express their expertise, who can use their 
expertise to advocate sound health policy. You 
definitely need phy icians who can understand 
the costs of medical care today, and if you are 
going to rely on other people to provide things 
like ocial work, you have to be a team player. To 
me there is a balance, and we will probably still 
spend seventy percent of our time developing 
the medical expert, but traditionally we have 
pent ninety-five percent of our time doing that. 
One of the toughe t things about this 
endeavor has been that it is happening "just in 
time". We will not have a whole package ready 
to go next year. We will roll out the new first 
year plan, and then incorporate another new year 
eac h year thereafter. If we had the whole 
curriculum ready for September, by the time the 
fir t cia s got to their fourth year, the curriculum 
would already be four year old. I don't know 
what it will look like when it done. Over 250 
people have been empowered to enact the 
changes, and o one idea cannot then be thrust 
upon those people. What I do fore ee is a new 
and flexible paradigm for medical education that 
will make We tern the leading medical school in 
Canada, and one that will be recognized world 
wide. n 
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Creating and del ivering innovative health 
care solutions enabling people to live 
longer, healthier and more active lives 
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Gene Therapy: Blessing or Curse? 
Recent advances in gene therapy present the very real possibility that inherited metabolic diseases will become easily treatable in the near future . 
Target-cell-specific virus vectors will soon be able to 
deliver and incorporate virtually any known gene or 
combination of genes into specific chromosomal target 
locations. Patients who suffer horribly merely because 
they inherited a defective gene now have hope. Doctors 
may be able to end these patients' suffering once and for 
all through the simple injection of a virus vector carrying 
a properly functioning copy of their defective gene. Once 
within the host cell, the viral mechanisms will cause the 
gene to become inserted into the DNA of the cell. The 
inserted gene will then operate to produce an effective 
gene product. 
The possibilities for good are almost limitless . 
Insertion of the genes responsible for identifying and 
destroying pre-cancerous and cancerous cells into a host's 
cytotoxic T cells or Natural Killer cells may provide a 
future vaccine for cancer. There is no question of the 
enormous benefit to mankind that this procedure would 
provide. Most of us have lost someone we know to what 
has been described as the plague of the 20th century. The 
notion that we may have the opportunity to rid the world 
of cancer the way we once rid the world of smallpox is 
truly intoxicating. Unfortunately, the possibilities for 
misuse are also easy to imagine. 
The day may come when we will be able to walk into 
a doctor's office and purchase any gene combination we 
desire. Sylvester Stallone's biceps, Elizabeth Taylor's 
violet eye colour, Stephen Hawking's intellect: all may 
become commercial commodities. What about the parents 
who want to give their child all the advantages in life? 
Parents already tend to imprint their children with their 
own hopes and aspirations. Imagine what effect it would 
have if they could alter their child's genetic structure to fit 
their ideals as well. 
We may end up with a society where the disparity 
between the rich and the poor is much more significant 
than mere money. Those who can afford to purchase the 
genes they want will be larger, stronger, more intelligent 
and live longer than those who cannot afford them. The 
nightmare spectre of the Master Race potentially may 
become reality. What can and should we do about it? 
We can and must have a legislative framework in 
place before gene therapy technology becomes 
commonplace. History teaches us that when the law lags 
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behind the technology, economic considerations tend to 
outweigh moral and ethical ones when a legal framework 
is finally created. We simply cannot afford to wait and see 
what the effects of widespread gene therapy will be 
before we enact legislation. The stakes are too high, the 
potential for abuse too great. 
For example, several genes have been identified and 
sequenced that are associated with longevity. What 
would an injection that could increase your life span by 
25-30% be worth? A million units at $25,000 each could 
easily be sold within six months. That comes to 25 billion 
dollars and represents only the tip of the iceberg. Recently 
scientists isolated a gene associated with obesity. Turning 
off or inactivating a gene is currently easier than inserting 
a gene with complete and accurate regulation of 
manufacture of the gene product. How about an injection 
that inactivated the obesity gene for say, a month at a 
time, marketed at $500 per injection? Considering the 
ongoing obsession with weight control, the only 
foreseeable sale problem would be maintaining stock. 
These are just two possibilities among many. 
The Human Genome Project is a world-wide 
collaboration of scientists whose purpose is to identify, 
map and sequence the entire library of human genes. 
They share the concern that this library may someday be 
used inappropriately. A portion of their budget has been 
set aside to examine the ethical, legal and moral concerns 
of gene therapy. There are no easy answers. Where do we 
draw the line between what is legitimate therapy and 
what is abuse? Shouldn't people have the freedom to 
choose to alter their genetic makeup and improve their 
lives if that is their wish? What about the theological 
implications of playing God? These complex issues and a 
myriad of others will require years of discussion with 
input from a wide variety of experts and intere ted 
parties . We cannot afford to wait and see how the 
technology develops and then decide how we want to 
control it. There is simply too much money involved and 
the potential societal ramifications are too grave. 
Doctors, lawyers, scientists, clergy and all concerned 
parties owe it to themselves and to their communities to 
tum their minds to the issues and begin discussions about 
how we wish to control this technology without delay. 
Considering the complexity of the issues and the 
competing interests involved, it would be naive to think 
that any consensus could be achieved without years of 
discussions. We simply must have a legislative 
framework in place before the technology arrives or we 
risk losing all the advances in social consciousness and 
equality that we have achieved. The potential impact is 
too great for us just to shrug our shoulders and adopt a 
wait-and-see attitude. A world where some can point to 
themselves with pride and say that they are definitively 
genetically superior terrifies me and it should terrify you. 
n 
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The Evolution of 
Disease 
Science is meaningless because it gives us no answer to our 
question, the only question important for us,"What shall we do 
and how shall we live?" . L Tolstoy 
Science alone cannot differentiate health from disease. Disease demands for it definition a sy tern of values. This is immediately problematic; we live 
in a secular society in which values are commonly een 
relativi tically, a a matter of personal choice. It thus 
eems likely that there can be no objective conception of 
di ea e. Medicine is on thin ice indeed. 
What is science? Science is a de criptive endeavour; 
by observing the world it attempts to answer question 
uch a the following: "What state is the world in 
now?", and "Given that the world is in tate X now, will 
it enter tate Y at orne later time?", and "Given that the 
world i in state X, what performed action, A, will 
guarantee that state Y i entered?" 
Yet this vast question set is also limited. It does not 
include questions like "Is state X good or bad?", or 
"Given that the world is in state X now, what state Y 
should we strive to enter?", or "Should I perform action 
A at the moment?" The e latter questions do not a k 
what the world is like, but what it should be like. By 
claiming that the world should be in tate Y, or that 
tate Y is especially good, or that state X is especially 
bad, we are etting up a value y tern in which state Y is 
more valued than tate X. 
The proces of medicine i inherently value-laden; it 
establishes certain physiological/psychological state a 
pathological, thus devaluing them and implicitly 
claiming that treatment hould be undertaken. Two ca e 
tudie , of Alzheimer's disea e and of obesity, may help 
to provide evidence of the role played by value in 
constituting a di ea e. 
ILITY 
In 1907, Alos Alzheimer wrote the fir t case report 
of a patient suffering from what would later become 
known a Alzheimer's disease. On autop y the patient's 
brain revealed neurofibrillar tangles in approximately 
1 I 4 of the ganglion cells, coupled with glial cell 
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proliferation. Vascular infiltration was absent. 1 Today 
Alzheimer's disease is considered one of the most 
prevalent dementing illnesses of the elderly in North 
America. Clinical manifestations of the disea e involve 
a progressive deterioration in mental functioning, 
where the victim suffers variously from confusion, 
forgetfulness, depression, disorientation, and agitation. 
Over the course of the 20th century, perceptions of 
the aging proces in the occident have changed 
dramatically. At the beginning of this century, senility 
wa con idered an inevitable part of aging. Over the 
past 25 year , Alzheimer' disease has evolved from a 
relatively obscure diagno i into a significant health 
policy issue and public concern. 2 The Alzheimer's 
di ea e experience is inherently interpersonal, in that it 
involves the patient and the caregiver. For the patient, 
Alzheimer's disease repre ents a gradual lo s of mind, 
whereas the caregiver has the uncomfortable duty of 
deciphering the needs of the patient. Treating the 
Alzheimer's patient devolves into a balancing act 
between the actual requirements of the patient, the 
caregiver's perception of those requirement and the 
needs of the care giver and the community at large. 
The proportion of elderly citizen in orth America 
is slowly but surely growing. In 1900, 4% of the 
American population wa over the age of 65, by 1994 
the proportion had grown to 12.7%.3 The emergence of 
Alzheimer' di ea e into the public arena has 
overturned the paradigm of senility as a natural part of 
aging. It is estimated that approximately 20% of people 
above 0 years of age will be affected with a dementing 
illne .• Governments are consequently motivated to 
find a "cure" for a potential epidemic in the coming 
century. The late 1970s saw the emergence of several 
large upport groups such as the Alzheimer's Disea e 
and Related Association (ADRA) which, as part of it 
mandate, formed a powerful lobby to compel the US 
government to inve tin Alzheimer's re earch.5 Funding 
for Alzheimer's disease research through both the IH 
and IMH ha increa ed dramatically during the 1980 . 
Over the pa t half-century there has been a trend to 
biomedicalize illne and the aging process. The 
down ide of this has been a lack of consideration given 
to the psycho ocial dynamics involved in the 
patient/ caregiver relation hip. The biomedical model of 
enile dementia, of which Alzheimer' di ea e make 
up a large part, con ists of the following points: the 
dementia is pathological and has a somatic etiology, the 
di ease proce manife t it elf in univer al typified 
stage of progre ive deterioration, and finally, while 
there i no cure for the disease, it can be managed. 2 
Viewing enile dementia in terms of a biomedical model 
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brings order to the care of patients. By labeling the 
condition and identifying its stages, the caregiver' s 
stress is lowered by having expectation of particular 
outcomes. 
Once a diagno is of Alzheimer's di ea e is made, 
family caregivers tend to adopt a "therape utic 
nihilism," in which the inevitability of intellectual 
decline and self deterioration are assumed .5 
Observation of caregivers in everal settings has found 
that once the label "Alzheimer's" is applied to a 
patient, behaviour that in unaffected people would be 
viewed as normal are in terpreted as deviant. Difficult, 
ornery behaviour (such as a desire for a modicum of 
independence) is generally frowned upon by both 
family and facility caregivers. Physical and chemical 
restraints are commonly used to control the elderly 
and are justified in light of perceived de iant 
behaviour. Su ch rest raint can make patients more 
dependent, whereas increasing the patient' s per onal 
responsibility has been correlated with improved well-
being among patients.6 Thus restraint mechanism may 
not alway be in the patient' s best interest. 
The presumption that Alzheimer's disease follows 
a set progression makes it ea ier for famili e s to 
consider institutionalization. As familie become both 
financially and emotionally drained by the burden of 
long-term care of a family member diagnosed with 
Alzheimer's disease, they may find some comfort in 
justifying institutionalization because of a perc ived 
disease progression, whether or not the patient's state 
has actually worsened.2 
At a time when there is still no cure for 
Alzheimer' s disea e, a conflict may arise between the 
dual goal of public funding in order to earch for a 
cure and developi ng infrastructure to care for the 
patient in the interim. Alzheimer's disea e ha two 
victims: the patient and the principle family caregiver. 
Both are put in difficult positions because o f the 
illness. It is clear that the social values of caregivers 
influence treatment of the patient. The choice of 
treatment decisions in turn has a direct influence on 
the conceptual framework by which the careg iver 
understands the disea e. It is important for caregivers 
to recognize that there is a per on behind the illne s. 
FLUCTUATING FASHIONS 
Erotica, Joycean style: 
Farring ton gazed admiringly at the plump arm which 
she moved very often and with much grace; and when, after 
a little time, she answered his gaze he admired still more her 
large dark brow n eyes .7 
And if, in our time, beauty and grace can no longer 
be found in the plumpest and fattest, it may be worth 
calling forth still more witnesses from fa h ion's 
tumultuous history. The Gothic nude, for instance, 
typically had a bulging stomach that appeared almo t 
5 months pregnant. Likewise, the nudes of Leonardo 
da Vinci, Raphael, and Titian es tablished as aesthetic 
ideals women with large stomachs, wide pelvise , and 
broad arm . By the early 1600s a bodily ideal had 
developed that approximated the waves of adiposity 
found in the work of Rubens.8 
Ideals of beauty vary not only historically but also 
geographically . Even today, many cultures view 
fatness as a ign of prosperity, success, and 
abundance. Thu the !Kung San food foragers deride 
thinnes a a sign of s tarvation, and both the Nigerian 
Tiv and Mexican Spanish words for fatness (kehe and 
gordura, respectively) carry definite positive 
connotations. In fact, the latter group has had to invent 
a new word to express the modern dissatisfaction with 
high body weights (gordura mal). Severa l other 
cultures demand a degree of fattening prior to 
marriage . Amongst the igerian Efik people , 
p ubescent girls spend up to two years in "fattening 
h u ts", at the end of which t hey are accepted as 
marriageable. Plumper Kenyan brides can demand 
higher bridal payments; and amongst the American 
southwest's Havasupai, fat women stand on top of 
thin girls to ritualistically aid them in the plumpening 
process.9 
If, as we will argue below, our medical conception 
of obesity depends on cultural values and fa hions, 
thi historical and anthropological survey will pose a 
di turbing que tion. The fact that medical practice 
relies on values that are o prone to fluctuations 
uggests that our current conception of obesity lacks a 
solid foundation . 
STIGMA AS DISEASE 
We live in a society where 6-year-olds are 
prepared to pre-judge obe e children as "lazy, dirty, 
stupid, ugly, cheats, and liars"; where the obese are 
less likely to be accepted into prestigious universitie 
than equally qualified peers of average weight; and 
where 16 % of employer refuse under a ny 
circumstance to hire an obese woman . Ind ed , 
Industry Week has found that each pound of fat costs 
corporate executives $1000 in salary per year.10 It i 
clear that the overweight may face tremendous 
psychological and social pressures on account of their 
bodies. Indeed, in listing the burden of obesity on 
patients, physicians d o not stop with the increased risk 
it po es for medical conditions such as coronary heart 
disease and diabetes . Rather, the psycho oc ial 
problems posed by obesity are explicitly listed as both 
a burden to the patient and a justification for 
considering hi or her condition a disease worthy of 
treatment. This approach was already apparent in an 
early report of the Metropolitan Life Insurance 
Company (MLIC): the overweight, wrote the MLIC 
Statistical Bulletin, should red uce weight because 
otherwise they will be ostracized as young te rs , 
denied equal employment, and obstructed in their 
que t for marriage. This analysis is commonly heard. 
The elson E entia! of Pediatrics list peer 
discrimination and negative stereotypes of the obese 
among the principal complications of obesity. 11 
Likewise, Dwyer notes that "In a weight-con ciou 
society such a ours, obesity is a handicap. These 
[psycho ocial] di advantages may be more potent than 
medical risks in motivating many patients to seek 
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obesity treatment." 12 A similar view wa articulated by 
an IH panel convened to build a consensus on the 
health implications of obesity. In considering the 
adverse effects of obesity they first note that "Obe ity 
creates an enormou p ychological burden. In term of 
uffering, this burden may be the greatest adverse 
effect of obesity." 13 Indeed, a typical recommendation 
to the physician dealing with overweight patients is as 
follows: recommend weight reduction if the patient is 
in the highest 5% of weight for height, or if the patient 
i in the highest 15 % and exhibits psychosocial 
difficultie with his or her weight. 
Each of the above writers elevates the ri k 
associated with the obe e by noting the psychological 
and social ills that may result from obe ity. Yet the e 
psychosocial problems stem directly from society's 
pre-existing ideals and the patient's deviance from 
them. By using the e p ychosocial ills in their 
classification of obe ity as a disease the e physician 
place themselves in a double bind. To their credit, they 
are conscientiously paying attention to the 
p ychosocial dimensions of illness; by empathizing 
with the patient's experience they are truly being 
patient-centred. On the other hand, they run the risk of 
labeling people as diseased olely for their deviance 
from standards of fashion and beauty. This is 
especially worrisome since as outlined above these 
aesthetic ideals have varied tremendously from 
culture to culture and from time to time; our 
conceptualization of obe ity as an objective disease 
tate lies in stark contrast with our fluid aesthetics of 
personal beauty. 
SO WHAT? RECO CEPTUALIZING DISEASE 
di ease (di'zi:z) 1. a. Ab ence of ea e; uneasiness, 
discomfort; inconvenience, annoyance; disquiet, 
disturbance; trouble. (Obsolete.)!• 
An ob olete definition, claims the Oxford English 
Dictionary; and yet our analysis reveals that the 
definition remains relevant in contemporary times. It 
may be thought that obesity and Alzheimer's disea e, 
by virtue of the controversie surrounding them, may 
be more usceptible to value judgements than di ea es 
uch a tuberculosi or pneumonia. Thi is not the 
case. What differentiates the fir t pair of illnesse from 
the latter is the degree of con ensus with which society 
has adopted the relevant values. The values 
underlying obe ity, for instance, have only recently 
taken root in our fashion ensibilitie . The lack of 
consensus over body image, fluctuating rapidly over 
time and pace, opens up a chasm from which our 
craving for slimness may be critiqued. Thus aomi 
Wolf castigates our fashion ensibilitie for leading to 
the imprisonment of contemporary women. 15 The 
interper onal nature of Alzheimer's di ea e establishes 
tension between the values of the caregiver and tho e 
of the patient. The caregiver i presumed to act in the 
best intere ts of the patient, while it i not always 
desirable or even possible for the caregiver to do so. 
The values underpinning both obesity and 
Medical Ethics 
Alzheimer's di ease lack widespread con en u . They 
therefore appear much more prominently in the social 
discourse concerning them. In contrast, a very 
wide pread agreement exists about the values that 
con titute tubercula i as a disease: pain and death 
should be avoided . Indeed, it is precisely to the extent 
that such a consensu can be attained that we can talk 
of an 'objectively defined disea e'. It eems, then, that 
the obsolete definition quoted above is accurate when 
it describes disease not in its current biomedical 
definition, but in reference to the wider notion of the 
illne s process. 
A LONELY DIALECTIC. QR WHAT ~ ALL 
O F THIS MEA N FOR TH E PRACTICING 
PH YSICIAN? 
The phy ician-value relationship is not a one-way 
treet. Just as values affect what the physician 
considers to be a disea e, o also the physician's 
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conception of di ease reinforces certain alues within 
the wider ocietal arena. By over-prescribing weight-
loss medication, or by chemically re training an 
Alzheimer' patient because of perceived devia nt 
behaviour, we run the risk o f olidifying our 
preconceived notions of beauty and aging re pectively. 
The responsibility for participating in uch a subtle 
dialectic i immen e, and it i made all the more 
difficult by the disappearance of the grand moral 
consensus that once guided whole communitie . It i 
only haltingly and with trembling uncertainty that the 
medical community gropes towards ethical certitude. 
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History of Cleanliness and The 
I n f ection Prevent i on 
and the Treatment 
in Surgery 
Wounds of 
The history of bacteria goes back two billion years, and infection has existed since long before the first trace of man. There is evidence, however, that 
mammals have always instinctively treated wounds in a 
manner that has battled infection and ultimately 
prevented premature death. Chimpanzee , for example, 
dab and lick their wounds clean to promote rapid and 
complete healing. ' The fact that apes make no attempt to 
hold their wounds together coincides with the present 
truism that sutures favour infection, and that dirty 
wounds are better left unsewn. 2 Even primitive man 
trepanned successfully 10,000 years ago, and primitive 
tribes in the mountains of Algeria attained close to a 100% 
rate of survival in this practice in the early 1900s.3 
Although people's beliefs have differed greatly about the 
reasons why their practices have been effective, the 
history of cleanliness and infection prevention in surgery 
and the treatment of wounds has been continuous. Man 
has always striven to battle infection. This article will 
discuss several representative examples from this 
historical continuum. 
Documentation of the history of cleanliness and 
infection prevention can be traced back to ancient Egypt. 
The Edwin Smith Surgical Papyrus dating from 1650 BC 
reveals a technique for closing "a gaping wound in the 
eyebrow" that requires binding "fresh meat upon it, and 
treating it with grease and honey every day until [the 
patient] recovers."• Grease prevents lint bandages from 
sticking to wounds, as do present-day first-aid creams. 
Further, meat applied to wounds as a clotting agent was 
used in neurosurgery well into the 20th century when 
safer methods became available.5 Honey appears in 500 of 
the 900 recorded Egyptian remedies for wounds, and was 
a key factor in embalming the dead to preserve them 
against bacterial action; honey is extremely hypertonic, 
and thus kills bacteria by drawing water from their cells. 
It also contains the antibiotic enzyme inhibine which is 
secreted by the pharyngeal glands of the bee.6 Honey was 
probably chosen because it is soothing, does not spoil, 
and, like grease, prevents bandages from adhering to 
wounds. The Egyptians probably used gum to fasten 
linen bandages over wounds as they did around 
mummies, for tapes spare the presence of foreign stitches 
which often lead to infection. Natron and resins were 
used both to embalm and to treat wounds, for natural 
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oda forms a mild sodium-detergent when mixed with 
fat. 7 Even though a religious motivation to prepare for the 
afterlife was the force behind embalming for the ancient 
Egyptians, one cannot help but admire their successful 
fight against bacteria evident today in the preserved 
remains. 
Ancient Greek wound treatment in 400 BC is evident 
in the Hippocratic writings where a "drug for fresh 
wounds" is prescribed, containing "copper acetate, lead 
oxide, alum, myrrh, frankincense, and grease of wool, all 
diluted in wine."8 Although Greek medicine was based 
on the belief that everything in nature must remain in 
balance, practitioners still managed to prevent infection 
in wounds . Copper is currently used to treat the 
staphylococcal skin infection impetigo.9 As well, brass is a 
source of zinc that, when heated with water and stirred 
with a "calamus" reed, produces calamine.10 Alum today 
is an ingredient in the Hepatitis B virus vaccine." Myrrh 
is currently used to combat gingivitis, being an effective 
anti-microbial agent that also stimulates the production of 
white blood corpuscles. 12 As well, "cold, white or red, 
astringent wines are u ed for wounds, because of their 
heat." '3 Greek wines from Samos and other islands are 
effective for wound sterilization because they contain 
polyphenol, a complex form of Lister's phenol that is 33 
times more powerful.'• For a society that spoke of sepsis 
without knowing about bacteria, the Greeks' emphasis on 
cleanliness and wine is remarkable, and their treatments 
rightfully survived for many centuries. 
Roman medicine contained traditional folk remedies 
for the treatment of wounds for many years before these 
were taken up in medical literature. By 79 AD, Pliny the 
Elder had completed his Historia aturalis, which 
compiled 20,000 of these remedies from over 100 authors. 
Among them are "admitted medical aids, [including] 
wool and eggs." '5 Wool was applied with honey, and the 
whites of eggs were used to close inflamed wounds. 
Amazingly, Dr Alexander Fleming would publish an 
article in the Lancet in 1924 "On the antibacterial power 
of egg-white." '6 Reinforced by charms, incantations and 
superstition, poultices were believed to be more 
efficacious if "laid upon [the wounded] by a naked 
maiden." '7 Pliny's choice of antiseptic wound dressings, 
however, could not possibly have been an accident. Of 
the 34 plasters and ointments he records, all but 5 contain 
heavy doses of alum, lead and copper salts, mercury, 
antimony, sulphides, oils and vinegars, substances 
possessing powerful antiseptic properties. Pliny even 
states that "copper ores and mines supply medicaments, 
[by which] all kinds of ulcers are healed with the greatest 
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Fig. 1 Achilles treats the wounded Telephos with scrapings from his bronze 
lance. Pliny may /rave seen this bas-relief of tire first century. 
rapidity." ' Pliny most likely recognized that common 
plants po e s active healing properties, for he ironically 
remarks that for "remedies, nobody looks into his own 
kitchen garden." '9 One might even argue that Romans of 
Pliny's time knew why they used these remedies, for in 
26 BC, Varro had already clearly stated that "in the 
neighbourhood of swamps .. . there are bred certain minute 
creatures which cannot be een by the eyes, which float in 
the air and enter the body through the mouth and nose, 
and there cause serious di ea es."20 
Even though Hugo of Lucca had never heard of 
bacteria in 1200 AD, he trove for aseptic measure in 
surgery, tating that wounds "should be abraded, 
clean ed, wiped with lint soaked in warm wine, the lips 
of the wound [should be] reunited, and [it hould be] 
bound with a light bandage." 2' Hugo's son Theodoric 
upheld this tradition, and, reverting to the Hippocratic 
doctrine of Ulcers, declared that it "is nece sary that 
[wounds] be made dry ." 22 This was an important 
revelation, for it countered the contemporary belief in 
"laudable pus", that encouraged the formation of pus as a 
nece sary stage in healing, and prevented the a eptic 
treatment of wounds. 
In 1747 George Berkeley wrote a letter to Thomas 
Prior on the usefulness of tar-water in the Plague. He 
writes that bleeding and wine "are both to be uspected; 
whereas Tar-water cool without weakening, and gives 
spirits without heating, a sure indication of its overeign 
virtue in all inflammatory ca e ."23 This comes a no 
surprise to us, since today the majority of phenols u ed to 
manufacture disinfectants are obtained from tar produced 
in the distillation of coaP• 
In 1826, John Bell recounted the common antiseptic 
practices of the French army in his Principles of Surgery: 
"One [cure] in particular was called the secret dressing, in 
which [the drummer would lay] the lips of the wound 
together to uck out all the blood. " 25 Although the 
effectiveness of this procedure wa believed to lie in 
signing the wound with a cross, the u e of saliva became 
a popular practice throughout France. Even La Motte, the 
mo t eminent surgeon of the time, is quoted as saying 
that it "i more ucce sful than any method that w e 
surgeons u e"26, and that "speedy adhesion [allows] no 
danger from bad consequences of the wound."27 
In 1847, Ignaz Semmelweis of Vienna noticed that 
after performing autopsies, physicians and students 
retained particle of decaying matter on their hands. 
Believing these particles to be the cause of "childbed 
fever" , a fatal condition of new mothers, he declared that 
it wa " nece sary to clean the hands with chlorine 
water" 28 before examining the e patients in order to 
decrease the mortality rate from sepsis. By October that 
year, he had di covered that childbed fever was also 
carried from living people, and through the air. In 1860, 
Jules Lemaire recommended the use of di infectants 
during surgery, and in 1890 the American surgeo n 
William Halsted introduced rubber gloves in the 
operating room, to prevent the septic infection of 
wound . 
While studying under James Syme in 1852, the British 
surgeon Jo eph Lister became intere ted in preventing 
infection or "sepsis" in wounds; this led him to try 
carbolic acid, a dark, tar-like sub tance, to promote clean 
healing and close wound . Although Lister was not the 
first to use carbolic acid, he was the first to understand 
why he u ed it. His fir t clinical success occurred in 
March of 1865, when he healed a boy who had been run 
over by a cart wheel. He later developed the method of 
dis olving the carbolic in four parts of boiled linseed oil 
to clean his surgical utensils, and mixed carbolic oil with 
carbonate of lime to make an "antiseptic putty" for 
wounds. By 1867, Lister had prevented infection and 
subsequent death in so many of his patients, that he 
declared in the Lancet that "the element of incurability 
ha been eliminated."29 Lister's methods allowed doctors 
to open bodies for surgical purpo es for the fir t time, and 
he himself went o far as to perform an operation to 
straighten a foot by opening the ankle joint. He even 
soaked catgut in carbolic, and thus created the fir t non-
infective suture . Lister had succes fully "cleaned up" 
infection in Edinburgh and Glasgow, and in July of 1870, 
Dr Saxtorph of Copenhagen wrote that he had "ne er 
tried any innovation which answered so admirably as this 
treatment of wounds. " 30 In 1872, von Volkmann 
prevented a ho pital closure by combatting ruthless 
gangrene with Lister's method of "washing with diluted 
carbolic acid in the proportion 1:8."3' Lister's ways were 
popularized by von Bardeleben in Berlin, von Busch at 
Bonn, Duplay in France, and most of all at the Congress 
of German Surgeons in Berlin, where the chairman said 
he "could not find words enough to tell of the good of 
it." 32 Von u sbaum wrote in April of 1875, that "Lister's 
treatment is already being greeted by the whole civilized 
world as an enormous advance." 33 A diluted carbolic 
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Fig . 2 Curt Sclrimmelbusclt's soda sterilizer for instruments: battling sepsis full steam. (1895) 
"spray was [later] devised [for use in operation ] in 
respon e to the idea that epsis wa largely due to air-
borne organism ."34 
In Curt Schimmelbusch' s 1895 Guide to the 
Antiseptic Treatment of Wounds, he indicated that 
during urgery: 
The surface is actively brushed for at least 1 minute 
with soap and water, as hot as can be borne. 
It is carefully rubbed and dried with sterile towels. 
The kin i rubbed for about a minute with 80% 
alcohol. 35 
A well , he de cribed urgeon ' materials 
"asepticized in a steam sterilizer [and] put in do ed tin 
boxes," and " urgeons [wearing] long, white sterilized 
linen gowns." 36 The surgeon wa al o to disinfect his 
hand with the utmost precaution. This thorough method 
of sterilization to prevent wound infection would et the 
standard for many years. 
The 20th century brought a new outlook on the 
treatment of epsis in urgery . In 1904, Paul Ehrlich 
discovered that dyes selectively ab orbed by cells could 
be effective as antibacterial drugs. With Kiyoshi Shiga, he 
prepared the 606th ar enical substance in 1907, and 
ventured to London in 1909 to share his discovery with 
others. In London, Ehrlich entru ted a man by the name 
of Alexander Fleming with the ta k of trying this 
Salvar an 606, as it came to be known, on a patient. In 
1917, Fleming assisted S. Douglas in preparing his 
"Studies in Wound Infections" for publication in the 
Lancet, which stated that "bacterial symbio i may play a 
very important role in wound infection ."37 In 1922, 
Fleming reported the discovery of an anti-bacterial 
substance, lysozyme, derived from the mould Penicillium 
notatum. Unknown to Fleming, Li ter had abandoned an 
experiment noted in his "Commonplace Book" of 1871, 
where he noted that the presence of a soft mass (which he 
thought was penicillium glaucum) "wa making the 
bacteria completely immobile and languid."38 In January 
of 1929, the use of penicillin to prevent bacterial infections 
in man was first sugge ted in the British Journal of 
Experimental Pathology. The first therapeutic test with 
purified penicillin, made po ible by a decade of research 
by Howard Florey and Ern t Chain, took place on the 
evening of August 6, 1942, and their patient recovered 
from meningitis on Augu t 27. An article in the Times 
hailed their success, and urged that "methods of 
producing penicillin on a large scale should be developed 
as quickly as possible."39 By 1943, the most active form, 
benzyl penicillin, had been crystallized, and the United 
States Armed Forces already had a ufficient supply of 
Fleming' drug. In 1944, Florey predicted that "some 
chemist will manipulate the penicillin molecule to 
improve its performance," 40 and in 1957 synthetic 
penicillin was produced for the first time at the 
Massachu etts In titute of Technology by John Sheehan 
and his collaborators. By 1961, acid-resistant trains were 
already being produced for oral ingestion. 
Current guidelines for cleanliness and infection 
prevention state that a surgeon must: Scrape/brush nails 
and apply antiseptic soap or detergent e.g., chlorhexidine 
or povidone iodine, to hands and forearm using a 
defined technique for a minimum of two minutes. Dry 
hands on sterile towel. Alternatively, clean hands with 
oap and water and apply two or more applications of an 
alcohol hand rub." 
It is interesting to note that the current method of 
terilizing skin is almost identical to that proposed by 
Schimmelbush in 1895. As well, alcohol is used today as a 
disinfectant, as it was by the ancients nearly 5000 years 
ago. Current surgical books on the management of war 
injuries prescribe "gentle and copious irrigation with 
saline," 42 which was foreshadowed in John Bell's 1826 
description of the French army' s use of saliva . 
Furthermore, this technique is described in the book of 
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Genesis of the Old Testament, where saliva i applied in 
circumci ion to prevent inflammation.43 One might even 
argue that such a practice i innate, for we have seen that 
other primate in tinctively lick their wounds clean to 
promote rapid and complete healing.44 
Whether based on magic, religion, sorcery, 
ob ervation or experimentation, human practice have 
always existed to battle infection. It can therefore 
rightfully be said that the history of cleanlines and 
infection prevention in surgery and the treatment of 
wounds has been continuous. 
But even today di ea es remain for which cure do 
not exist, and we do not know what mankind will face in 
the future. In 1959, a continuing quest for new antibiotics 
led to a review of 2222 plant , of which 1362 were 
reported a having some antibiotic effect. 45 Pliny's 
ob ervation that Arabia and India were considered the 
storehou e of remedie , while nobody looked into his 
own garden has retained its validity. With this in mind, 
and five thousand year of effective medical knowledge 
at our fingertips, it is clear that we must not forget the 
ancients a we boldly enter the third millennium. 
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• 1 n Ear I y 
If the poet's tongue might breathe the prayer 
that i on the lip of all, I would pray that 
Cheiron, son of Philyra, who i dead and gone, 
were now alive again, - he who once ruled far and 
wide as the offspring of Cronus, who wa the on 
of Heaven. Would that that rugged mon ter with 
spirit kindly unto men, were reigning still in 
Pelion' s glens, even uch a when, in olden day , 
he reared Asclepius, that gentle craftsman who 
drove pain from the limbs that he healed, - that 
hero who gave aid in all manner of maladies 
(Pindar. Py. 3.1-7, Sandys). 
For nearly three thousand years Asclepius has been the patron of phy icians in the West, first a a mortal, then a a god, and now as an iconographical fragment. Like 
the Cheshire eat's lingering grin, all that remains today of 
Asclepius' s once-meaningful cult-image i his snake-
entwined taff. His body has been absented from our visual 
representations and his story has passed from our repertory 
of tales. Yet, however faintly his name is known to u , we 
are in need of Asclepius to link us to the mythological past 
from which he sprang and to introduce u to place and 
individuals whose remembrance is far fainter. These figures 
of Greek mythology, the associates of Asclepius, reveal by 
their interconnection and commonality the origin of a 
medical tradition which i ancestor to our own. 
Fig. 1 Map of Thessaly, in 
ancient Greece, showing sites 
associated with the myths of 
Cllt'iron and his followers. 
Presumed to be Coronis, tl1e 
mother of Asclepius 
by Apollo. We will reeucounter 
the geographical fea tures which 
allude to her identity in 
subsequent versions of the myth. 
by David I Beile 
It is likely that Asclepius dates from at least as far back 
as the Greek Dark Ages (1200 BC-800 BC), since the brevity 
of his citations in Homer' Iliad (c. 750 BC) suggest that the 
poet's audience was already familiar with his mythology. 
The same poem al o documents his character as a 
phy ician, for he is said to have received certain medicines 
from Cheiron (Iliad 4.219), the mo t righteous of the 
centaurs (and a later subject of this article). To turn to the 
earliest recollections of Asclepius' parentage, a fragment of 
Hesiod (contemporaneous with Homer) mentions an 
unnamed maid, who dwelt in the Plain of Dotium by the 
River Amyrus and washed her feet in the Boebian Lake 
(MW fr. 59) . Another fragment preserves the tiding 
brought by the raven to Apollo at Delphi that Ischys 
Eilatides had wed Coronis the daughter of Phlegyas (MW 
fr. 60). The Homeric Hymn to Apollo describes Ischys and 
the god as rival suitors (3.209-10), while the Hymn to 
Asclepius proclaims the celebrity's Apollonian paternity a 
well as hi birth by Coronis in the Dotian plain (16.1-4). 
However, not until Pindar (c. 500 BC) is a full account of the 
myth provided. There, Coronis had previously consorted 
with Apollo and carried within her the pure seed of the 
god, but, without her father's knowledge, she consented to 
be wedded to Ischys son of Eilatu . Apollo in Delphi, 
cognizant of this deception by his characteristic 
omniscience and the word of hi raven me enger, 
wrathfully ent his sister, Artemis, to Lacheria where 
AEGEAN 
SEA 
U. W.O. Medical Journal 66 (2) 1997------------------------- 75 
H 1 sto r y ot Med 1 c 1n e 
Coronis dwelt near the banks of the Boebian Lake. There 
the resistless might of the goddes e destroyed both the 
offending girl and many of her neighbours. Yet, when her 
body was placed upon the funeral pyre, and the pyre 
kindled, Apollo could not bear to lose his innocent child in 
the fulfillment of its mother's doom. He reached through 
the flames, snatched Asclepius unborn from the corp e and 
bore him away to Cheiron to learn from the centaur to heal 
all mortals of disease. He grew to become a great physician, 
but in the end was tempted by a payment in gold to raise a 
man from the dead. This deed outraged Zeu , who killed 
both Asclepius and the one he resurrected with the divine 
justice of his lightning-bolt (Py. 3.8-58). 
The belief, which Pindar expres es, that Cheiron and 
not Apollo instructed Asclepius in the art of medicine was 
general among the ancient Greeks . It seems strange, 
however, that the god who could both bring and remove 
plagues, who healed Glaukus in the iliad (16.527-29), and 
whose sister and mother healed Aeneas (5.447-48), was not, 
himself, the inceptor of his son's prodigious medical ability. 
Yet, the question of why Apollo was excluded from the 
honour of educating his own son can be easily answered by 
turning to an analysis of the period when the myth of 
Asclepiu were being formed . For although Apollo 
gradually acquired a reputation as a god of healing, this 
characteristic had not been fully assimilated to his divine 
identity even by the time of the Archaic period (800 BC-500 
BC) . This is clearly shown by the fact that Paeon, a 
physician-god who existed before the Dark Ages (Burkert, 
43f.), appears twice in the iliad and once in the Ody sey 
independently of Apollo (Gantz, 96). It must be assumed, 
therefore, that in the Dark Ages the eparation of Apollo 
from the medical attributes which he posse sed in later 
periods was even more pronounced. 
We are left, however, with a second and more 
perplexing question which concerns the apparent 
oppo ition between Cheiron, whom Pindar characterizes a 
a pher agroteros (rugged monster) (Py. 3.4), and the 
inherent humanity of the craft of healing that he advances. 
By the Greek agrotero is meant the wildnes of the open 
countryside (agros) in distinction to the sophistication of the 
polis, while pher (descriptive of the animal component of 
the centaur's hybrid body) is cognate with the Latin fera 
and the ancestor of the English "feral". The combination of 
the e two words leaves no doubt of the wildness of the 
centaur (Robbins, 96ff.). How then can a creature which 
haunts the wilderness around Mt. Pelion and dwells in a 
cave on the lopes of that Thessalian mountain be imagined 
to cultivate and teach the civilized medical craft? A 
reconciliation of this seeming contradiction can be achieved, 
however, by inspecting the common geographical situation 
of the mythological characters who, like Asclepius, profited 
from the centaur' tutelage. 
Before we proceed, it is necessary to place the 
landmarks introduced by the Asclepius myth in their 
proper geographical context, that is, within the larger 
region of Thessaly. From Mt. Pelion, which is at the base of 
Cape Sepias and overlooks both the Gulf of Pagasae and the 
Aegean Sea, Lake Boebia , the Dotian Plain and the River 
Amyrus each lie north-eastward as successive points in a 
gradual arc. In distinction, Achilles, who was another ward 
of Cheiron em. 3.43-63.), is described at the time of the 
Trojan War as ruling variou cities somewhat further down 
the coast of Thessaly and around the Malian Gulf (ll. 2.681-
85). Yet his father, Peleus, had found amnesty in the city of 
Iolcus, had been aided by Cheiron, and had solemnized a 
marriage which led to Achilles' own birth all within sight of 
Mt. Pelion. In addition to Achilles' doubly Thessalian 
provenance, the Iliad reveals that he possessed a 
knowledge of medicines which had been shown to him by 
Cheiron (11.829-31). As well, one finds from book 16 of the 
same poem that Achilles' ash spear, too, came from the 
centaur, who originally cut it from the forests atop Mt. 
Pelion as a gift for his father (16.143-44). Like the Thessalian 
medicines obtained from Cheiron, this Pelian spear also 
seems to have demonstrated curative properties in the 
hands of the hero. With it, Achilles healed a wound which 
he had formerly dealt to Telephus, the king of Mysia, thus 
fulfilling the famous prophecy of the Delphic Oracle that ho 
tro as kai iasetai (he who wounded will also heal) (Iths. 
8.49-50; Ap.E. 3.17-20). 
Jason, son of Aeson, is the third and last of the young 
heroes whom Pindar mentions as the students of Cheiron 
(Py. 4.102-19; em. 3.54). His birth in the city of Iolcus 
(south-eastward below Mt. Pelion, at the top of the 
Pagasaean Gulf) confirms him as a native of the same 
corner of Thessaly with which we are becoming familiar. 
Yet Jason is a pecial case, and there is a reason why Pindar 
neglects to describe his receipt of any medicines or medical 
instruction from the centaur. Since Iason in ancient Greek 
means healer, there was certainly no rea on for the poet to 
specify the type of education that a hero of that name 
necessarily underwent. Be that as it may, the examples of 
Jason employing his healing craft are comparably rare. One, 
however, is provided by some recently published 
fragments of a Corinthian column crater dated to around 
575 BC (Vojatzi 19 2, 71-86). The fragments sort themselves 
out into two groups, on the first of which Jason is pictured 
reaching forward from behind the blind eer, Phineus, to 
place his hands over his sightless eyes. The first publisher of 
these fragments has suggested, on analogy with the literary 
accounts, that this action is meant to ignify the healing of 
Phineus' blindness by a "laying on of hands" (Gantz, 355). 
In returning full circle back to Asclepiu , it is 
appropriate to add the Homeric account of his ons, 
Machaon and Podaleirius, to the mythological 
characterization of the country around Mt. Pelion and of its 
native phy icians. According to the "Catalogue of Ships" in 
the Iliad, both the ons of A clepius were lords over a 
region in the interior of southern The aly the centre of 
which wa Tricca (2.729-32). They thus ruled we tward 
from the coastal area in which their father experienced his 
god-induced birth and north-westward from where Jason's 
city stood, once home to Peleus ( em. 3.33-34; 4.54-56). 
Their distance from the area around Mt. Pelion is 
commensurate with their lack of direct contact with 
Cheiron. It must be noticed that Machaon, in treating the 
arrow-wound of Menelaus, '1aid healing medicines upon it 
that Cheiron in friendship had long ago given his father (ll. 
4.218-19 (italics mine))." Yet this passage al o shows that, 
despite their removal from the eastern coast of Thessaly, the 
brother were part of a tradition of medical skills and 
medicines from Ch iron to Asclepius and from Asclepius to 
them. As an exemplar of this tradition, it is Podaleirius who 
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provides the means of an w ering the second of the 
questions po ed earlier: why, after all, was Cheiron the 
instructor of Asclepius? 
Following an explication of a passage in the Iliad, 
Eustathius, a Byzantine commentator on the Homeric 
poems, supplies the mis ing detail by revealing the 
etymological ignificance of Podaleirius' name: 
moreover, Podaleirius is the "flower-footed" (lit. '1ily-
footed") not only, as is stated elsewhere because of his good 
fortune, but also because he diligently studied flowers. For 
as a physician he was for the most part an herb-gatherer 
(rhizotomo ), a was fitting (Eustathius, XIIT.830). 
This ancient conception of physicians as gatherers of 
herbs finally explains away the discrepancy between 
Cheiron a agroteros and hi role as the originator and 
di eminator of medical art. For only one who lived in 
clo e proximity to the wild could take advantage of what 
the earth, unaided, puts forth. In the same way, Homer in 
the Odyssey calls all Egyptians doctors not because they 
were the sons of Paeon, but because they dwelt "where the 
fertile earth produces the greatest number of medicine 
(4.229)." Even more than the ile valley, the area around 
Mt. Pelion was famed in antiquity for its pharmacological 
wealth (Kern, 2.304). It w as told that Medea, another 
rhizotomo (Radt, 410), in her flight through the nearby 
Thessalian plain scattered her collectiQn of drugs and 
caused the entire region to sprout with herbs of equal 
virtue (Aristides, Oratio 38.15). The Latin elegists (50 BC-50 
AD) as well, reflecting upon the compedia of Archaic 
Greek texts produced by their Helleni tic predeces or , 
remember Thessaly as a pro verbial source of drugs, 
poisons, and those skilled in their use (Tib. 2.4.56; Prop. 
1.5.4.). Cheiron, therefore, the "Magne ian centaur (Py. 
3.45)" who "reigned in Pelion's glens (Py. 3.4)", was ideally 
ituated to benefit from this local abundance of medicines. 
It is in such a proprietary capacity that Catullus describes 
him, his characteristic drug transmuted to blossoms for 
the marriage of Peleus and Thetis: first from the summit of 
Pelion came Cheiron, bearing sylvan gifts; for all the 
flowers that the plains bear, all that the Thessalian region 
brings forth on its mighty mountains, all the flowers that 
near the river' treams the fruitful gale of warm Favonius 
discloses, these he brought himself ... (Cat. 64.278-83). 
The Cheironidae, or the descendants of Cheiron, 
perpetuated this sense of his rural claims a can be een 
from the boa t that they po sessed pharmacologicals which 
originally belonged to their father. Moreover, the 
Magnesian (a local people from eastern Thessaly), 
worshipped the centaur as a healer and the inventor of the 
gentle science of medicine (Edelstein, 5) . Since early 
medicine as attested in Homer was primarily surgical and 
pharmacological, and since the latter branch, as ob erved 
by Eustathius, eems to have been the dominant one, it is 
easy to see why Cheiron as the rhizotomo par excellence 
was also a physician par excellence. It is also easy to ee 
why all the mythological heroes who had some experience 
in the practice of healing were not only born in Thessaly, 
but were rai ed and educated in the herb-bearing 
wilderness belonging to Cheiron. With the advent of Dark-
Age pharmacology, this small area and its legendary 
produce became the fountainhead of a physicianship 
which was to be remembered throughout ancient Greece. 
Our story, however, cannot end without first attending 
History o f Medi c ine 
to Podaleirius, the author of our solution. In the aftermath 
of the Trojan War, he eventually settled in the Carian 
Cher one e (on the S.W. corner of Asia Minor) and 
fathered a line of children who, like those of his brother, 
were called the Asclepiadae (Ap. E. 6.18). In the 
intervening centuries between the period which Greek 
mythology remembers and that which is documented from 
historical knowledge, it may be imagined that a number of 
the Carian Asclepiadae migrated elsewhere, some along 
the coast of Asia Minor, some to the Ionian Islands, and 
some back to the Greek mainland. For historically, the 
neighbouring island of Cos boasted a family of 
Asclepiadae, pre-eminent among its nobility, who traced 
their ancestry back to Podaleirius and their geographical 
origin to Thessaly (Kerenyi, 52). Into this family that 
Hippocrates was born whose subsequent renown attracted 
an entire corpus of medical writings to his name. It is a 
testament to the medical importance of Cheiron and the 
land over which he presided, that this man, the greatest of 
the ancient physicians, named his eldest son The alus, 
"the one from Thessaly" (Kerenyi, 56). 
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the Mapping 
Functional 
Human Brain with 
Resonance M agn 
I mag 
A Brief Introduction 
Since Seiji Ogawa di covered functional magnetic re onance imaging (fMRI) in 1992, the world of functional brain mapping has never been the arne. 
This new technology, which offers di tinct advantage 
over Po itron Emi ion Topography (PET) and Single 
Photon Erni ion Computed Tomography (SPECT), ha 
ent re earcher aero the globe racing to functionally 
map the human brain . Recently, the Robarts Re earch 
Institute became the first centre outside the US to hou e 
an fMRI machine with a tr ngth of 4 Te las, which i 
about 0,000 times as trong as the earth's natural 
magnetic field (Figure 1). Thi is one of only even 4-Te la 
machine in the world. Although co tly ( 4-5 million), 
this machine allow us to view object a mall a ocular-
dominance column in human vi ual cortex (0. mm X 1.6 
mm)'. And unlike PET, where ubject typically mu t be 
injected with or inhale a radioactive tracer to measure 
regional cerebral blood flow , fMRI i non-inva ive . 
Subject can be canned repeatedly without expo ure to 
ionizing radiation. 
The clinical application of fMRI are many. It is 
already being u ed in pre urgical mapping of primary 
motor and peech area , and researcher at the Robarts 
Re~ear~h In~titute are currently u ing it to inve tigate 
eptlephc foCI, early degeneration in prefrontal and motor 
cortex in patients with Amyotrophic Lateral Sclera is, 
early detection of glaucoma through examination of 
tructural change in primary vi ual cortex, 
cerebrova cular and cerebrore piratory regulation, neural 
circuits which may be responsible for schizophrenia, 
brain pla ticity in respon e to removal of an eye, and 
ar~as that ar~ respon ible for peech and swallowing. 
Th1 paper will focu on r earch conducted in Dr Tutis 
Vilis' s laboratory, part of the UWO Vi ion and Motor 
Imaging Group. 
ABOUT THE A U1HORS 
About the Author : Sean Dukelow i a firs t-year 
~/Ph~ tudent in the euro cience program at the 
Uruver tty of We tern Ontario. He will be joining the 
cia of 2002 after completing his fir t two year of 
re earch. Prior to entering the MD/PhD program, he 
completed a BSc at the Univer ity of Guelph. Jo ph 
DeSouza is a fir t-year PhD tudent in the euro cience 
program at the University of We tern Ontario. Prior to 
tarting his PhD, he completed an M in euro cience 
and a BA in P ychology at the Univer ity of We tern 
Ontario. 
• e t 1 c 
• 1 n g 
by Sean P Dukelow and Joseph FX DeSouza 
VISUAL CORTICES 
Anatomists divide the vi ual y tern into two 
processing stream , the dor al and the ventraJ.2 
Originally, theori t proposed that the ventral stream 
handles vi ual form recognition while the dor al stream 
deal with patial vi ion2, but more recently it ha been 
propo ed that the dorsal tream handles on-line control of 
vi ually guided movement while the ventral stream 
works off-line, building up a visual model of the world3 . 
Fig. 1. Tire new 4-Tesla Varian fu nctional Magnetic Resonance Imaging 
machine in lire Cuddy Wing of tire Robarts Research Institu te. 
Fig. 2. Ventra l Perception 
Schematic diagram of a Stream 
lateral v iew of tire lr uman brain showing tire dorsal & ventral processing 
strea ms. Tire dorsal stream, n mning mainly tlrrouglr tire posterior parietal 
cortex, is responsible for encoding visual motion & visually guided movements 
while tire trentral stream is thought to be more invoh>ed in object recognition. 
(Numbers represent Brodmann's areas.) 
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As shown in Figure 2, both streams originate from 
primary visual cortex, also known as VI . The dor al, 
action-oriented stream runs through regions in the 
posterior parietal cortex where neural activity correlates 
with visual motion and visually guided movements. 
Deficits to this stream can cause optic ataxia and / or 
disorders of spatial attention. The ventral stream runs 
mainly through regions of the inferotemporal cortex that 
deal with object recognition. Deficits in this stream may 
lead to visual form agnosia, prosopagnosia (problems 
recognizing faces) and I or achromatopsia (colour 
recognition deficits). The ventral stream is currently 
under investigation by a number of researchers• in the 
Vision and Motor Imaging Group, but in this article we 
shall focus on the dorsal stream. 
Our studies to date have dealt with areas in the 
dorsal stream that respond to moving visual stimuli 
and / or saccadic and pursuit eye movements. We aim to 
determine the physiological response properties of these 
areas using fMRI. Our research into visual motion has 
concentrated largely on the human homologues of the 
macaque monkey's Middle Temporal (MT) and Medial 
Superior Temporal <MSn Areas. In monkeys, almost all 
cells in MT and MST show directional5 and speed 
selectivity, meaning they respond best to objects moving 
with some favoured speed and direction6• £MRI work has 
shown that human MT is likewise activated by moving 
stimulF and is located posterior to the junction of the 
ascending limb of the inferior temporal and lateral 
occipital sulci8. Currently we are investigating stimulus-
speed sensitivity in this area. As well, we are attempting 
to determine the responses of MT and MST to pursuit eye 
movements. 
In some of our experiments we have the subject make 
visually guided eye movements. It is known that 
electrical recordings from neurons in the monkey parietal 
regions in the Lateral Intraparietal Area and Area 7a 
show an increased firing rate during saccadic eye 
movements9• Once these cortical areas are determined in 
our group of subjects, we will employ various memory-
guided saccade tasks in order to study areas in the 
parietal lobe processing the intention to make a 
movement and the attention to the task. One of the initial 
eye movement experiments we have conducted has 
investigated differences in activity for small and large 
saccadic eye movements in the posterior parietal cortex 
(PP) and frontal eye fields (FEF). 
METHODS 
In our imaging protocol, we use Blood Oxygenation 
Level Dependent (BOLD) contrast imaging. In this 
technique, areas of the brain which receive increased 
blood flow show up brighter. As increased blood flow is 
thought to indicate increased neural activity, we can 
visualize regions of the brain which display increased 
activity by performing a functional subtraction. 
Signal Time course for Primary Visual Cortex During a Grey/CheckerBoard Presentation 
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Fig. J. 
A signal time course taken from the primary visual cortex (Vl) during a tw<Htate experiment. Subjects viewed a stationary grey display follawed by a checkerboard stimul11s flashing at 8 
Hz. During tDch state, 10 imDges were collected aver a 24-s period. Bath states wert repeated 4 times. Area V1 shi1WS a significant incrtDse (p<O.Ol) in signal during presentation of the 
flashing clrecknboard and this response is corrsistent across trials. 
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A functional subtraction, performed using the trongly to a stimulus speed of go Is than to 16° Is (p<0.05). 
oftware package Stimulate, removes the basal level of 
neural activity on a voxel-by-voxel basis. A voxel is a 
small volume of the brain, and in our experiments we 
typically scan with a voxel size of about 2-3mm x 2-3 mm 
x 5-6 mm, although much higher 
Further studies will involve a wider range of speeds (0° Is, 
2°ls, 4°ls, 8°ls, 16°ls, 32°ls, 64°ls and po ibly 128°ls). 
Re earch on stimulus speeds will help us determine the 
optimal stimulus speed for future movement paradigms. 
spatial re olution is possible with this 
machine . One image (slice) in our 
experiments is composed of a matrix 
of 64 x 64 voxels. Larger matrices are 
al o po ible. 
To u e a functional subtraction 
we must de ign a stimulu condition 
that i closely related to the control 
condition in all but one re pect. For 
example, image collected during the 
presentation of a stationary stimulu 
o n our MRI video goggle are 
ubtracted from images collected 
during the pre entation of a leftward 
moving stimulus to reveal motion-
sensitive areas within the brain. All 
other attributes of the vi ual stimulus 
such as luminance and contrast are 
held constant. This allows u s to 
conclude that any chang e in 
activation are likely to have re ulted 
from the stimulus motion. 
After generating a functional map 
using the Stimulate software, we plot 
the ignal time course for s pecific 
regions of interest (ROis), as shown in 
Figure 3. The signal time course plots 
the signal of activated voxels 
contained within the ROI. From the 
signal time cour e we can determine 
the re pon e of the area during the 
control and one or more stimulus 
conditions. This response can then be 
compared aero s stimulus condition 
and we can draw conclu ions about 
the inherent properties of certain areas 
of the brain. 
CURRENT INVESTIGATIONS 
One of our current project i to 
determine the sensitivity of human area 
MT to the speed of a visual stimulus. In 
this tudy, a "shutter" is moved 
rightward, once every second, aero s 
the central g degrees of the display at 
various speed (0° Is, go I , 16° I s). A 
functional subtraction is performed, 
removing activity during a stationary 
stimulus from activity occurring during 
movement of the "shutter" at go I , to 
generate the map depicted in Figure 4. 
Analysis of the signal time course 
generated by this experiment has 
allowed us to conclude that human 
area MT responds significantly more 
A. B. 
Left MT Right MT 
Fig. 4. Data from a subtraction: neural response to a "shutter" maving at 8°/s min liS the response 
to a stationary stimulus. A) Left-side view of a schematic brain showing orientation of the image 
slice. 8) Image through the Iutman homologue of area MT showing bilateral activity during 
shutter mcrvement (8 °/S) compared to stationary. 
A. 
Frontal 
Eye fields 
B. 
Fig. 5. Data from the subtraction of large (28°) saccadic eye movements with fixa tion for Subject 
LA. A) Left-side view of a schematic brain showing orientat ion of the image slices. B) Image 
through parietal cortex (PEF) showing activity during large (28 °) saccadic eye movements 
compared to fixation . C) Image through frontal eye field (FEF) during the same experiment. 
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In another study, we compared activity during large 
(28°) and mall (3°) saccades. Subjects viewed a mall white 
dot against a black background. To analyse this experiment 
we "subtracted" each saccade task from a control ta k in 
which the subject fixated a central cro . This ubtraction 
revealed activation in the visual cortex (Brodmann's Area 
17
•
1 ) , frontal cortex (FEF, Frontal Eye Field , Brodmann' 
Area ), and parietal cortex (PEF, Parietal Eye Fields, 
Brodmann' Area 7; see Figure 5). Subtraction of the small 
saccade task from fixation revealed the same areas activated 
by the large saccade ta k, but the e area di played a 
significantly decrea ed (p<O.OS) ignal during the mall 
accades. When recording electrophysiologically in the 
monkey, Dougla Munoz and Robert Wurtz10 noted that 
large saccades cause more firing in the uperior colliculus 
than do mailer eye movements. It would appear that our 
results support increased neural activity at higher cortical 
levels in both the parietal and frontal eye field (PEF and 
FEF). 
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DISCUSSIO 
Our s tudies have shown stimulu -speed-relat d 
changes in activity in area MT a well a accad e-
amplitude-related change in PEF and FEF, which were 
quantified by change in fMRl ignal. Future tudies will 
continue to map dorsal- stream areas to further determine 
the topography and regional functional pecialization of the 
human visual system. 
Our inve tigation into dor al-stream neural activity 
u ing fMRl have allowed u to map regions of the brain 
with a spatial resolution that was previously unattainable. 
High spatial re olution and the ability to repeat cans in 
individual make the fMRI a valuable tool for both 
re earcher and clinician . Over the pa t year we have 
functionally mapped out our own primary visual cortices, 
motion- ensitive areas, primary motor, and saccade-related 
areas. Our current tudie have focu ed on only a few 
extra triate visual areas within the human brain, but these 
investigations are amongst thousands in a worldwide push 
to functionally map the human brain. 
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Su r g 
a H i storica 
Thi year mark the tenth anniver ary of the first laparo copic cholecystectomy to be performed on a human being. It was carried out by Philippe Mouret 
in Lyon, France. ' Since that time, the technologically 
exciting and innovative field of laparo copic surgery ha 
expanded to encompass a number of other intraperitoneal 
operations, as well a finding regular u e in thoracic 
surgery, orthopaedics, and otolaryngology. Because 
laparo copy i revolutionizing urgery in the late 20th 
century, now is an appropriate time to review its evolution 
and, in particular, its bearing on surgical practice. 
Physicians' attempts to examine the interiors of body 
cavities most likely began with the Greeks around 400 BC.2 
Chronicles from that time reveal tudents of Hippocrates' 
school employing rectal and vaginal specula. These devices 
were refined through the centuries, with Arabic physicians 
adding mirrors around 1000 AD. In 1806, Bozzini u ed 
lantern-light and a tube to view the urethra and vagina.2 
Thomas Edison's invention of electric light in 1879 
provided the precursor for the light sources used in 20th-
century laparoscopy. 
Modern-day laparoscopy ha its roots in the work of 
three early 20th-century pioneer . In 1901, Kelling 
established a pneumoperitoneum in a live, anaesthetized 
dog, with air filtered through terile cotton.3 Using a itze 
cysto cope (de igned in 1877), he in pected the stomach, 
oesophagus and other viscera of this fir t laparo copic 
subject, reporting his results at the German Biological and 
Medical Society meeting of the same year. Although his 
method and instruments were primitive, Kelling 
contributed ubstantially to the development of 
laparoscopy. 
In the same year, Dimitri Ott, a gynaecologist from 
Petrograd, pioneered his own version of laparoscopy, 
which he termed "ventroscopy".• Making an incision in the 
anterior abdominal wall of a pregnant patient, he examined 
the inside of the cavity using light reflected from a head 
mirror. Ott's technique re embled laparotomy more than 
laparoscopy because no endoscope was actually used, but 
the incision was held open with a peculum. 
If Kelling and Ott were pioneers in the development of 
laparoscopic tools and techniques, H.C. Jacobeus, in 1912, 
was the fir t to apply their innovations in a sy tematic, 
clinical fashion. 5 Jacobeus, moreover, did not re trict 
him elf to examining the abdominal cavity, but a! o 
devised endoscopic methods for examining the thorax. The 
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Swedish surgeon performed 115 examinations of the 
peritoneal and thoracic cavities in 75 patient , making 
laparoscopic diagno es of yphilis, tuberculosi , cirrho is, 
and malignancy. With the publication of hi report/ the 
modern era of laparoscopy was born. 
The following year brought many advance , with 
contributions from physics and surgery. The German 
hepatologist Kalk introduced a number of new innovations, 
including an oblique viewing scope with a 135-degree lens 
y tern, and the dual-trocar technique.6 The latter advance, 
in which two incisions are made o that two instrument 
can be employed, laid the foundation for modern-day 
laparoscopic surgery. Veress of Hungary developed a 
pring-loaded needle for safely creating a 
pneumoperitoneum; the Veress needle, almost unchanged, 
is till used to this day.7 Also of note is Semm's work, which 
involved the invention of a number of endoscopic 
in truments, mo t importantly an automatic in ufflation 
device which carefully monitors abdominal pres ure and 
ga flow.8 
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The development of light sources and optics did not lag 
behind that of other instrumentation for laparoscopy. 
Originally, light was provided by a bulb positioned at the 
end of the laparoscope.2 This proved to be unsatisfactory, 
however, a the device became very hot and often burned 
the hand of the operator. The first cold light source was 
developed by Fourestiere in 1943, who used a quartz rod to 
deliver light from an external source to the laparoscope2. 
Fibre-optic cable were added to the laparoscopic 
armamentarium in 1957, providing the cold light source of 
today. 
Until the late 19 Os, the role of laparo copy wa 
confined to diagnosis and selected gynaecologic 
procedures. In the 1930 , for instance, Kalk and Ruddock 
u ed laparo copy to diagnose intraperitoneal disea e, 
especially of the liver.9 Ruddock, a general practitioner in 
the US, published a eries of 500 cases (in which 39 
laparo copic biop ies were taken) in a major surgical 
journal, po ibly in an attempt to interest surgeons in the 
technique. 10 But the perception of laparoscopy among 
general surgeons as a blind and incomplete procedur , in 
which the surgeon was limited in viewing or palpating the 
interior of the abdomen, remained. 
Thi stereotype lingered until 1987, when the first 
laparo copic cholecystectomy was performed in a human 
patient. The event that made this pos ible wa the 
development of the ilicon chip television camera.2 This 
lightweight attachment to the endoscope allowed the 
laparoscopic image to be magnified on a viewing screen. 
Hence, a surgeon could be free to operate with the 
videolaparo cope held by an assistant. 
The advent of laparoscopic cholecystectomy ha 
revolutionized the management of gallbladder disease, 
and indeed the whole field of general surgery in the la te 
20th century. In a mere three-year period, the percentage 
of gallbladders removed by the conventional open 
approach fell from 100% to 10-20% in most ho pitals.11 
Moreover, it i e timated that over 5000 surgeons were 
trained in the laparo copic procedure in 1990 alone. 11 The 
benefits of gallbladder re ection by laparo copy are by 
now well-known: minimized po t-operative pain, 
reduced ho pital stays, and a faster return to full activity. ' 
Dri en by patient demand and the curiosity of 
intrepid, innovative urgeon , a number of other intra-
abdominal procedure have been adapted to the le s 
invasive laparoscopic approach. Inguinal hernia repair, 
appendectomy, and the treatment of benign gastro-
oe ophageal disease have all been approached by 
laparoscopy.2 Moreover, as noted above, therapeutic 
laparoscopy has found broad applicability in urology, 
gynaecology, ENT, orthopaedic and thoracic surgery. 
The vigorous enthu iasm for laparoscopic surgery 
exhibited by many patients and surgeon has been noted. 
It i critical, however, that any new application be 
subjected to rigorous cientific evaluation and analysis. If 
a laparo copic procedure is accepted becau e it is ea ier 
on the patient, de pite the po sibility that outcomes are 
ubstandard, then the operation will have been a 
"triumph of technique over common ense" .'2 
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INTRODUCfiON 
D eformity resulting from damage to the epiphyseal plate i o ne of the most difficult problems in Orthopaedic Surgery. Congenital anomalies, 
injury, tumour and infection can all lead to growth 
abnormalitie (Figure 1) in the form of limb-length 
discrepancy and/or directional deformity. Historically, 
many techniques have been used to manage these 
problems, but none of the limb-lengthening methods 
currently available in clinical practice is ideal. The 
number of clinical cases may not be large compared with 
orne diseases, but the burden is heavy because each 
patient i faced with a lifelong challenge. 
Pre ently, leg-length discrepancy can be managed 
using a number of different technique including : (1) 
epiphy iodesis; (2) epiphy eal stapling; (3) ingle-stage 
shortening of the longer limb; (4) single-stage lengthening 
of the horter limb; (5) timulation of epiphyseal-plate 
growth; (6) gradual lengthening by distraction; or (7) 
gradual biological lengthening (e piphyseal-plate 
transplantation). Each approach is discussed below with 
particular attention paid to the future po sibility of 
epiphy eal plate transplantation. 
EPIPHYSIODESIS 
Epiphysiode is is a procedure that arrests growth in 
the longer limb. The fir t reported case wa publi hed in 
1933 by Phemister.IU A method of prematurely arre ting 
epiphy eal plate growth in one or more of the epiphy eal 
plates in the longer limb was outlined. The procedure 
involves the complete destruction of the epiphy eal plate 
in the longer limb. 14 It ha to be timed very carefully to 
allow the increa ing length in the shorter limb to catch up 
exactly to that of the longer limb at the time of skeletal 
maturity. 
Thi procedure is completely reliable and can 
produce limb of equal length. Many consider it the 
treatment of choice for the correction of limb-length 
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discrepancies a it is straight forward and the child i 
di abled only minimally and for a short time.•9•79 It 
drawback, however, is that it shortens the longer limb 
and therefore results in two legs that are shorter than 
normal. 
EPIPHYSEAL PLATE ST APLI G 
Epiphyseal stapling is a technique which, 
hypothetically, hould re ult in a temporary retardation 
of growth of the longer limb. In 194 Haas demonstrated 
that when epiphy eal plate growth was interrupted by a 
wire loop, growth could resume upon its removal.28 The 
concept of epiphyseal stapling was sub equently 
introduced by Blount and Clark in 1949.8 Thi procedure 
differs from epiphysiodesis in that it can theoretically be 
rever ed by removing the taple when the limb-length 
di crepancy is corrected.29 This technjque was attractive 
becau e it alleviated the need to make accurate 
predictions of future growth. 
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The effect of tapling i primarily a mechanical 
restraint of growth but, perhaps secondarily, it ha been 
hown to cause a decrease in epiphy eal plate gluco e 
uptake, lactate formation, cellular proliferation and 
matrix synthesis.34 Stapling does not, however, inhibit 
growth a efficiently a epiphy iode i . In addition, 
problems have occurred because there is no guarantee 
that epiphy eal plate growth will resume after the taple 
are removed; the growth may continue a it hould, or the 
plate may fuse prematurely .n·25 Thi is al o a leg-
hortening procedure resulting in limb of les than ideal 
length. 
51 GLE-ST AGE LIMB SHORTEN! G 
Single-stage keletal shortening procedure are often 
carried out after keletal maturity ha been reached.711 The 
operation involve re ecting a portion of the shaft of a 
long bone. It is different from epiphysiodesis in that it is 
not based on predictions of future growth. 
Skeletal shortening, although reliable, can 
unfortunately produce mu cle weakne if 3 em or more 
of the tibia or 5-7 em or more of the femur are removed.'\2 
Single-stage hortening are, therefore, best done in cases 
where relatively mall changes in length are required. 
51 GLE-STAGE LIMB LENGTHEN! G 
Techniques to lengthen the s horter limb are 
theoretically preferable to tho e that horten the longer 
limb becau e they aim to correct the abnormal limb and 
produce an end re ult where the limb are of normal 
length. 
The first documented single-stage lengthening of the 
femur was attempted in 1905 by Codivilla with an 
oblique osteotomy and a sudden pull on a nail inser ted 
into the calcaneus.'6 He reported increa es in length of 3 
to 8 em in 26 ca es. Tibial lengthening was introduced in 
1927 by Abbott .' In the two decades that followed, 
lengthening of the tibia fell into relative disuse as a r ult 
of numerou complications including hock, para! sis, 
epsis, amputation and death . Since that time, many 
different techniques have been used where the gap 
between the bone ends is maintained by autograft or 
allograft bone and / or varying types of internal fixation 
devices.2.•o.• ·47 
EPIPHYSEAL PLATE STIMULATION 
Another method by which limb-length discrepancies 
have been managed is epiphy eal plate timulation in the 
shorter limb. A variety of techniques have been used to 
do this. 
Both experimentaJ20.26.JI.JJ.JM2•44•75 •.&J and clinical'5•43 •40 
example of perio teal division or stripping have resulted 
in increa ed epiphy eal plate growth. There are a number 
of theories a to how this works. A favoured explanation 
i related to the release of ten ion exerted by the 
perio teum on the epiphy eal plate.54 
Mo put forward this biomechanical theory.53 It wa 
propo ed that the perio teum acts as an elastic I eve 
which i ubject to ten ile forces when the epiphy eal 
plate grows. As a re ult, the chondrocytic columns are 
indirectly compressively loaded through their 
collagenous network and growth is slowed . Th e 
perio teum counters thi stres by growing interstitially 
resulting in a decompression of the epiphy eal plate and 
growth s timulation . This is based on the Heuter-
Volkmann Thesi which po tulates that epiphy eal pla te 
compress ion cause a decrea e in growth and 
decompres ion the oppo ite.'-'.73 
The biomechanical explanation is further supported 
by studie which have demonstrated that incompl te 
perio teal transection tend to lead to growth stimulation 
only on the side w here the perio teum i relea ed.6.n·"' 
Surgical t rials have hown that the most favourable 
results are achieved in younger patients with faster 
growing epiphyseal plates and when the divi ion is made 
do e to the epiphy eal plate that i to be timulated .43•44·'"'..., 
It has not, however, been hown to be clinically u eful as 
the overgrowth is mall and inconsistent. '2 
Another technique that ha been u ed to timulate the 
epiphysea l plate is inserting foreign material in the 
ubepiphy eal region.• Case have been reported in which 
ivory or metallic crew have been inserted into the 
ubepiphy eal region of the proximal end of the tibia and 
di tal end of the femur re ulting in growth stimulation 
varying from 0.2 to 2.2 em. Unfortunately, no tandard 
amount of length increase could be predicted, making 
this technique unreliable.•• Other technique have also 
been pro posed but non e has been very u eful 
clinically Y.J2.4S.I>2 
Several different techniques that rely upon the 
distraction of bone or cartilage to lengthen the limb have 
been u ed. They are discussed below. 
Distraction and Bone Grafting 
Gradual distraction followed by the filling of the gap 
with bone graft has been done for many years. '7.24•00.74•76•77 
For the e techniques, the bone and periosteum are cut. 
Although it is po sible to attain large increa es in bone 
length, the e procedure are as ociated with many 
hazards and complications often related to the number of 
operations required.52 
Epiphy eal Plate Distraction 
Chondrodiata i , introduced by DeBastianF'.22, is 
another distraction technique. It involves slow and 
gradual epiphy eal plate distraction re ulting in bone 
lengthening by extending epiphyseal plate width without 
forming a fracture gap. The increase in epiphyseal blood 
upply and the tension exerted on the epiphyseal plate 
induce a increase in its activity. 22 Upon completion of the 
di traction, the epiphyseal plate continues to function. 
This re ult in an increase in total bone length. 
Epiphy iolysis, introduced by Monticelli and Spinelli 
and other 21•49.so.s• , is a different technique which employs 
traction forces that exceed the strain tolerance of the 
epiphy eal plate, re ulting in a fracture at the junction of 
the epiphy eal plate and the metaphysis. The heights of 
the proliferative and hypertrophic zone expand . 
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Increa ed proliferation i detected adjacent to the fracture 
gap in the hypertrophic (only initially) and proliferative 
zone cell populations.• The longitudinal expansion of the 
epiphyseal plate is in part associated with increased 
epiphy eal and decrea ed metaphyseal blood supplies.3 
The bone length increase i the result of biologic 
processes comparable to tho e of the Ilizarov technique 
discus ed below.21 
When considering epiphy eal plate distraction it 
should be noted, however, that the complication rate is 
high, the procedures are painful, and the epiphyseal plate 
may be irreversibly damaged.30•19 
Distraction Osteogenesis 
Today, Ilizarov's experimental and clinical studies on 
controlled mechanical distraction osteogenesi have 
permitted the lengthening of limb through conditions 
that allow new bone formation in di traction gaps.37 
The biological principle behind Ilizarov' technique, 
called the Law of Tension-Stress, purports that well-
vasculariz ed, weight-bearing tis ue that are subjected 
to slow consistent traction are metabolically activated, 
triggering proliferative and biosynthetic cellular 
processes.38 
Distraction o teogene i involve a metaphyseal or 
ubmetaphy eal corticotomy followed by the application 
of an external fixation device that allows loading. 
Ilizarov' technique differs from other becau e the 
periosteum is not cut and distraction is delayed until 
fracture callus forms so that it may be distracted. After a 
pecified waiting period, the limb i gradually distracted. 
Osteogenic activity within the di traction pace re ult in 
lengthening of the horter limb J8 The process correlates 
fracture repair with di traction .'9 With highly table 
fixation and specific rates of distraction (approximately 1 
mm / day) 38•39, the gap is eventually filled with newly 
formed bone. The resulting trabeculae lie parallel, in both 
directions, to the longitudinal axi of elongation initiated 
at the centre of the defect. 38 In children, the procedure i 
de igned so as to minimize ten ion at the epiphy eal 
plate."' 
It ha been recommended that distraction techniques 
be used only for limb-length discrepancies of 5 em or 
greater. The joints proximal and distal to the elongated 
bone must be stable, the neuromuscular function and 
circulation must be normal and the patient mu t have the 
mental capacity to cooperate with the imperative 
po toperative schedule a sociated with distraction 
device . The e procedure , however valuable in certain 
cases, may not be ideal in situations involving joint 
instability, paralysis (lengthening could further weaken 
musculature or promote hyperten ion as a re ult of 
stretched nerve fiber ), poor bone tructure, mental 
instability or young children.71J It hould al o be noted 
that the distraction period is painful, not well tolerated, 
and subject to numerou complication .71J 
Featu r e Sect i o n 
GRA D UAL BIOLO GICAL LE G T H E 
EPIPHYSEAL PLATE TRANSPLANT A TIO 
The possibility of carrying out revascularized 
epiphy eal plate tran plantations has intere ted 
microvascular surgeon for some time. In theory, 
microvascular epiphyseal plate transplantations could 
form the ideal solution to a wide variety of clinical 
problems, particularly tho e involving congenital absence 
of an epiphyseal plate or damage/destruction of an 
epiphy eal plate at an early age. 
Unlike conventional limb-lengthening technique , a 
revascularized epiphy eal plate transplant should 
maintain its ability to grow and increase bone length until 
it fu es at skeletal maturity. The technology necessary to 
carry out microva cular epiphy eal plate transplantations 
i available and investigator have hown that, providing 
that the microva cular anastomose are patent, the e 
grafts remain viable and continue to grow in length.12 A 
small number of clinical autograft transplantation 
operations have now been done.27.55.56.57.SS.M.I>0.68.7I.72.82.84 
Allograft epiphyseal plate transplants offer 
theoretical advantages over autografts a they reduce 
donor-site morbidity and allow the surgeon to choose 
from a large number of donor sites to find the ideal graft. 
Although experimental allograft transplants have been 
ucce fully carried out in the laboratory 1 2.ll .<~~.t>•, current 
immunosuppression techniques are ufficiently toxic that 
clinical ca es must till rely on autograft donor tissue. 
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Minimally Invasive Coronary 
Artery Bypass Grafting 
INTRODUCfiON 
Minimally invasive direct coronary artery bypass grafting (MIDCAB) i a surgical intervention aimed at reva cularizing cardiac ti ue without 
using cardiopulmonary bypass (CPB) or performing a 
median sternotomy. The idea of performing coronary 
artery bypass grafting (CABG) without u ing CPB is not 
new. In 1958, Longmire performed the fir t left internal 
mammary artery (LIMA) to left anterior descending 
coronary artery (LAD) bypas on a human as a 
complication of a thrombo-endarterectomy procedure on 
the beating heart. 1 Beating-heart surgeries continued until 
the late 1960s, when cardioplegia with CPB gained 
widespread use. Hypothermic cardiac arrest with CPB and 
microsurgical anastomotic techniques wa utilized by 
Spencer in 1964 leading to excellent long-term patency of 
the LIMA-LAD graft_2 
Traditionally, CABG ha been performed u ing the 
median sternotomy technique in which the ternum is 
divided longitudinally, the ribs are laterally retracted and 
the pericardium is expo ed. Cardioplegia is achieved by 
thermal or chemical means and CPB is initiated providing 
oxygenation and driving circulation. Ana tomosis is 
performed on the arrested heart allowing for maximum 
control of the operating field and simplified technique. 
World-wide, over 800,000 bypas surgerie aimed at 
reva cularizing cardiac tissue are performed each year 
utilizing both arterial and vein grafts.3 In-ho pital mortality 
of thi procedure is le than 1% for elective case and 
morbidity is very low.2 One of the most significant causes 
of po t-operative morbidity in patient who have 
undergone traditional bypa grafting are complications 
related to the cardiopulmonary bypass itself. The use of 
extra-corporeal circulation can cause a sy temic 
inflammatory response, which can lead to organ injury and 
po toperative morbidity.• Implicated factor include 
urgical trauma, contact of blood with the extracorporeal 
circuit, and lung reperfu ion injury on di continuing 
bypass .• Owing to these complication and the 
inva iveness of the procedure, the rationale for developing 
new methods of revascularizing the heart is apparent. 
Currently, two therapeutic options are available for 
patient with inadequate coronary circulation. Cardiac 
revascularization is accomplished by CABG or 
percutaneous transluminal coronary angiopla ty (PTCA). 
Randomized trial comparing the two treatment options in 
cases of multive sel disease have shown that the 
procedures have imilar mortality rates and occurrence of 
composite end points (death, Q wave myocardial 
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infarction, or large ischemic defect on thallium scanning).5 
However, PTCA-treated ca es are sub tantially more likely 
to require repeat revascularization. According to the EAST 
investigation, which involved 392 participants, after three 
years 13% of patients who received CABG a their method 
of treatment required repeat revascularization and over 
50% of PTCA patients required repeat reva cularization.5 
The surgery group also hawed a greater degree of 
perfusion and fewer angina symptoms.5 
Similar studies in Germany (GABI trials) involving 359 
participant found that 44% of PTCA patient required 
further intervention within one year, while only 6% of 
CABG patients required a follow-up procedure.6 However, 
median ho pitalization time for the PTCA group wa only 
five days in comparison with 19 days for the CABG group.• 
Additionally, new advance in PTCA, including the 
increa ing use of stents, may substantially enhance the 
long-term patency of this form of reva cularization. 
Reviewing the common current therapies, there 
appear to be the opportunity to develop a procedure 
which is less inva ive than traditional CABG and more 
definitive than PTCA . Minimally invasive bypas 
technique through a left thoracotomy may eventually 
ervice this need, providing a definitive urgical olution 
with diminished po t-operative morbidity and hospital 
co t. 
SURGICAL PRO EDURE 
As a developing surgical technique, there i 
considerable variation in how the MIDCAB procedure i 
performed. The original MIDCAB procedures were single 
LIMA to LAD ana tomoses, although more recent 
advances in technology and technique have allowed 
multiple bypas es using both left and right internal 
mammary arterie a well as inferior epiga tric and 
ga troepiploic arteries . Typically, standard cardiac 
anesthesia is applied and the patient is intubated with a 
double-lumen endotracheal tube, which can deflate the 
left lung, facilitating thoracoscopic dissection of the 
LIMA. 7•8 Tran e ophogeal echocardiography may be 
employed to follow ventricular wall motion.8 
The LIMA is revealed through a left anterior 
thoracotomy with the patient in the 30-degree left lateral 
decubitus po ition, often with left arm raised over head.8•9 
It can also be harve ted u ing a thoraco cope placed 
either through a trocar in the fourth interco tal space at 
the posterior axillary line or through the thoracotomy 
it elf.7 The pedicle of the LIMA is dissected and 
mobilized towards it origin and di tally to 
approximately the sixth costal cartilage." The patient is 
heparinized and the dissected pedicle is injected with 
papaverine, a smooth muscle relaxant, preventing arterial 
pam. 
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Pericardial incision is made and control of the LAD 
on the beating heart is established using snare sutures 
proximally and distally to the site of anastomosis. Since 
performing the anastomo is may require up to 20 minutes 
of coronary-vessel occlusion, monitoring ventricular wall 
motion is critical to ensuring that hemodynamic stability 
is maintained. 10 In vessel which are less than 75% 
occluded, significant segmental wall motion disturbance 
has been noted when occlusion times are in exce of 
twenty minutes.10 Ischemic preconditioning by repeatedly 
occluding and releasing the ves el or using drugs such as 
adeno ine has been propo ed as a method of dimini hing 
h y pocontractility while the anas tomosis is be ing 
performed. 
If necessary, the heart is slowed, and the anastomosis 
is performed under direct vision using tradit ional 
suturing techniques with a blower device to keep the 
operative field clear.9 
CLI ICAL DATA 
Although this technique has only recently gained 
interest in orth America, in nations with limited ace to 
CPB equipment it has been used on hundreds of patients 
and clinical information is available. In Brazil, Buffolo t al. 
have performed over 1200 bypass surgeries without CPB 
and completed several tudies comparing their outcomes 
to those of traditional CABG with CPB. In one study, they 
found that patients with CPB had a statistically significant 
(p<0.05) increased risk of arrhythmias, pulmonary, and 
neurological complications than those who did not go on 
CPB.11 Average hospital s tays were 5.2 d ays for those 
operated without CPB and 9.6 days for those operated with 
CPB. Total hospital costs were about US $3300 less per case 
when CPB was not used, with most savings coming from 
the u e of less disposable equipment in the operating 
room.11 
In Italy, Calafiore found that in a study of 378 patients 
undergoing MIDCAB, 24-month surv ival was 97.9%, 
which compares favourably with the traditional CAB 24-
month survival rate of 94% as determined in the EAST 
trails.5•12 In the US, Landreneau et al. performed MIDCAB 
on 46 patients and reported patent anastomoses in all cases 
as verified using ultrasound Doppler flow a e sm nt. 13 
Their study reported a median hospital stay of 4.3 days.13 
Similar ho pital stays were reported by Benetti et al. in 
studie in Argentina, Italy, and the etherlands.9•14 In 
Germany, Reichenspurner et al. performed 12 MIDCAB 
operations and reported a mean ho pital stay of 8.0 days.15 
By comparison, the GABI study, also from Germany, 
reported a mean hospital stay of 19 days for traditional 
CABG.6 
Unfortunately, much of the information available 
about MIDCAB is not based on trials in which patien are 
randomly assigned to traditional CABG and MID AB 
groups and the outcomes of the two groups are followed 
over a long period.16 There are few orth American data, 
and virtually none from Canada about this procedure to 
date. A joint committee of the Society of Thoracic Surgeons 
and the American Association of Thoracic Surgeon has 
recently tarted critically evaluating the use of this 
procedure.16 
CONCLUSION 
The initial studies regarding MIDCAB appear to be 
very encouraging. The promise of shorter hospital stays, 
decreased morbidity with no CPB-related complications, 
and lower hospital costs with definitive surgical result is 
very enticing. With continued refinement of surgical 
technique and technological innovation, MIDCAB is 
providing a viable, minimally invasive, definitive 
intervention to revascula rize cardiac tissue. It will 
provide the patient with a new therapeutic option in 
addition to PTCA and traditional CABG, which have both 
improved the lives of millions of patients around the 
world. With the development of methods to perform two 
and three grafts using the MIDCAB approach and the 
promising results of new stent techniques with PTCA, 
significant longitudinal tudies will be necessary to 
determine the exact niche of each therapeutic modality in 
an era of declining health care resources and an aging 
population. 
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Obstetrical U It 
Past, Present 
rasound: 
and Futu re 
Since the introduction of ultrasound to the field of obstetrics in the early 1960s, its number of uses and its ability to image the fetus have dramatically 
increased. 1 Advances in ultrasound technology have 
permitted imaging of the fetus in both tatic and dynamic 
states, opening the door to earlier determination of fetal 
age, early detection of multiple pregnancies, diagnosis of 
fetal anomalies and evaluation of fetal well-being. 
WHAT IS ULTRASOUND? 
Diagnostic Ultrasonography u es sound waves in the 
ultra ound frequency range to create images. Ultrasound 
is any sound wave with a higher frequency than is 
audible to the human ear. The range of frequencies that 
can be heard by humans is approximately 20 to 20,000 
Hz . Ultra ound image are created by tran mitting a 
ound wave from an emitter through a medium: air, fluid 
or olid. These waves travel faster through den er object . 
When a sound wave crosses an interface between objects 
of different densities, orne of the wave i reflected back 
and orne is tran mitted through. The receiver positioned 
next to the emitter picks up the reflected wave. A 
processor then calculate the distance to this object from 
the emitter by measuring the time it took for the reflected 
wave to return. This method, known as the A-mode, is 
the basis for SO AR detection of submarines. It was u ed 
on the fir t diagnostic ultra ound machine .2 
Types of Ultrasound Scanners 
In the early to mid-1970 , B-mode grey-scale static 
imaging became the dominant scanning mode in 
diagnostic ultra ound. B-mode measure the distance the 
object interface is from the emitter, and draws a 
corresponding coloured dot on a display screen 
repre enting that spot. The intensity of colour of the dot 
corresponds to how much of the wave was reflected back. 
The portion of the wave which is transmitted through the 
interface continue till it hit another interface and is 
partially reflected back, and o on till the wave dissipates. 
It is for this rea on that pelvic ultra ound examinations 
are performed with a full bladder. The fluid in the 
bladder transmits the wave with fewer reflection , 
allowing it to penetrate the deep pelvic structures. These 
numerous reflections along a single line of sight form a 
picture of the object along a ingle axis. To form an image 
of a plane within the subject, many waves are sent out 
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from the emitter along different line of sight over a 10 to 
20-second period and are saved in the scanner' memory. 
The computer combines the results to form a 2-D picture 
of the object on the creen. The more lines of sight that are 
emitted, the greater the resolution of the picture. Most 
scanner use between 50 and 200 lines. Loss of resolution 
can occur if the object moves while being scanned since 
the information from the individual lines of sight are 
acquired at different times.3 
Advances in ultrasound continued with the 
development of real-time canners. These scanners use a 
modification of B-mode. They make a 2-D picture as 
described above, then rapidly can over the same area 
again to make a econd picture and so on . The e 
equential picture are like the frames of a film, allowing 
the ob erver to visualize movement of the object. The 
more rapid the movement of the object, the quicker the 
canner has to take pictures - i.e. the higher must be the 
frame rate- to keep the motion from appearing jerky on 
the creen. Scanners are currently available with frame 
rates from 5 to 40 image per second. Mo t institution 
use real-time canners for all of their obstetrical imaging. 
Some advantages of real-time scanning are that it it shows 
fetal movement, it allows rapid changes in the can plane, 
and it reduces total examination time becau e the 
operator gets in tant feedback about anatomical 
structures in the field of view.3 
A recent development is the Duplex scanner, a 
combination of real-time ultrasound with Doppler 
ultrasound. Using the Doppler phenomenon, the canner 
can determine if an object is moving away from or 
towards the emitter. Sound waves can be bounced off red 
blood cells to determine the direction of blood flow in 
ves els. When colour is added, it helps delineate ve sels 
in the placenta, umbilical cord, and fetus•. The hand-held 
ultra ound stethoscope used by obstetricians for 
detecting fetal heart sounds u es the Doppler principle to 
detect heart-wall motion. 
How Safe is it? 
One of the reasons ultra ound was so quickly 
adopted into the field of obstetric and gained such wide 
use o quickly wa its use of ound waves instead of 
ionizing radiation. At pre ent, there are no confirmed 
biological effect on fetuses from the use of diagnostic 
ultra ound. 5 Randomized clinical trials have been 
performed which howed no difference in 
developmental, neurological, or psychological outcomes, 
with as much as 12 year follow-up. 6 Theoretical afety 
risks from ultra ound energy include viscous tress, 
thermal damage and cavitation effects. High levels of 
ultrasound intensity can cause agitation of molecules 
leading to increases in temperature. Ultrasound-induced 
cavitation in tissues can result in disruption of molecular 
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bond and free-radical production. Vi cous stre e can 
occur at ti sue boundarie leading to disruption of 
membranes at the interface.2 The Bioeffects Committee of 
the American In titute of Ultra ound in Medicine 
relea ed a ta tement on current re earch and concluded 
that with the judiciou u e of ultra ound, the benefit 
outweigh any potential risks.7 
CURRE T USES _I PREGNANCY 
The number of clinical ituations in which ultra ound 
examination is recommended has grown rapidly with the 
advance in re elution. It' low-risk, non-inva ive 
properties also make it an attractive choice for evaluation 
of the fetus. The ational In titute of Health Con ensus 
Development Conference reviewed the available 
literature on ob tetric ultrasonography in 19 4 and 
produced a list of clinical situations in which ultra ound 
might be beneficial. They are hown in Table P . At that 
time they did not endorse routine ultrasound creening in 
the US because of a lack of evidence that it benefited the 
low-risk fetu . Other countries uch a Germany, 
England, orway and Canada endorse routine creening. 
In Germany, two routine ultrasound examination are 
performed at 1 and 30 week of ge tation. The e are 
integrated into the maternity-care regulation and are 
covered by sickness fund . o pro pective, randomized 
study on the effectivene s of this policy has ever been 
conducted. '0 The Canadian Ta k Force on Periodic Health 
Examination reviewed the current literature on prenatal 
ultra ound creening in 1992 and concluded that there 
wa fair evidence to support the inclusion of a ingle 
routine ultrasound examination, usually between 16 and 
20 weeks gestational age, in the management of women 
with no clinical indication for prenatal ultra onography. 
They al o concluded that there was poor evidence to 
upport routine erial ultrasound creening in women 
with no clinical indications." 
Thi article will address in further detail the u e of 
ultra ound examination for estimation of ge tational age 
and weight, and for detection of multiple pregnancies 
and malformations. 
Estimation of Fetal Age and Weight 
The accurate e timate of fetal age allow the 
ob tetrician to determine the approximate date of 
spontaneou deli ery or plan for the elective delivery of 
the baby at term (37 to 42 weeks). Accurate dates allow 
the ob tetrician to implement the nece ary measures for 
both preterm deliveries (i.e. RDS prophylaxi ) and p t-
term deliverie (i.e. induction). Compari on of the 
ultra ound-determined age with the age calculated from 
the la t normal men trual period allows the obstetrician 
to evaluate the rate of fetal growth. Ultra ound estimates 
of fetal age are given in the number of menstrual weeks, 
thus allowing for quick comparison. 
Ge tational age can be e timated during the first 
trimester using crown-rump length or ge tational sac 
size. Crown-rump length is the preferred method and 
when performed between 7 and 12 weeks is accurate 
within plu or minus 5 day .12 The high degree of 
accuracy at thi stage in the pregnancy is thought to be 
due to the small amount of biological variability in fetal 
ize during the early stages of development, and to the 
rapid rate of growth. Later on in the pregnancy, genetic 
and environmental factor play a larger role in fetal ize. 
Figure 1. High-resolution, real-time ultrasound images of fetal head on left , the abdomen in middle, and femur on rig/Jt in a 16-week fetus. 
Suitable images for age estimation. 
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Figure 2. A. Transvaginal ultrasound image of monochorionic, diamniotic hoins in a 12-week pregnancy. B. Arrows indicate diamniotic membrane. 
Determination of age during the second and third 
trimesters is calculated using a variety of fetal 
mea urements. The four primary mea urement used are 
biparietal diameter, head circumference, abdominal 
circumference and femur length as shown in Figure 1. 
Real-time scanning has increased the ease and accuracy of 
taking the e measurements. These measurements are 
plotted on tables corre ponding to menstrual age 
e timates and an average of the four i calculated. Thi 
average can be determined by simply dividing by four, or 
can be calculated using linear regre ion equations to 
increa e the accuracy of the e timate. With the u e of 
linear regre sion equations, the accuracy of the age 
estimate in one study wa quoted as estimated age plus 
or minus 7% at any time during the pregnancy.12 For 
example, a 30-week agee timate would have an accuracy 
of plus or minus 2.1 weeks. 
Fetal weight estimates are calculated in the arne 
manner using combinations of the fetal measu rements 
described above. Fetal weight estimates are quoted from 
variou studie in the range of plu or minus 12 to 25%. 12 
In the future, advances in 3-0 ultrasonography may allow 
accurate calculation of fetal volume, thus improving fetal 
weight estimation. 
Multiple Pregnancies 
Multiple gestations are at increased risk of perinatal 
morbidity and mortality from a variety of causes. Early 
diagno i of multiple gestations allow do e monitoring 
of the pregnancy and early decision-making regarding 
Figure3. A. Parasogital ultrasound image of the spine showing a myelomeningocele sac (5) beginning at 1..5 . B. Transverse image shows splayed 
posterior elements (arrows). 
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management and delivery . Thirty per cent of all 
unscanned twin pregnancies are clinically missed until 
birth.13 An ultra ound can hould be performed between 
16 and 18 weeks for size, fetal number, placentation, 
visualization of the membranes, amniotic-fluid volume 
and congenital anomalies. Determination of the type of 
placentation provides prognostic information for the 
obstetrician as morbidity and mortality rates vary with 
chorionicity and amnionicity. For example, the mortality 
rate for monochorionic, monoamniotic twins is 50% 
compared with 9% for dichorionic, diamniotic twins. '• A 
first-trimester ultrasound of monochorionic, diamniotic 
twins is shown in Figure 2. Serial ultra ound during the 
pregnancy can monitor growth and creen for anomalies 
as there is a higher incidence of anomalies and 
intrauterine growth restriction in multiple ge tations.13 A 
third-trimester ultrasound can give information on the 
position of the fetuses and placentae thu aiding in the 
decision of vaginal ver us caesarean delivery. 
Congenital Anomalies 
With ultrasound, many congenital anomalies can 
now be diagnosed ea rl y in pregnancy. In high-risk 
populations, the accuracy of diagnosis i over 90%. 9 
However, the accuracy is still highly dependent on the 
ty pe of congenita l malformation, the quality of the 
Featu r e Sect i o n 
equipment and the expertise of the sonographer. C S 
anomalies are some of the more common a nomalie 
picked up on ultra ound between 16 and 20 weeks. A 
cro s-sectional view through the ventricles can pick up 
hydrocephalus, which i often the presenting sign of 
subarachnoid haemorrhages, Dandy-Walker syndrome, 
spina bifida occulta and aqueductal stenosis. Views of 
the hemispheres and cerebellum can detect anencephaly 
and cerebellar agene is. Spinal anomalies such a spina 
bifida occulta with a ociated meningocele or 
myelomeningocele can be detected by longitudinal and 
cro s-sectional views of the spine. Figure 3 shows an 
image of a myelomeningocele. Gastrointestinal 
anomalies commonly detected in the second trimester 
include omphalocele and ga tro chisis. Duodenal atresia 
ca n be diagnosed by the characteristic image of an 
overdistended stomach and enlarged duodenum. This is 
known as the double-bubble sign. Fetal kidney can be 
een by ultra ound routinely at 18 weeks, thus allowing 
detection of major abnormalities such as agenesis. '3 
Congenital heart disease is one of the most common 
co ngenital malformation . A cross-sectional, four-
chamber view of the heart after 16 week of age has the 
potential to pick up 50 to 60 % of congenital heart 
malformation . However, it has been shown that only 
10% of congenital heart di ease is diagnosed prenatally.9 
Table 1. Indications for Ultrasound Examination* 
1. Estimation of Gestational Age: uncertain 13. Vaginal Bleeding not yet diagno ed 
or verification of dates for cae arian, induction 14. Su pected Fetal Death 
or termination of pregnancy 
2. Evaluation of Fetal Growth: 15. Suspected Uterine Abnormality 
uteroplacental insufficiency uspected 16. Localize IUD 
or pregnancy complication 17. Monitor ovarian follicle development 
3. Estimation of Fetal Weight: PROM, 18. Biophysical Profile: fetal well-being premature labour 
after 28 weeks, limited prenatal care 
4. Determine Fetal Presentation: uncertain 
pre enting part 19. A sist Delivery: 2nd twin, placenta removal 
5. Su pected Multiple Gestation: multiple fetal 20. Suspected Polyhydraminos/Oligohydramnios 
heart beats, increased SF height, fertility drugs 21. Su pected Abruptio Placentae 
6. Serial Evaluation of Multiple Gestation 22. Follow-up of Congenital Anomaly 
7. Discrepancy in size compared to dates 23. Previous Congenital Anomaly 
8. Pelvic Mass on clinical exam 24. Abnormal AFP level for age 
9. Suspected Hydatidiform Mole: high BHCG 25. Adjunct to In Utero procedures: fetoscopy, 
10. Ovarian Cysts on pelvic exam shunt placement, chorionic villous sampling 
11. Suspected Ectopic or screen in high-risk 26. Adjunct to External Version 
12. Localize Placenta after prior previa identification 27. Adjunct to amniocentesis 
,. adapted from Carmel SH, D=Alton ME. Diagno tic ultra ound in pregnancy: an overview. Seminol Perinatol 
1994;18(3):117-32. 
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FUTURE DEVELOPMENTS 
Real-Time Scanning 
The re olution and frame speed of real- time 
canning continue to increas e . This development 
permits access to the fetu . Procedures u ch a 
amniocentesis, chorionic villou sampling and fetal 
blood ampling have been made possible and afer by 
ultra ound. Developments in the area of in utero 
urgery such as feto copy are guided by high re olution, 
real-time ultrasound.15 
Scanning Techniques 
During the last 10 years, ever- mailer probe have 
led to n e w technique s u ch a s transvaginal 
ultra onography . Th is technique h a improved 
resolution by allowing the sound waves to be sent 
directly into the deep pelvic region, thus avoiding 
transmission through the bladder as in the ca e o f 
abdominal ultra ound. The addition of Doppler and 3-D 
ultra ound to these small probes i becoming po ible a 
the miniaturization of electronics continues.3 
Contrast Agents 
The purpose of these agent is to increa e image 
quality by changing the acoustic propertie of ti ues in 
which they reside. Agent are being developed w hich 
displace air from the path of the ound wave thu 
allowing deeper penetration and less reflection. Another 
group of agents is used to increase the echogenic 
property of the organ being vi ualized by introducing 
encap ulated, air-filled micro pheres. 
3-D Ultrasound 
One problem with 2-D ultrasound is the small field 
of view and the inability to see neighbouring anatomy. 
Interpretation of the anatomy is accomplished clinically 
by making many slices. This is made easier and quicker 
with real-time ultrasound. Sometime a view through 
the third axis, the z-axi , is not possible with 2-D 
ultra ound because of other anatomy blocking the line 
of sight. 3-D ultrasound is being developed to provide 
the mi sing z-axis, thus eliminating the need for many 
lices to be made by the operator. Currently 3-D 
ultrasound is in its infancy . It i following much the 
same cour e of development as 2-D ultra ound did over 
the la t 20 year , but at a faster rate. At this time in it 
development, only tatic views are available. The 
complex emitter / tran ducer is quite bulky, and 
reconstruction of the 3-D view i very time-con uming. 
A clinical trial performed on an experimenta l 3-D 
canner found that the third axis helped pick out orne 
features not seen in the other 2-D views .16 Ano ther 
promi ing feature i its ability to estimate volume. Thi 
can be applied to improving the accuracy of fetal weight 
and agee timation. With the development of high- peed 
computers and the miniaturization of complex 
electronics, 3-D real-time ultrasound may be a reality in 
the near future . 
Advances in technology have made ultra ound one 
of th e fa tes t g rowing and most exciting area o f 
di ag nos tic imaging. Ultrasound has beco me 
co mmonplace in obste trical practice as a tool fo r 
diagnos i and for evaluation of fetal well-being. It 
continues to establi h it elf in medical practice as a safe, 
non-inva ive method of imaging. If the pa t 20 years are 
any indication, ultrasound imaging will continue to 
improve and expand in use well into the future . 
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Peripheral Nerve 
BACKGROUND 
Peripheral nerve injurie are a common entity 
as ociated with mu culo keletal trauma. Simple axon 
tran ection may be repaired by suturing the opposing 
epineurium or corresponding fa cicles of the two 
oppo ing neural stumps. ' This allows prouting axons to 
enter the di tal nerve stump and regenerate through it to 
contact and reinnervate peripheral end organs. Such axon 
regeneration follow the process of Wallerian 
degeneration which serves to clear the distal stump of 
axopla m and myelin in preparation for subsequent axon 
regeneration.2 However, in the situation where large gaps 
exist between the cut axonal ends, they cannot be 
oppo ed primarily without tension. In these cases there is 
the necessity for nerve grafting.' 
The e deficits pre ent a recon tructive challenge for 
the surgeon. Currently, nerve grafting involves using a 
sensory autograft acquired from the patient. This clearly 
is as ociated with donor-site morbidity such as a loss of 
sensation, scarring and neuroma pain over the harvested 
area.3 A commonly used ource is the cutaneous sural 
nerve, which is located in the po terior aspect of the 
lower leg. ' Another consideration is the possibility of 
inadequate expendable autogenous nerve grafts to allow 
for optimal recon truction. • 
Peripheral nerve allografts present a favourable 
alternative to autografts . ot only are donor-site 
complications eliminated, but there is a limitless supply 
of graft rna terial. evertheless, there is a rejection 
re ponse elicited by the allograft ti ue. Consequently, 
immunosuppression with it associated complications is a 
nece sity when this reconstructive avenue is utilized.5.1> 
The nerve allograft serves only as a temporary 
caffold for regenerating host axons. Host Schwann cells 
eventually replace allograft Schwann cells.7 Therefore, it 
is possible to discontinue immuno uppres ion after the 
sprouting axons have transver ed the allograft.8•9 U ing 
the e principles, the first peripheral nerve allograft was 
performed by Dr. SE Mackinnon in 1988.• 
CASE REPORT 
An 8-year-old boy sustained everal injuries to both 
legs by a motor boat propeller on May 29, 1988.• Among 
these injuries, he had an extensive left sciatic nerve injury, 
a 23-cm gap which extended from the proximal gluteal 
region to the region of the popliteal fossa. Peripheral 
nerve tran plantation was considered as an alternative to 
limb amputation. 
On September 24, 1988, a suitable donor, with respect 
to blood type and antigen profile, was located in London, 
ABOUT THE AUTHOR 
Dariusz Brzozowski is a fourth-yenr medical student at 
UWO with an interest in plastic and reconstmctive surgery. 
Feature Section 
Transplantation 
by Dariusz Brzozowski 
Ontario. Ten nerve graft from both upper and lower 
limb of the donor were prepared and microsurgically 
used for the patient's sciatic nerve reconstruction. 
Immunosuppression wa achieved using 100 mg of oral 
cyclo porin A twice daily, and 10 mg of oral prednisone 
once daily . Thi regimen wa begun the evening of 
surgery and continued until there wa evidence of 
sen ation in the peroneal and posterior tibial nerve 
distribution 26 months after surgery. 
Presently, the patient walks unassisted and is free of 
pain . Although his sensations are quantitatively 
diminished, he is able to perceive painful stimuli, light 
touch and vibration in his left foot. He has no evidence of 
motor recovery. 
DISCUSSIO A D SUMMARY 
The rate of peripheral nerve regeneration witnes ed 
in thi case was the same as would be anticipated using 
autogenou graft material. erve regeneration is limited 
to approximately 1 mm per day .10 Given the large 
distance between the most proximal nerve injury and the 
muscle target in this case report, the lack of motor 
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recovery could be anticipated. It i known that muscle 
mu t be reinnervated within 18 to 24 month for 
functional recovery to be po ible. 11 In contrast, ensory 
receptors can be reinnervated even year after a nerve 
injury to provide rea onable sensation.'2 
With the advent of the first uccessful peripheral 
nerve transplantation, the capacity of reconstructive 
surgery has e calated. As outlined in theca e above, this 
development offers an alternative to limb amputation and 
can repair at least orne of the morbidity associated with 
peripheral nerve loss. It is in extensive injuries where the 
ources of expendable donor nerves required for 
allografting a re insufficient for reconstruction that 
peripheral nerve tran plantation is most useful. 
Future developments will focus on attempt to 
reduce graft immunogenicity. Recent inve tigations have 
involved graft pretreatment13 and manipulation of the 
host's immune system.14 
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Virtual Reality 
For the past two years I have had the great opportunity to work at the Human Interface Technology Laboratory (HIT Lab) at the University 
of Washington. This facility is unlike any other in the 
world, as we work on development of fundamental 
technologies and applications for Virtual Reality (VR) . 
WHAT IS VIRTUAL REALITY? 
VR is based on active interaction with a computer 
graphics environment. Many things in our society of the 
late 1990s are described as "virtual", but few are true VR. 
In a VR system, a head-mounted display (HMO) presents 
an image to each eye that is created by a computer 
graphics engine. The image is of a scene, or "virtual 
environment", a place that is completely generated by the 
computer. The key to VR is interactivity with this 
environment. As the user moves his head and body, 
ensors detect the changes in position. The computer is 
fed the new coordinate and the image sent to the HMO 
is updated to correspond to the new point of view. Other 
sensors may detect hand gestures or other signals that 
allow the user to send control commands to the 
computer. Such commands might include picking up an 
object or triggering a scene change. If the scene rendered 
by the computer is compelling enough and the 
interactivity is fast enough, the user will experience a 
sense of "pre ence" or "immersion", which is usually 
described as the feeling of being in another place. 
Photorealism of the scene is not essential as even scenes 
with simple or unusual features can induce presence. This 
very important quality has prompted such eminent 
researchers as Dr. Lawrence Stark of Berkeley to identify 
VR as a key technology of the future. Good virtual 
environments exist even now, and transfer of the 
technology to the medical realm is under way. 
VR is not limited to visual displays and detection of 
movement of body parts. 3-D audio environments greatly 
enhance the sensation of presence and can provide cues 
to many items out of the immediate field of view of the 
display. Tactile or "haptic" feedback is becoming more 
and more compelling. As one picks up, or cuts or touches 
an object in VR through mechanical implements, 
motorized feedback through the instrument gives one the 
sensation of a solid object with weight, or even elastic 
tissue qualities. 
Important technologies related to VR are Augmented 
Reality (AR) and Telepresence. In augmented reality, the 
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computer graphics images are superimposed onto the 
real world. This allows such things as data values or 
graphic showing internal features to be presented on top 
of objects in the real world. Telepresence is a means of 
actively interacting with a remote location. Instead of 
movements of the user being used to drive computer 
graphics, cameras in the remote location are driven 
interactively. Thus, turning one's head left or right 
changes the view from the cameras. 
HOW CAN VR BE USED IN MEDICINE? 
The sense of pre ence and the views of information 
are the features of VR that make it potentially useful in 
medicine. Furthermore, the user of VR is well 
instrumented: we can monitor what they are seeing as 
well as what movements they make. 
3-D data sets from imaging modalities already exist in 
medicine. Instead of viewing slices or 2 1 /2-dimensional 
images on a screen, anatomical objects can be seen in 3-D 
and the viewer can make natural movements to change 
the field of view. Relations between surface features and 
deep objects are readily seen with this type of view. 
Active research is under way to see if interventional 
radiology techniques or planning of multiple angles of 
radiation exposure for cancer can be done more 
effectively in VR. 
Training and simulation are most actively being 
researched as applications of VR. The VR system can 
display anatomic relations that cannot be seen in the 
operating room. This allows a surgeon to safely practice 
techniques and fully understand the anatomic relations in 
the site. For example, a simulator of sinus surgery allows 
the practicing of techniques close to delicate anatomic 
structures such as the optic nerve. The recent trend in 
surgery is toward "minimally invasive procedures", 
where surgery is carried out through instruments while 
the scene is visualized via a TV camera. Minimally 
invasive surgery is immediately transferable to 
simulation through VR technologies. Larger scale scenes 
can also be simulated in VR. These include an emergency 
room, where compelling situations that are altered by the 
user's actions can be created. Handling of trauma, cardiac 
arrest or anae thesia protocols may be carried out in VR 
in the future, where the student will have an impressive 
level of involvement through "presence". 
An interesting use of a virtual environment has been 
developed by a team at the HIT Lab. The Laboratory for 
Integrated Medical Interface Technology (LIMIT) was 
designed to research medical information display. VR 
was originally developed by the HIT Lab director Dr 
Thomas A. Furness III to integrate widely dispersed 
visual information for pilots. Instruments in the cockpit 
have become so numerous and varied in type that the 
pilot may be overwhelmed in critical situations, such as 
landing in bad weather. By integrating the information 
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into a virtual world, aircraft sy terns, traffic, weather and 
other necessary information can be presented in au eful, 
ea ily recognized manner. 
Like a pilot, a modem phy ician in a critical situation, 
such a emergency triage, is faced with widely di parate 
forms and type of information . The LIMIT lab is 
designed to display information a it might be een by the 
phy ician of the near future. Should radiology image be 
presented "attached" to the patient's body? Should 
critical vital signs or alarms be fixed in the phy ician's 
field of view (as though they were attached to his h ad)? 
The e questions and more can be addressed in the virtual 
environment te tbed. 
Ab tract information uch a epidemiological data 
might be effectively di played in VR rather than a eries 
of 2-D images. Even 3-D Internet browsers are now being 
tested where the third dimension is used to represent 
variou relations between data. 
VR AS THERAPY 
The pecial characteri tics of VR make it potentially 
useful for certain form of therapy. The feeling of 
pre ence evoked by a virtual environment make it a 
promi ing tool for behaviour-modification therapy. 
Current mode of therapy for fear of height , flying, open 
spaces, spiders etc. involve visualization techniques. The 
patient is asked to mentally vi ualize their phobic 
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timulu . Succe ive visualization e ion are u ed to 
attempt to prepare the patient for an encounter with the 
real thing. Many centres are now researching the u e of a 
virtual environment instead of mental visualization. Fear 
of flying i of particular interest because many people are 
affected and they have a trong desire to travel. Further, 
the co t of renting a plane to gradually get used to the 
idea is prohibitive. In contra t, in a virtual environment, 
the patient' s " ticking point" can be approached 
repeatedly, be it walking up the gate to the plane, or 
taking off or landing. Ongoing clinical tudies will 
demonstrate efficacy of thi method. 
VR can al o be effectively u ed to demon trate 
neurological defects to patient and others. Rita Addi on 
is a traumatic brain injury urvivor. With the help of the 
Supercomputing Center at University of Illinois, she wa 
able to have a virtual environment created that 
demonstrates her neurological problems with vision. She 
has cotomas and intermittent visual blurring as the 
re ult of her injury. Her VR experience demonstrate 
what a scotoma i functionally like and how her condition 
compare to normal vi ion. This technique may be 
extended to other condition to help patients describe 
symptoms and help the re t of us understand their 
problems. 
My own re earch u ing VR as therapy concern 
defects in motion detection from damage to the vestibular 
apparatu . Patient with long term inner ear damage 
from Meniere' Di ease, infection, surgery or adv r e 
drug reactions are left with defects in detecting motion of 
the head. This lead to instability of vision and gait. My 
project i inve tigating methods of improving residual 
vestibular function through the u e of a custom designed 
virtual environment. The vi ual motion of the cene 
relative to the patient's actual motion will be de igned to 
attempt to drive the vestibular function back toward 
normal, farther and more rapidly than normal adaptive 
processes would go. 
AUGME TED REALITY 
The uperimpo ition of graphic images onto the real 
world view of the patient's body may be very useful in a 
variety of application such as interventional radiology. If 
the phy ician can "see" internal structures that are 
matched to the appropriate po ition on the surface of the 
patient's body then navigation and intervention rna be 
ea ier. Particularly in field uch as neurosurgery, the 
navigation information must be precise. Having an 
integrated view might be more efficacious than switching 
view from radiology screens back to the urgical field . 
CO CLUSION 
VR i an emerging technology. Many hurdles have to 
be cro d before it can effectively be used in real world 
applications. Yet, the number of situation where 3-D 
information (real, reconstructed or abstract) appear in 
medicine is very large . Simple, unobtrusive VR 
technology may be part of your future training, surgery 
or information display. .Q 
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I um Renewal: 
the to 
Century Twenty-First 
T he Faculty of Medicine at the University of Western Ontario graduated its first class of medical students in 1883. Since then, We tern has had a tradition of 
excellence in medical education; Western graduates have 
earned a reputation that ranks with the best in the 
country, and the world. 
Throughout the history of the medical school, 
countless improvements and revisions have been made to 
the undergraduate medical curriculum, but none as 
ambitious as the current curriculum renewal process. 
The process began in April1996 with the formation of 
fourteen Subject Development Group , the Curriculum 
Coordinating Team, and four Resource Task Teams. Dr 
John Howard, Director of Curriculum and Evaluation, is 
heading the renewal proce s, and the new MD 
curriculum will be implemented in September 1997 for 
the Class of 2001. In all, the process currently involve 
more than 200 individuals, with repre entation from the 
basic and clinical science departments, the medical 
student body, and the communities of London and 
Southwestern Ontario. 
The Subject Development Group were formed to 
evaluate the material currently taught, in an effort to 
coordinate and integrate basic and clinical sciences within 
fourteen general subject area . The Subject Development 
Groups are Introduction to Medicine; the Life Cycle; 
Reproduction and Embryology; Blood; Endocrine and 
Metabolism; Immunology and the Skin; Heart and 
Circulation; Respiration and Airway ; Genitourinary 
System; utrition and the Digestive System; 
Mu culoskeletal; euro ciences, Eye, and Ear; Psychiatry 
and the Behavioural Science ; and Health, Illness, and 
Society. 
The mandate of the Curriculum Coordinating Team 
i to facilitate the activities of the Subject Development 
Groups, and to make recommendations on curriculum 
reform. The four Resource Task Team were created to 
provide faculty support in teaching methods, re earch in 
education, and faculty and tudent evaluation. The four 
Resource Task Teams are Teaching Methods, Educational 
Re earch, Evaluation, and Curriculum Re ources. Other 
Task Teams formed include Patient Centred Learning, 
ABOUT 1HE A UTHOR 
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by Alexander L Lee 
Oncology, utrition, Career Choice, Rural Medicine, and 
Geriatrics. 
The goals of curriculum change are to integrate 
ubject matter between cour es and to create a curriculum 
that is responsive to both tudent and community needs. 
The new undergraduate medical curriculum will be 
"student-centred in its delivery, and patient-centred in its 
content." 
Prior to renewal, the MD curriculum included 
cour es such as anatomy, biochemi try, histology, etc. 
Each cour e had been revised and balanced for many 
years, but each cour e operated independently of the 
others, with minimal coordination. The curriculum 
renewal process will foster integration between basic 
sciences, between clinical ciences, and between ba ic and 
clinical sciences. It is clear that the underlying theme is 
"integration." 
The "patient-centred" curriculum acknowledge that 
medicine is both a science and an art, reflecting a 
commitment to individual patients, their families, and the 
community. Patient-Centred Medicine is a concept that 
wa fir t developed by the Department of Family 
Medicine at Western. The ix interactive component of 
the patient-centred proces are: exploring the di ea e and 
the illne s experience, understanding the whole per on, 
finding common ground regarding management, 
incorporating prevention and health promotion, 
enhancing the patient-physician relationship, and being 
realistic in managing time and re ources. ' Physicians 
must understand the patient's condition from the 
patient's own unique perspective, and must under tand 
that no two patient are alike. The four dimen ions of 
illness (feelings, ideas, function, and expectation ) hould 
also be explored. The e principle will be emphasized 
throughout the undergraduate medical education from 
the first day, right on through to graduation. Early patient 
contact and a variety of community experience will 
complement these goals. 
Medical student have played a significant role 
throughout the curriculum renewal process, contributing 
on the Curriculum Coordinating Team, Subject 
Development Group, and Resource Task Teams. Student 
opinions were gathered, and pre ented at the October 23, 
1996 Curriculum Renewal Half-Day by Andy Thompson 
(Meds '98) and I. Student-centred need were identified, 
and included integration within and between ba ic and 
clinical science , active learning, an approach to 
symptoms, and techniques of critical apprai al and 
evidence-ba ed medicine. Student were unanimou in 
their desire for a unique, innovative, and dynamic 
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curriculum that repre ented the needs and values of the 
tudent body, the Faculty of Medicine, and the 
community .2 These issues have subsequently been 
adopted into the guiding principle and aims of the 
renewal proce s. 
Learning will be more active, with emphasi on 
mall-group tutorial and problem-oriented learning. 
Ca e cenario will be used extensively to allow tudents 
the opportunity to develop clinical approache to patient 
pre entations and to addre s disease and illne is ue . 
Other teaching methods that will be used include elf-
instructional materials, laboratories, large-group 
discus ions, and lectures. 
The new preclerkship curriculum will be divided into 
two halves. Ba ic sciences and clinical sciences will be 
integrated, with emphasis on basic cience in the fir t 
half, and empha is on clinical sciences in the econd half. 
The curriculum will begin with Introduction to Medicine. 
The remainder of the first year will be made up of 
Foundation Blocks. Second year will be made up of 
Clinical Blocks. Subjects (as defined by the Subject 
Development Group ) will be grouped in Blocks based on 
regional anatomy. An example is the Thorax Block which 
w ill include Re piration and Airw ays, Heart and 
Circulation, and Blood. Each subject will be divided in 
half; the first half will be taught in the Thorax Foundation 
Block, and the second half in the Thorax Clinical Block. 
To Your 
This "double block" system i a student initiative. 
The new undergraduate medical curriculum will take 
Western into the next millennium. The entire renewal 
process ha occurred through cooperation from all those 
involved . ew and innovative learning, teaching, and 
evaluation techniques will be employed. It is our hope 
that We tern's new MD curriculum will be a model for 
others to follow. The tradition of excellence upon which 
the Faculty of Medicine is built will undoubtedl y 
continue. 
Acknowledgements: I wi s h to thank Dr Jo hn 
Howard, Director of Curriculum and Evaluation, Faculty 
of Medicine, UWO, and Andy Thomp on, Meds '98, 
Hippocra tic Council VP Academic Sr, Faculty of 
Medicine, UWO. 
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Peri ampullary Tumour 
Elderly Gentleman 
• 1n an 
by Paul J Collins 
A 70-year-old gentleman presents to his family physician complaining that over the past few weeks his skin has turned yellow and his urine 
has turned brown in colour. 
PLEASE STOP AND ANSWER THE FOLLOWING 
QUESTIO S 
1. arne the condition. 
2. Define the condition. 
3. Classify the etiologies of the condition. 
4. List possible causes under each classification. 
The gentleman is referred to a general surgeon. On 
history, the patient's symptoms include jaundice, dark 
urine, weight loss (40 lb . over the past few months) 
and abdominal pain (diffuse, worse at night, radiates 
to back). He also mentions intermittent episodes of 
weakness, nausea, vomiting and diarrhea. He is a 50-
pack-year maker and a heavy drinker. Medical 
history reveals cholecystectomy at the age of 40. 
Family history is negative. On examination, the man 
has a temperature of 37.5°C, BP 110/60, HR 65, height 
5'11 ", weight 130 lb. There is diffuse abdominal 
tenderness. The liver is palpable 2 em below the costal 
margin. The remainder of the physical examination is 
normal. Lab tests and imaging studies are ordered. 
PLEASE STOP AND ANSWER THE FOLLOWING 
QUESTIO S 
5. What diagnosis does the clinical picture suggest? 
Why? 
6. List the most common symptoms of this disease. 
7. List the most common signs of this disease. 
8. List the risk factors for this disease. 
9. What is the importance of early diagnosis? 
ABOUT 1HE AUTHOR 
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Lab tests revealed elevated conjugated bilirubin 
and alkaline phosphatase, characteristic of 
extrahepatic biliary obstruction . Ultrasound 
demonstrated dilated common bile duct, dilated 
intrahepatic bile ducts, and a mass in the region of the 
pancreas. CT scan demonstrated a mass in the area of 
the head of the pancreas with extension to the 
duodenum, bile ducts and stomach. There was no 
vascular invasion, lymph-node involvement outside 
the boundary of resection, or distant metastases. 
Pathological examination of a CT -guided fine needle 
aspiration biopsy showed ductal adenocarcinoma of 
the pancreas. 
PLEASE STOP AND ANSWER THE FOLLOWING 
QUESTIONS 
10. What is the differential diagnosis for a tumour in 
the periampullary region? Why is tissue diagnosis 
important? 
11. What is the most common histopathological type of 
pancreatic carcinoma? What is its pathogenesis? 
12. Describe the staging of pancreatic carcinoma? What 
stage is this patient? 
The patient arrives at the office to discuss the 
options for treatment and the prognosis of his 
condition. 
PLEASE STOP AND ANSWER THE FOLLOWING 
QUESTIONS 
13. What potentially curative therapy is available? 
14. arne and briefly describe the procedure. 
15. Comment on the risks involved in the procedure. 
16. Comment on the efficacy of the procedure. 
The gentleman underwent standard 
pancreaticoduodenectomy with adjuvant radio-
chemotherapy. He is still fighting a year after his 
operation. 
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ANSWERS 
1. Jaundice (=icterus). 
2. Jaundice (=icterus) refers to the yellow pigmentation 
of kin, clerae, mucous membranes and excretions 
due to hyperbilirubinaemia (>35 (mol/1) and 
depo ition of bile pigments. Examine the sclerae in a 
good light (they are the most sen itive indicator). 
3. (a) Prehepatic (acholuric) jaundice. Bilirubin is 
formed from the breakdown of haemoglobin and is 
usually all conjugated by hepatocytes. If there is 
excess bilirubin or an inborn error of uptake or 
conjugation, some bilirubin i unconjugated and 
remains in the circulation. Being water in oluble, it 
does not appear in the urine. 
(b) Po thepatic (obstructive or chole tatic) jaundice. 
ormally, conjugated bilirubin flows out into the gut, 
where inte tinal bacteria convert it to urobilinogen, 
some of which is reab orbed and appears in the urine. 
The rest i converted to stercobilin, which colours 
faeces brown. U the biliary system is blocked, plasma 
conjugated bilirubin rises. Being water oluble, orne 
is excreted in the urine, making it dark. By contrast, 
le bilirubin passe into the bowel; the faece now 
have les stercobilin and so are pale. 
(c) Hepatocellular jaundice. This implie diminished 
hepatocyte function (u ually with varying degrees of 
chole tasi ) and results in conjugated and 
unconjugated hyperbilirubinaemia. 
4. (a) Prehepatic (acholuric) jaundice. Haemolysis 
(exce s bilirubin), Gilbert's syndrome (failure of 
uptake), Crigler- ajjar syndrome (failure of 
conjugation). 
(b) Po thepatic (ob tructive or cholestatic) jaundice. 
Ob truction anywhere in bile duct sy tern cau ed by 
gallstones, tumour , congenital anomalies, strictures, 
primary biliary sclero is, primary sclero ing 
cholangitis. 
(c) Hepatocellular jaundice. Viru e (hepatitis , B, 
C, E, EBV), drugs, toxins, cirrhosis. 
5. In per ons over 60 year of age, the combination of 
jaundice and significant weight loss usually means 
carcinoma of the head of the pancrea or 
periampullary region. Pain, dark urine, weakne s, 
nau ea, vomiting, diarrhea, and palpable liver also 
contribute to the diagno is. 
6. The mo t common presenting ymptom of carcinoma 
of the head of the pancreas include weight lo s, 
jaundice, pain, anorexia, dark urine, light stools, 
nausea, vomiting, weakness, pruritis, diarrhea, 
melena, constipation, fever, haematemesis. 
7. The mo t common presenting signs of carcinoma of 
the head of the pancreas include jaundice, palpable 
liver, palpable gallbladder, tendernes , a cites, 
abdominal rna s. 
8. Pancreatic cancer i more common in men than in 
women and develops most often in the eventh 
decade of life. Environmental etiologic factors include 
smoking, dietary fat and chemical carcinogen . There 
is no compelling evidence to support a role of coffee 
or alcohol. Ho t etiologic factor include abnormal 
gluco e tolerance and genetic factors. There i no 
compelling evidence to support a role of chronic 
pancreatiti . 
9. Many of the problems in the treatment of pancreatic 
cancer can be traced to our inability to diagnose the 
disea e in its early stages. The vague early symptoms 
of pancreatic cancer are often minimized by both 
patient and physician, typically leading to a dela of 
months in making the diagnosi . It i usually not until 
the patient develops jaundice or extreme weight lo s 
that the diagnosis is made, and by this time the 
pancreatic tumour is typically large and has grown 
beyond the confines of the pancreas. 
10. Lesion in the periampullary region may originate 
from the duodenum, ampulla of Vater, di tal 
common bile duct, or the head of the pancreas. The 
fir t three site are a ociated with a reasonable 
chance of cure following complete removal of the 
tumour. 
11. Despite the fact that ductal cells make up les that 5% 
of exocrine ti ue, they appear to be the cell of origin 
of over 90 % of pancreatic carcinoma . Ductal 
adenocarcinoma of the exocrine pancreas is by far the 
most common form of pancreatic cancer. It probably 
arises a a progressive process beginning with ductal 
hyperplasia, followed by dysplasia, carcinoma in situ 
and finally invasive carcinoma, a is the ca e for 
many neopla ms. 
12. The current staging system for cancer of the pancreas 
is ba ed on the TNM definitions: T = primary tumour, 
= regional lymph node involvement, M = di tant 
meta ta e . Thi patient is Stage I (T1-2, 0, MO); 
there i limited direct extension to adjacent viscera, 
with no regional node extension and no distant 
metasta e . Limited direct exten ion is defined as 
involvement of organ adjacent to the pancrea that 
could be removed en bloc with the pancreas if a 
curative resection were attempted. ormally, pati nts 
presenting with jaundice already have extension and 
metastasis. However, thi patient's tumour was so 
localized to the ampullary region that jaundice 
occurred when the tumour wa till small enough to 
be resectable. 
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13. Surgery is the only potentially curative therapy for 
pancreatic cancer. Unfortunately, few patients are 
actually cured of the disease; fewer than 1% of 
patient survive 5 year after the diagnosi of 
pancreatic cancer. Typically, only 10-20% of 
pancreatic cancer patients can undergo attempted 
resection for cure. 
14. Pancreaticoduodenectomy (Whipple procedure) . 
During this procedure, the antrum of the stomach, 
duodenum, proximal jejunum, head of the pancreas, 
gallbladder and distal common bile duct are removed 
en bloc. Continuity is reestablished by anastomo ing 
the distal pancreas to the proximal jejunum. 
Sequentially then the tran ected common bile duct is 
reimplanted into the jejunal limb and the transected 
stomach is implanted distal to the other 2 
ana tomo es into the jejunal limb. 
15. Pancreaticoduodenectomy is a formidable operation 
with historically high morbidity and mortality rates. 
Until recently, the average operative mortality was 
approximately 20%. However, operative mortality 
Turn our 
Think i ng on Your Fee t 
rates have declined to 5-10 % recently owing to 
improved management of eriously ill patient . The 
most dreaded complication is disruption of the 
pancreaticojejuno tomy with consequent necrotizing 
infection, disruption of major vessels and 
intraperitoneal haemorrhage. Other complications 
include upper ga trointestinal haemorrhage, 
marginal ulceration, biliary fistula, and delayed 
ga tric emptying. 
16. In terms of cure, the results are discouraging. On one 
hand, most known cures of pancreatic cancer have 
been achieved by pancreaticoduodenectomy. On the 
other hand, only 5% of patients undergoing that 
operation are alive and disease-free 5 years later. 
Average survival after standard 
pancreaticoduodenectomy is about one year and 
reflects the inability to render patients disease-free 
with standard surgery alone. Additional approaches 
include increasing the extent of surgery to prevent 
local recurrence, using adjuvant radiotherapy to 
improve local control, and using adjuvant 
chemotherapy to control sy temic disease. Q 
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My clerkship rotation in Dermatology was one of the most pleasant. Clinics did not begin until the civilized hour of 9 a.m., which by University 
of Toronto convention, means 9:10a.m. I was thus able 
to revert to my preferred nocturnal activity chedule 
without fear of the sleep deprivation fugue state so 
common during surgical rotations. 
Dermatology, like neurology, is a specialty in which 
the physical examination assumes a central importance 
in diagnosis. To be honest, I have never found that the 
phy ical examination contributed much to the final 
medical asse ment of mo t patients. Once in a while, 
the diagnosis is clinched by physical finding but in 
mo t cases the history and laboratory te ts are sufficient 
to make the diagnosis and formulate a treatment plan. 
Dermatologists, on the other hand, like to perform the 
physical examination first and use the hi tory 
(sometimes with lab tests) to provide confirmatory 
information. This make . ense because the appearance 
of a cutaneous eruption is everything and question like 
"How long have you had this?" and "Does it itch?" are 
of econdary importance. 
In many countries the diagnosis and treatment of 
exually transmitted disea es is the respon ibility of the 
dermatologist. I suspect this is because of the protean 
presentations of syphilis, which in its secondary tage, 
often presents as a rash. My rotation supervisor, Dr 
Gasher (name changed to protect the innocent), told me 
during one of my first clinics that there was nothing he 
found so unpleasant in the entire sphere of medical 
practice as pelvic examinations. He went on to t ll me 
that he became an expert at thi procedure in order to 
minimize the trauma to his psyche. I have found this to 
be excellent advice over the years which is broadly 
applicable to the areas of medicine which are le than 
pleasant. Let's face it, everybody has certain asp ct of 
medical practice which they find unplea ant, unle they 
are o riddled with p ychopathology that they can no 
longer discern the good from the bad. 
It had been a long, long night, I had not been able to 
obtain a wink of sleep. I felt like the bottom of a parrot's 
cage. It seemed like I had to make critical deci ions 
every moment. In other words, I had been at another all-
night card game, playing for money. I have alway been 
intrigued by people who ay they don't gamble. To me 
life is a gamble and it i hard for me to imagine that 
gambling could not be entertaining (particularly if you 
are on a winning streak). evertheless, some folks don't 
like it and I re pect that. I just don't under tand it. The 
game broke up just before 8 a.m. The pot leader bid up a 
questionable hand and promptly blew his entire hoard. I 
grabbed a shower and made some coffee amid the 
wreckage of the evening activities. I arrived late for 
dermatology clinic by about 20 minutes but luckily met 
Dr Gasher in the foyer of the ho pital, hurrying in just as 
tardily as myself. It is hard to chastise another person 
for being late when you are just as late your elf. 
by Dr. Colby 
evertheless, my initial euphoria turned to fear when I 
saw him heading for the stairwell in tead of the 
elevator. The dermatology clinic was on the 12th floor. 
He beckoned me to follow and proceeded up the stairs 
double time, two steps per stride. By the time we got to 
the 12th floor I was a florid example of dyspnea, 
cyanosi , chest pain and a feeling of impending doom. 
Most of the patients that morning had what is called in 
the trade a "Don't do anything rash". I survived the day 
despite my incredible fatigue and did not perk up until I 
quaffed a few ales at the Brunswick House that evening, 
that being a Friday-night ritual for University of Toronto 
medical tudents. 
The next day, I headed up to a friend's cottage at 
Jackson Point where I ran into a number of my 
classmates. One of them a ked me what rotation I was 
doing and after I told him he showed me the ole of his 
foot. There was the largest plantar wart I have ever een, 
being a full 2 inches long, 1/2 inch wide and 1 inch 
thick. I aid "Rob, why don't you come around to clinic 
on Tue day and we will take care of that for you?" 
''Will it hurt?" he asked. 
" a", I said. When Tue day rolled around I told Dr 
Gasher that I had asked a buddy of mine to top by so 
we could treat his plantar wart. 
" o problem" said Dr Gasher. Sure enough, Rob 
turned up. Dr Gasher surveyed the bottom of his foot, 
put hi ankle in a front headlock, grabbed a paring blade 
and immediately started carving the wart off the bottom 
of his foot. 
Rob said "I can feel that, Dr Gasher." Dr Ga her 
continued his work. Rob aid "Dr Gasher, that is starting 
to hurt a little bit." Dr Ga her continued hi work. Rob 
started breaking out in a sweat and said "Dr Ga her, 
that i really starting to hurt." Dr Gasher continued hi 
work. Rob aid "Holy Mackerel! This is really hurting!" 
Dr Gasher said "It won't be long now." and put 
down the curette. Rob breathed a sigh of relief, but this 
was premature. Dr Gasher removed the largest Q-tip I 
have ever seen, something that is normally used to 
swab out rigid sigmoido copes, from a boiling pot of 
liquid nitrogen. Tightening his headlock on Rob's ankle 
he jammed the liquid nitrogen swab onto the remnant of 
his wart with all the strength he could muster. Rob's 
foot plantar-flexed so much that he was almost touching 
his toe to his calcaneum. He actually lost the ability to 
speak momentarily. Dr Ga her aid "There." 
Rob aid "Gee, thank you, Dr Gasher." 
" o problem," said Dr Gasher as he walked away. 
"Come back one week from today and we will finish the 
job." Rob looked at me, started to put on his shoes and 
limped out. He never returned. As far as I know, he still 
has his remarkable plantar wart. Through this I learned 
another valuable lesson. People in general don't go back 
for a econd round unle the experience was a pleasant 
one. One of the only exceptions to this rule i 
postgraduate medical training. Q 
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For more details on elficacy results by IR-<Iefined classilication and pooled data by F1edridcson types, see 
PIWIMACOI.OGY, Clinical Studies. 
Prior 1o ilrtiating t11erapy with LFITOR, secondary causes should be l!liClJded for elevations in plasma lipid 
levels (e.g. poorly contrnled diabetes melilus, hypotllyroidism, nephrotic syndrome, djsp<Aeinemias, obstructive 
liver disease, and -.olsm), and a lipid profile performed 1D meaS1n 1Dtal cholesterol, l.Dl-C, HDI.-C, and TG. 
For patierAs with TG <4.52 mmolll (<400 mg/~. LDL-C eM be estimated using the following equation: 
l.Dl-C (~ = 1Dial choles1erol - ((0.37 x (TG) + Hill-C)) 
l.Dl-C (mgldl.) = total choles1eroi • ((0.2 X (TG) + Hill-C))' 
For patierAs with TG levels >4.52 mmolll. (>400 mg/dl), this equation is less ecante and LDL-C concen1ra-
1ms should be deterrnOied by IAtracentrfugat 
CONTRAINDICATIONS 
HypeisensitMty ID MY COII1IIOf1l!lll of this medication. 
Active liver disease or unexplained per-.t elevations of sen.m b lltSalilillaseS exceedi1g 3 times the upper 
· of normal (see WARNWGS). 
PlegnMcy and lactation (see PRECAIITlOHS). 
WARNINGS 
liiDIIJI 
The elfects of atonastatln-lnduced cllanges In lipoprolalilllewels, Including reduction al10111111 
~ on cardiovascular .....-ty or mortality or _. mor1ally 111-.e not been establislled. 
In dinlcal trials, per-.t increases In sen.m transaminases -'"' 1han three times the upper limit of normal 
OCCUlTed in <1~ of patients wllo receiwd LFITOR. When the dosage of LFITOR was-· or when drug 
treatment was intemJpted or discontinued, serum transaminase levels rebJmed 1ll pretreatment levels. The 
Increases wm genonly not associated with jall1dice or other clirlcal signs or symp4orns. Most patients 
contnued treatment with a reduced dose of Ui'ITOR without clirlcal sequelae. 
IJonr lunc!iln tests sl!ou!d be oerlpnned be!qe !be Dtiatjgo oll!eabne!lt jM!d oeriodjc;ll!y tllereafter. Special 
attention should be paid 1D patients wllo develop elevated sen.m lrWisaminase ....... and in these patients 
meauernents should be repeated prornpay and then performed more frequently. 
If lnc:nlua In llanlne amlnoii11LSflloase (All) or aspll1lte llllinolr11LSflloase (AST) .,_l¥idenc:e 
of progression, pll1ic:uilr1y If they rile ID grul8r- 3 an.. tile ...,..- 1m11 aiiiCinlllllllld are 
.,...._, tile douge should be redUced or tile drug discontinued. 
lli'ITOR should be used with caution in patients wllo consa.me substwrtial quantities of alcohol atVJ/or have a 
past hislory of liver disease. Active liver <1sease or unexplained lrWisaminase elevations are coutraindicalious 
1o the use of LFITOR; K sudl a anlition should develop during tllerapy, the drug should be discontinued. 
etrteEIIects 
Myopolhy, defined as...- ad*1l or..-- in aJI$Ildion with Increases in cnali*le JAuspdauase 
(CPIQ vauoslo _.. ""' 1111 tines the - lmit of normal, should be <XlRiidered in MY patient with lilluse 
myalgia. muscle ll!ndemess or weakness, atVJ/or m..-1<ed elevation of CPK. Patients should be IIMsed 1o f1!11011 
prornplly lllelq)lained muscle pain, ll!ndemess or weakness, particularly ff accompanied by malaise or re.er. 
I..IPITOR therapy should be discontinued ff na1<ec11y elevated CPK levels OCCII' or myopathy is diagnosed or 
suspected. 
The risk of myopathy during treatment with HMG-QlA noductase inliiJiUs is increased with conamnt 
admiistratiol• of cydosporlne, lbic acid deriwtiYes, erythromycin, niacin (nicolnc addl or azole antilulgals. 
Allhougl1 there is no experience 1o date with the use of LFITOR giwn an:amntly with these drugs, with the 
-.wrot~t.CIII0..1972: 111161:48!1-502. 
exception of a pharmacokinetic study with erytll()fnydn (see PllfCAIJTlONS, Drug lnteractionsl. the bef1elits 
and risks of sudl combined therapy should be care11.ty considered. 
lllaiJdornyolys with renal dysMction secondary 1D myoglobiuia has also been reported with HMG-CoA 
reductase inhibib-s. LFITOR tl1erapy should be ternporariy wilileld or discontinued in MY patient with M 
acute serious condition suggestive of a myopathy or having a risk lac1or predisposing 1o the development of 
renallaiUII secondary 1o rt1abdon1yolysi (sudl as sewre acute infection, hypoll!nsion, 1T1<Ijor ugery, tnuna, 
- metabolic, endocrine and electrolyte clisonlon, and uncontroled seizl.ns). 
PRECAUTIONS 
lilllml 
Before instituting therapy with LFITOR (aDvastam calcium), ..-. attempt should be made 1o aJntrol elevated 
serum lipoprotein - with ~ die!, exercise, and weight reduction in ~ patients, and ID 
treat other onler1ying medical problems (see INDICATIONS AND ct.JNICAI. USf). Patients should be IIMsed 1D 
inform Slbsequent physiciMs of the prior use of I..IPITOR or MY other lipid-lowMng agents. 
Effect on !be Lens 
a.rent long-term data from cinical trials do not indicate ..-. adverse e11ec1 of atorvastam on the tunan lens. 
Effect 011 Ul!jquj!one !C!!O-t oll.m!l 
Significant deaeases in ciraJialing IDquinone - In patients treated with a1DrYastatin and other stltins 
have been obsened. The dinlcal s90ficance of a potential long-term statin-inclJced deficiency of IDquinone 
has not been eslablished. tt has been reported t11at a dec:rease in myoca-dial ubiquinone levels aJUid lead 1o 
impaired cardiac IIJnction in patients with border1ine ronges:tive '-' laiUe (see S8.£CTED BllUOGRAPHY). 
Effect 011 !.Jpoorpb!jnla) 
In same patients, the beneficial e11ect of - 1ota1 choles1erol and LDL-C levels may be partly bU1ted by a 
concomitant increase in 4l(a) levels. U1ti """* experience is obta01ed, • is suggested, when feasiiAe, tl1at 
meauernents of senrn 4l(a) be followed up in patients placed on alorYasl3tin tl1erapy 
(see S8.£CTED BtBlJOGRAPtiY). 
An apparent hypersensitMty syndrome has been reported with other HMG-QlA reductase inliiJiUs which has 
incUied 1 or more of the lol1owfng featlns: anapllytaxis, Mgioedema, lupus erythema!Dus-lke syndrome, 
polymyalgia rtleunatica, vascuitis, IUJliR, llvombocy1opellia, letA<openia, hemolytic anemia, positive NIA. 
ESR increase, eosi1opl1ilia, ll'llvitis, arthralgia. Lflicll'ia, aslllenia. photoseusitivity, !eYe<, chils, lklshing, 
malaise, dyspnea, 1Dxic ec*lermal necrolysis, erythema nUtiforme, including Slevens-Jofl1son syndrome. 
Allhouglllo date hypersensitMty syndrome has not been described as sudl, umOR should be discontinued ff 
hypersensitiYit is suspected. 
Use In Preanancy 
UPITOR Is oontraindlcated during pregnancy (- COifTIIAIIIDICATlONS). 
Atherooclerosis is • - prncess and discontnlation of lipid-lowMng drugs during IJil91lf1CY should have 
ltlle inpacl on the oW:ome of long-term therapy of primary hypeid.-'*"llia. ~and- products 
of choles1erol biosynthesis are essential COII1IIOf1l!lll for fetal development fn:llding synthesis of sleroi<ls and 
eel memllranes). Since HMG-CoA- lntiln decrease ~ synthesis and possillly the synthesis 
of -lli<*lgically active substances derived from cl1oleslenll, they may cause harm 1ll the lebls when 
admirlist2red 1ll pregnant -
There are no data on the use of UI'ITOR during 1J1191111CY. l.I'ITllR should be administered to -.en of dild-
bell'ing age any when sudl patients are highly 1l1iikely 1o conceive and have been informed of the potential 
hazards. I the patient becomes pregnant ""'* lakilg LFITOR, the drug should be discontinued and the patient 
llill'lsed of the potential risk ID the fetus. 
In rats, .,. concen1rations of alorYasl3tin are similar 1o those in plasma. tt is not known whether this drug is 
exaeted in human mil<. Because of the potential for adverse reactions in fUSing infants, women taking 
LFITOR should not breast-feed (see CONTRAINOICATlONS). 
Ped)al!lc Use 
Treatment experience in a ~!ric IX)IlUiation is limited 1omses of Ui'ITOR up 11l80 mg/day for 1 year in 
8 patients with homozygous familial hypeic.holesteoolemia. No clinical or biod1omical aiJnormalilies -e 
reported in these patients. 
Treatment experience in-70 years or <*ler =221) with mses of LFITOR up 1D 80 mg/day has 
demonstrated that the safety and effectiyeness of alorvastJ1in in this PQ111Ation was similar 1o that of patients 
<70 years of age. Phll'macokineti evaU!tion of alorYasl3tin in sOOjects over the age of 65 years indicates M 
increased AOC. As a precautionary measan, the lowest mse shottl be ~ iitialy (see PIWlMACOLOGY, 
tUnan Pharmacokinetic and S8.£CTED 8l8l.lOGIW'IIY) 
Plasma ooncentrlltions and LDL-C lowMng efficacy of I..IPITOR are similar in patients with moderate renal 
insufficiency OOfTII*ed with patients with normal renaiiiJnction. In patients with severe renal insufficiency 
(creatinine clearance <30 mU11101), the - dosage should be used and Implemented cautiously 
(see WARNINGS, 1o1usc:1e Effects). 
HMG-CoA noductase inliiJiUs intelfore with - synthesis and as such rni!;rt u--etically bloot -
atVJ/or gonadal steruid proOOction. Clinical studies with a1DrYastatin and other HMG-CoA reductase inliiJiUs 
have suggested t11at these agents do not reduce plasma - concen1ration or lmpai' a<Rnal reserve and do 
not reduce basal plasma tesmterone concen1ration. H<Mever, the e11ects of HMG-CoA noductase inliiJiUs on 
male fertility have not been studied in adequatJ! 1lll1ilon of patilllls. The e11ects, il MY. on the pituitary-gonadal 
axis in premenopausal women are Ll1known. 
Patients treated with a1DrYastatin wllo develop dinlcal evidence of endocrine dysMction should be evaluated 
appropriately. Caution should be exercised W M HMG-CoA reductase W1lli1Dr or-agent used 1o ~ 
ct.-a levels is~ 1o patierAs receivi11- ~{e.g. ke1ocona2Die, spionolacbe or cimetidine) 
that may dec:rease the levels of endogenous steruid hormones. 
Drua lntenc:t!qns 
Concomitant Therapy wttll Other lipid - Regulltars: CombOied drug therapy should be 
llliJ'1)IIChed with caution as information from oontroled studies is limited. 
IIIIAcld~ 
l'lti!!nls with mid m rngdcralc IM!!:!!;!Qc;!"'*nri;t LDL-C reduction was _.. when I..IPfTOR 10 mo and 
aJiestipof 20 g wm coadmirist8led (-45~1 1han when either drug was administered atone (-35~ for 
Ui'ITOR and -~for aJiestipof). 
Pa!jeo!s with smrc lr!pea;bgles!em LDL-C reduction was similar (-53'-l when l.I'ITllR 40 mo and 
aJiestipof 20 g wm alild1Tiilisler when OOflll*eel with that of I..IPITOR 80 mo alone. Plasma concen1ration 
of a1DrYastatin was low. (appraxina12ly 26%) when LFITOR 40 mo 1*JS aJiestipof 20 g wm ooadminisbnd 
OOflll*eel with LFITOR 40 mg alone. 
l.1~ IDR* 
AlVRI#l51A77N CALGUM 
However, 1he oombilation drug 1llelllpy was less eftecti'le 11 ~ 1he lnglycendes ttm I..I'ITOR l1lOI10iherapy 
in boll1 types or hypelc:holestelolemic patiems (see PIWIMACO!.OGY, Cliical Stucies). 
When I..I'ITOR IS used conamntty with ~ or any other resrt, an ll11eiVal or at least 2 1101n sin*! be 
maon1aoned between 1he two drugs, since 1he absorptJon or UPITOR may be impanel by 1he resn 
Flbric Acid Derivltives (Gemllbrozil, Fenofibra llezaflbnlte) and Niacin (Nicotinic Acid): Altholql there 
is no _.,.,. with 1he use or UPITOR goven conamntty with fibric acid derivatives and niaCin. llle benefits 
and risks or suc11 cornlwwld 1llelllpy *"*' be ca-elldly considered. The r1s1< or myopallly dunng u..tment with 
other drugs in lhis class IS increased with aJIICI.ITenl administration (see WARNINGS, Muscle Eflectsl. 
Erythromycin: 1n 11ea1111y indiYiduals, plasma concentratms or alorVaslalin increased 8IJI)IOXIIII8te .w.. with 
coadrninistrlltion orli'ITOR and eryllvomycin, a known inhilli1Dr or cyD:hrome P450 3A4 (see WARNINGS, 
Muscle Effects). 
Coumarin Anticoagulants: UPITOR had no ciDcaly sognificant effect on protlvombr! time when Uninistered 
lo patiems recerring clvonic warfarin therapy. 
Digoxin: Coadministration or multiple doses ori..I'ITOR and digoxin increased steady-state plasma digoxin 
concentrations by approlllll3tely 20%. Patients takilg digoxin should be monilored closely and appropriately. 
Antipyrine: AntJpyme was used as a model lor drugs metaboized by 1he microsomal hepatic enzyme sys1em 
(cyD:hrome P-450 system). I..I'ITOR had no e11ect on 1he phannaaJI<Ileti or antJpyme, tills intlnctJons with 
other drugs metaboized via 1he same cyD:hrome osozymes are not expected. 
Oral Contraceptives: Coadministration or UPITOR with an 01111 oontraceplive, c:on1a1n11g 1 mg norethrldrone 
and 35 1-'!1 e11w1y1 est'adiol, increased p1asma concentratms (AlJC 1eoe1s1 or - and et1w1yt est'adiol 
by apprcamately ~ and 20%, respectively. These incnases sin*! be ...-when selecting an oral 
oontraceplive. 
Antac:lds: Admnslration oraloolnrn and~ based antacods, such as-TC ~. Wl1h 
UPITOR decreased plasma co ... 41ations ori..I'ITOR by "'JJllilinatee35%. LDI.-G reduction was not allored 
but 1he ~ elfect ori..I'ITOR may be affected. 
Cimetidine: AdminiStration or cimetidine with I..I'ITOR did not alter plasma concentratms or l.Dl-G -..g 
elficacy ori..I'ITOR, however, 1he ~ effect ori..I'ITOR was reOOced from 34'!1. 1o 26'!1.. 
Other ConcomHant Therapy: caution sin*! be exercised with ooncomitrrt use or inmooosuppressive 
agents and a2IJie antilt.l1gals (see WARNINGS, Muscle Effects~ 
In di1ical studies, I..I'ITOR was used concomitantly with anti1ypertensiv agents and estrogen replamenl 
therapy wi1houl evidence of clinocally slgrificant adverse onteractions. Interaction studies with speclftc agents 
have not been conducted. 
Cytochrome P-450 Inhibitors: Allrvastatin is metabolized by 1he microsomal hepatic enzyme system 
(cyD:hrome P-450 system) as are most other HMG-CoA reductase iMibclors. Wl1ile alorv.lstabn did not interact 
with antipynne, ft did interact with erythromycil, a known lnhibilor or cyD:hrome P4SO JM. Glapelnit juice 
has also been shown to inhibit c:ytociVume P450 3M. There may be a polontiallor oncreased plasma 
concentrations or HMG-CoA reductase inhiiJilors IJIIOII coadrninistrlltion Wl1h glllllllruit juoce, and other 
.....,.,...a wllicll affect hs enzyme system (see srucTED 8lllUOGIW'HY). 
Higher drug dosages (80 mg/day) required lor some patiems with heterozygous familial hypelc:holestelolemia 
or - hypelc:holestelolemia •e associated with increased plasma levels or alorv.lstatn caution shollld 
be exen:ised in suc:ll patients who are atsa severely renatly lm!Jalred, eldll1y, ..- are concomllanlty 
being administered digoxin cw eoflhnlmYdn (see WARNINGS, Muscle Effects; and PRECAUTIONS, llnlg 
Interactions). 
l!!uq/l.a!!O!Jiory Jest ln1mctions 
I..I'ITOR may - serum lrleaminase and aeatinile l>)osjtooblilSe levels (from skeletal muscle). In 1he 
differential diagnoSis or chest pain in a patient on therapy with I..I'ITOR, cardiac and noncardiac fractions or 
1hese enzymes - be delennined. 
ADVERSE REACTIONS 
UPITOR is generaly -tolelated. Adverse reactions have usually been mild and transient In con1rlllled 
clinocal studies (lllacebo-contr and activ&-<:ontrol COf11lla3live studies with other lipid ~ ~ 
involving 2502 pabents, <2'!1. of patients -e discontinued due to adverse _.,.,.. a-1o I..I'ITOR. 
01111ese 2502 patients, 1n1 were treated lor at least 6 months and 12531or 1 Jeil' or more. 
Adverse experiences occurring at an llcidence ;,1'!1. in patients participating in ~ di1ical 
studies ori..I'ITOR and reported 1o be possibly, probably or definitely drug related •e shown in Table 1 below: 
TABlf 1. Associated Allvlne Events Reporled In ;, 1% of Patients In Placebo ~ Clinical Trials 
GASTROOfTEST1IW 
Constipabon 
Dmhea 
Dyspepsia 
Aa11Aence 
Nausea 
NERVOUS SYSTBol 
-MISCELlANEOUS Pain 
Myalgl3 
As1llenla 
Placebo ... (11=270) 
1 
1 
2 
2 
0 
<1 
1 
<1 
UPITOR '!1. (11=1122 ) 
The following additional adverse events were repcrted in dinical ~ not al events lsted below have been 
associated with a causal rela~ 1D I..I'ITOR 1herajJy. Muscle aamps, myositis, myopallly, pareslllesia, 
penpheral newopallly, panaeatitis, hepatitis, c:hllestatic jaoodice. anorexJa, vomiting, alopecia, prwdUs, 111Sh, 
inpotence, hypeoglycemia, and hypoglycemia 
Oph1hainlologic obsemtions: see PRECAUTlOHS. 
l.aboralory Tests: Increases in senrn lrleaminase levels have been noted in di1ical1nals (see WARNINGS). 
SYMPTOMS ANO TREATMENT OF OVERDOSAGE 
There is no specific treatment lor alorv.lstatin overdosage. Should an overdose CICCI>', 1he patient sin*! be 
treated symjJOnalicaly and suppor1iw! ........,. instituted as requRd. Due 1o extensive drug binding lo 
plasma proteons, hemodialysis is not oxpocted 1o sigrifican11y emanc:e alorv.lstabn c~ear.n:e. 
DOSAGE ANO ADMINISTRATION 
Pabents sin*! be plaoed on a standarl1 cholestefol-~ diet (at least eqoivalenllo 1he America1 Heart 
Association (AHAI S1ep 1 diet) belore rec:eMng I..I'ITOR, and sin*! c:ontinJe on lhis diet dl.rlng teatment with 
I..I'ITOR. K appropnate, a program of ~ control and physical exertise sin*! be implemented. 
!'!jam Hyoercho!esterg!emia n Coml!jned !Mixedl Hvoet1iojdemia.lndudjng Famjljal Cgmbjoed 
ttyoertjojdemja 
The recommended dose ori..I'ITOR is 10 mg once a day. The majority or patients achieve and maintain Target 
chclesterol levels with UPITOR 10 mg/day. A s9ificant lllerapeutic response is evident wi1llin 2 weeks, and 1he 
maximum response is usualy aclleved wi1llin 2-4 weeks. The response is main1aoned dl.rlng chronic lherapy. 
Doses can be IPven at any time of1he day, with or withoullood, and sin*! preletallly be given in 1he evening. 
Doses should be indiridualized according lo baseline LDI. -c levels, 1he desired Ull-G Target (such • that 
recommended by 1he US National Cholesterol Education Program (NCB'! and/or 1he Canadian Consensus 
Corlh!rence Glldelines), 111e goa1 o1 therapy and 111e patielfi response. Adfuslmenls or dosage, • necessary, 
sin*! be made at intenals or4 weeks or more. The recommended dose rtWlQ8 lor most pabents IS 10 1o 40 
mg/day. The maxrnum dose IS 80 mg/day, wlw:h may be reqLWed in a minordy or pabents (see section below). 
Cholesterol levels - be monitored perlodlcaDy and consideration - be giYen to reducing tile 
dosage ol UPITOR If -- falls below 1he targeted range suc:llas that recommended by guidelines. 
The following reductions in lotal cholestefOI and Ull-G - have been -.ecs 11 2 dose-response slides, 
and may ..,., as a gude 1o treatment or patients with mild 1o moderate hypeo c:holestelolemia: 
TABlf 2. Dose-Response In Patients W"llll Mild to -.te Hypercholesterolemia 
(Mean Plrcent Change from Baseline)' 
lipid Par1lmeter 
10 20 40 
(N:22) (N=20) (N=21 ) 
Tolai-C: 7.1 mmolll. • -29 -33 -37 
(273 mg/cl)' 
Ull-C: 4.9 mmolll.' -39 -43 -50 
(190 mg/cl)' 
• Results .... pooled from 2--studies 
• Mean baseline values 
Smre tlyperJ:I!glesll3 
80 
(N:23) 
-45 
-60 
In pabents Wl1h- hyperc:hoiestel'*>llia, incUfing heterozygous- hypeod-•ma, lligher 
dosages ~ lo 80 mg/dayl may be required (see WARNINGS, Musde Effects and PRECAUTlOHS, Drug 
Interactions). 
ConcomHant Therapy 
See PRfCAU110NS, Drug Interactions. 
Dosage In Patients With Renallnsufficlency 
See PRECAII110NS. 
PHARMACEUTICAL INFORMATION 
Pn>per Name: Alorvastabn calCium 
Cllernical Name: (R-(Ir ,R")]-2-{4-IklcJropheoyt)-, l\-dihydroxy-5-(1 -metliylelllyl)-3-phenyl-4-((phenytamino) 
l3bonyl)-1~pynole-1-lteptanolc acid, calcun salt (2:1) tmy<nte 
Erqlirical Fumula: (CJI,IN,O,),Ca • 311,0 
MoleadarWeight 1209.42 
Sbuclural Formula: 
2 
Desc:riiJtlon: Alorwslatin calcirn is a -lo oil--~ powder lhat is practically- in_.. 
solutions or pH 4 and below. Alorvastatin calcium is very slightly soluble in distiled water, pH 7. 4 phosphate 
butler and acetoritrie, slightly soluble in ethanol, and freely soluble in methanol. 
T~~~l;!!l!l!!!!!; Each tablet oontans either 10 mg, 20 mg or 40 mg alorv.lsta · • 1he active ir9'edient. £am tablet also con1ains 1he following non-medicinal inplients: calcium carbonate, candelila wax, 
aoscaunellose sodium, hydroxypropyl cetilse, laclose nQ!Ohydrate, ~stearate, microcrystalne 
ceiUose, hydroxypropyl methytceiUose, polyethylene glycol, talc, titanitrn dioxide, polysorbate 80 and 
simetl*lone emUsion. 
AVAILABILITY OF DOSAGE FORMS 
I..I'ITOR (alorYastatin calcium) IS .,._ in dosage strengths of 10 mg, 20 mg and 40 mg allnastabn per 
tablet. 
10 mg: Wllite, ~ lilm-<:Oated tablet. coded "10" on one Side and "PO 155" on 1he other. A~ 11 
bottles or90 lablets. 
20 mg: Wllite, elliptical, lim-coated tablet, coded "20" on one side and "PO 156" on 1he other. A- in 
bottles or90 tablets. 
40 mg: Wllite, eliptical, lilm-<:Oated tablet, coded "40" on one side and "PO 157" on 1he otller.A-11 
bottles or 90 tablets. 
1. UPITOR (atorvastatin calcium] Product Monograph, Pme-Qavis Div., Warner-Lambert Canada Inc., 
February 1997. 2. Oart A. Jerums G et al. A mullicentre, double-blind, 1-year study companno the safety 
and efficacy of once-daily atorvastatin with that of simvastatin patienTs wrth hypercholeslerolem18. Am J 
Carrlio/1997; in press 3. Bertol1111 S, Bitollo BonG, et al. The efficacy and safety of atorvastatin compared 
to pravastabn in pabents with hypercholesterolem18. Alherosderosis 1997; 130:191 -197. 4. DaVIdson MM. 
McKenney JM, Stein EA. et al. Long term effacy and safety of atorvastatin compared lo lovastatin in hyper-
cholesterolemic pal~ents. Am J Cardio/ 1997; 1n press. 5. Heinonen TM et al. Atorvastallll, a new HMG-CoA 
reductase lllhibitor as monotherapy and combmed with colestipol. J Carrliovasc Pflarmact}/ Therapeut 1996; 
1(2):117-22. 8. Pme-Dms 1997 catalogue and 008 Formulary 1996. 
For a copy or111e lui Product 1o1onc9aP11 or lui Prescribing Information please contact 
®PARKE-DAVIS 
*TM Warner-Lambert Company 
f'arl(e-Oavis Div. 
Warner-lambert Canada Inc., lie. use 
Scarborough, Ontario MIL 2N3 
Co-promoted with 
We ·re part of the wre 
Kir1dand. Quebec H9J 2M5 
~.---.--... ~31-~ 
(azithromycin dihydrate1 I pfizer) 
NAME OF DRUG 
ZJTliROMAX 
(ozithromyon dihydrate) 
• Capsules 250 mg USP 
• Tableu 250 mg 
• Powder for Oral Suspension 1 00 mg/5 mL and 200 mg/5 mL 
• One gram single dose packet 
THERAPEUTIC CLASSIFICATION 
Antibiotic 
ACTION AND CLINICAL PHARMACOLOGY 
Azithromycin dihydrate, a macrolide antibiotic of the azalide subclass, exerts iU antibacterial action 
by binding to the 50s ribosomal subuniU of susceptible bacteria and suppressing protein synthesis. 
Following oral administration, azithromycin is rapidly absorbod (T,.. = 2-3 hou") and d istributed 
widely throughout the body. Rapid movement of azithromycin from blood into tissue resuiU 1n 
significantly higher azithromycin concentrations in tissue than in plasma (up to 50 times the maximum 
observed concentration in plasma). The absolute bioavailability is approximately 37'1&. 
When azithromycin capsules were administered with food to 11 healthy adult male subjects, the rate 
of absorptJon (c.....J of azithromycin from the capsule formulation was reduced by 52% and the 
extent of absorption (AUC) by 43%. However, when azithromycin suspension was administered with 
food to 28 healthy adult male subjects, the rate of absorption (c.....J was increased by 56% while the 
extent of absorption (AUC) was unchanged. Then!lore, azithromycm capsules and powder for oral 
suspensoon should be given one hour before or two hou" after a meal. 
Food does not affect the absorption of azithromycin in the tablet and the one gram single dose packet 
dosage forms. Unlike the capsule and powder for oral suspension, azithromycin tableu and the one 
gram single dose packet can be taken without regard to meals. Azithromycin tableU are bioequivalent 
to the capsule formulation; the oral suspension as a one gram single dose packet is bioequivalent to 
four 250 mg capsules or tableU 
Adult Pharmacokinetics: 
Plasma concentrations of azithromycin decline in a polyphasic pattern, resulting in an average 
terminal haft-life of 68 hou". The prolonged hafl-lffe is likely due to extensive uptake and subsequent 
release of drug from tissues. Over the dose range of 250 to 1 000 mg orally, the serum concentrations 
are related to dose. The long tissue half-life and large volume of distribution result from intracytoplas--
mic uptake and storage in lysosomal phospholipid complexes. 
In adults, the following pharmacokinetic data have been reported: 
DOSUDOSAGE FORM I Subjects c,.. T,.. AUC o.2• T,n 
(IJg/mL) (hr) (l.g•hr/mL) (hr) 
-
500 mg/250 mg capsule 16;fasted 0.40 2.4 3.69' 
500 mg/250 mg tablet 12;fasted 0.34 2.1 2.49' 
500 mg/250 mg tablet 12; fed 0.41 2.3 2.40' 
1 g/250 capsule 33; lasted 0 .84 2.0 10.5' 43.9 
1 g/Single Dose• 33; fasted 0.95 1.4 10.2' 43.9 
1 g/Single Dose• 12; fasted 0.75 1.5 6.49" 
1 g/Single Dose· 12;fed 1.05 2.0 7.37" 
2 g/250 capsule 15; fasted 1.69 1.3 18.8" 59.8 
• One gram single dose packet 
• 0-48 hr; b 0-72 hr; < 0-120 hr; d 0-144 hr. 
When studied in healthy elderly subjects from age 65 to 85 yea", the pharmacokinetic parameters of 
azithromycin capsules in elderly men were similar to those in young adulu; however, in elderly 
women, although higher peak concentrations (increased by 30 to 50%) were observed, no signifiCant 
accumulation occurred. There are no pharmacokinetic data available from studies in hepatically- or 
renally-impaired individuals. 
Biliary excretion of azithromycin, predominantly as unchanged drug. is a main route of elimination. 
Pedia trk Pharmacokinetics: 
The table below shows mean pharmacokinetic parameters on day 5 in children 1 to 5 yea" and 5 to 
15 yea" of age when azithromycin oral suspension was dosed in the absence of food at 1 0 mg/kg on 
day 1 and 5 mg/kg on days 2-5. 
Pharmacokinetic parameters on day 5 at dosage 10 mg!kg (day 1) and 5 mg!kg (days 2-5) 
Age 1-5 Age 5-15 
c.,.. T,.,.,. AUC 0.2• c..,.,. T,.,.,. AUC o.2• (IJg/mL) (h") (l>g• hr/mL) (IJg/mL) (h") (1J9• hr/mL) 
0 .216 1.9 1.822 I 0.383 2.4 3.109 
There are no pharmacokinetic data on azithromycin suspension when administered at a dose of 
12 mglkg/day in the presence or absence of food . 
INDICATIONS AND CLINICAL USES 
ZJTliROMAX (azithromycin dihydrate) is indicated for treatment of mild to moderate infections 
caused by susceptible strains of the clesignated microorganisms in the following diseases and specifiC 
conditions. As recommended dosages, durations of therapy, and applicable patient populations vary 
among these infections, see DOSAGE AND ADMINISTRATION for specffic dosing recommenclations. 
ADULTS 
Upper Respiratory Tract 
Phal)'r19itis and tonsillitis caused by Streptococws fJ'r'09"fH'S (group A &-hemolytic streptococd) occur-
ing in individuals who cannot use fi"t line therapy. 
NOTE: PeniCil~n is the usual drug of choice in the treatment of S. fJ'r'09"fH'S phal)'r19itis, including the 
prophylaxis of rheumatic fever. ZITH ROMAX is often effective in the eradication of susceptible strains 
of streptococd from the oropharynx. Howeve<, data establishing the effiCacY of ZITHROMAX in the 
subsequent prevention of rheumatic fever are not available at present 
Lower Respiratory Tract 
Acute bacterial exacerbations of chronic obstructive pulmonary diseases caused by Hoemophikls 
influmzoe, Moroxdlo cararrl!olis, or Streptococcus pnennonioe. Community-acquired pneumonia 
caused by S. pMUmor11oe or H. intlwnzoe in patienu for whom oral therapy is appropriate. 
Skin and Skin Structure 
Uncomproted skin and skin structure infections caused by St~cus oureus, S. fJ'r'09"fH'S or 
Slteplococcus ogaloctloe. 
Genitourinary Tract 
Urethritis and cervicitis due to Neisseria go11arrt>a«~e or Chlamydia trochomalis. Genital ulcer disease in 
men due to Hoemophilus ducreyi (chancroKl). Due to the small number of women included in dinical 
trials, the effiCOcy of azithromycin in the treatment of chancroid in women has not been established. 
Patienu should have a serologic test for syphilis a nd approp<iate cultures for gonorrhea performed at 
~ ·- ~···~ ~· ~-~··~-·~ · . ...,...t""". ~r--·-- -··-··---- ·-· -·- · -r-.1 - ·· - · - - · ·· - r- --- •· - -··- ··-·· 
should be initiated ff infection is confirmed. 
Appropriate culture and susceptibility tesu should be initiated before treatment to determine the 
causative organism and iU susceptibiflty to azithromycin. Therapy with ZJTliROMAX may be initiated 
before resuiU of these tests are known; once the resulu become available, antibiotic treatment 
should be adjusted accordingly. 
CHILDREN (see DOSAGE AND ADMINISTRATION; Use in Children, PRECAUTIONS section). 
Acute otitis media caused by H. in~~ positive and negative strains), M. cotarrl!olis or 
S pnexnonioe. (For specifiC dosage recommenclation, see DOSAGE AND ADMINISTRATION section). 
Phal)'r19itis and tonsillitis caused by S. fJ'r'09"fH'S (group A ~ streptocoro) occuring in 
individuals who cannot use li"t line therapy. (For specifiC dosage recommenclation, see DOSAGE 
AND ADMINISTRATION section). 
NOTE: Penicill•n is the usual drug of choice in the treatment of S. fJ'r'09"fH'S phal)'r19itis, including 
the prophylaxis of rheumatic fever. ZJTliROMAX is often effective in the eradication of susceptible 
strains of streptococd from the oropharynx. However, data establishing the effiCacy of ZITHROMAX 
in the subsequent prevention of rheumatic fever are not available at present 
CLINICAL STUDIES IN PEDIATRIC PATIENTS 
From the perspective of evaluating pediatric dinical trials, because of the extended hafl~ffe of 
azithromycin, days 11-14 were considered on-therapy evaluations and are provided for dinical 
guidance. Day 30 evaluations were considered the primary test of cure endpoint 
Otitis Media 
EffiCa<)' Protocol 1 
In a double-blind, controlled dinical study of acute otitis media performed in North America, 
azithromycin (1 0 mg!kg on day 1 followed by 5 mg/kg on days 2-5) was compared to an 
anbmiCIObial~lactamase inhibitor. For the 55 3 patienU who were evaluated for dinical effiCacY, the 
clinical success rate (i.e ., cure plus imJlfO'II"'T1errt) at the day 11 visit was 88% for azithromycin and 
88% for the control agent For the 528 patienU who were evaluated at the day 30 visit, the dinical 
success rate was 76% for azithromycin and 76% for the control agent 
EffiCa<)' Protocol 2 
In a non<omparative dinical and microbiologic trial performed in North America, and in which 
signifont numbers of Jl-lactamase producing organisms were iclentified (35%), the combined 
clinical success rate (i.e. cure plus imJlfO'II"'T1errt) was 84% at the day 11 visit (n= 131) and 70% at 
the day 30 visit (n= 122). 
Microbiologic determinations were made at the pre-treatment visit Microbiology was not reassessed 
at later visiu. The following presumptive bacterial/clinical cure outcomes (i.e., cf~nical success) were 
obtained from the evaluable group: 
Sacteriologic Dayll Day 30 
Eradication Azithromycin Azithromycin 
S. pMUmonroe 61 / 74 (82%) 40/56(71%) 
H. ~nflumzoe 43/54 (80%) 30/47 (64%) 
M. catarrl!olis 28/ 35 (80%) 19/26 (73%) 
s. fJ'r'09"fH'S 11 / 11 (100%) 717 (100%) 
Overall 177/ 217 (82%) 97/137 (73%) 
Pharyngitis and Tonsillitis 
In three double-blind North American controlled studies, azithromycin (12 mg/kg once a day for 
5 days) was compared to penicillin V (250 mg three times a day for 1 0 days) in the treatment of 
phal)'r19itis due to documented group A ~ streptococd (GA8HS or S. fJ'r'09"'H'S). 
Azithromycin was dinically and microbiologically statistically superior to penicillin at day 14 and day 
30 with the following clinical success (i.e., cure and imJlfO'II"'T1errt) and bacteriologic effiCacY rates 
(for the combined evaluable patienU with documented GASHS): 
Three North American Streptococcal Phal)'r19itis Studies 
Azithromycin vs. Penicillin V 
EFFICACY RESULTS 
I Day 14 
Sacteriologic Eradication 
Azithromycin 
I 
323/ 340 (95%) 
Penicinin v 242/332 (73%) 
Oinical Success (cure plus imJlfO'II"'T1errt) 
Azithromycin 
I 
336/ 343 (98%) 
Penicillin V 284/338 (84%) 
1 Day 30 
I 
261 / 329 (79%) 
214/ 304 (71%) 
I 
313/ 328 (95%) 
240/ 303 (79%) 
Approximately 1% of azithromycin-susceptible S. pyogm15 isolates were resistant to azithromycin 
following therapy. 
NOTE: Penicillin is the usual drug of choice in the treatment of S. pyogmt5 pharyngitis, indu<f.ng the 
prophylaxis of rheumatic fever. ZITHROMAX is often effective in the eradication ol susceptible strains ol 
streptococd from the oropharynx. Howoever, data establishing the efficacy ol ZJTliROMAX in the 
subsequent prevention of rheumatic fever are not available at present 
Appropriate ruture and susceptibility tesU should be initiated before treatment to determine the 
causative organism and its susceptibility to azithromycin. Therapy with ZJTliROMAX may be initiated 
before results of these tesU are known; once the reults become available, antibiotic treatment should 
be adjusted accordingly. 
CONTlWNDICATIONS 
ZITliROMAX (azithromycin dihydrate) is contraindicated in patients with known hypersensitivit to 
amhromycin. erythromycin, or other macrolide antibacterial agenu. 
WARNINGS 
Rare serious alergic reaction!, including angioedema and anaphylaxis. have been reported in patienu on 
ZJTliROMAX (azlthromycin dihydrate) therapy (see CONT1WNDICATION5 section). Alergic reactions 
may occur during and soon after treatment with ZITliROMAlL Despite initially successful symptomatic 
treatment ol the alergic symptoms, when symptomatic therapy was discontinued, the allergic symptoms 
recurred soon thereafter in some patienU without further azithromycin exposure. These patients required 
prolonged periods of observation and symptomatic treatment ~ an alergic reaction occurs, the drug 
should be discontinued and appropriate therapy should be instituted. Physicians should be aware that 
reappearance ol the allergic symptoms may occur when symptomatic therapy is discontinued. 
ZITHROMAX should not be used in patients with community-acquired pneumonia who are judged to 
be inappropriate for oral therapy because of the presence of severe ilness or because of accompanying 
risk factors. 
Pseudomembranous colitis has been reported with nearly all antibacterial agenu including ZITliROMAX 
and may range in severity from mild to lle-threatening. Therelore, it is important to consider this 
<iagnosis in patienU who present with diantlea subsequent to the administration of antibacterial agent>. 
Treatment with antibacterial agents alters the normal flora ol the colon and may permit <M!rgfOWih ol 
clostridia. Studies indicate that a toxin produced by Cbstridl.m dilfic* is a primary cause ol 'antibiotic-
associated colitis'. After the <iagnosis ol psaJdomembranou colitis has been estabished, therapeutic 
measures should be initiated Mild cases of pseudomerrbrano coitis usualy respond to discontinua-
tion of the drug alone. In moderate to ,.,_.e cases, consideration should be given to management with 
Huicls and electrolytes, protein supplementation, and treatment with an antibacterial drug dinicaly 
effective against Clostridium diffde. 
In the absence of data on the metabolism and pharmacokinetics in patients with lysosomal flpid storage 
diseases (e.g., lay-Sachs disease, Niemann-Pick disease) the use of ZJTliROMAX in these patienU is 
not recommended. 
PRECAUTIONS 
General: 
Sina fM!r is the major route ol elimination for ZllliROMAX (azithromycin dihydrate), the use ol 
ZllliROMAX should be undertaken with caution in pa~ts with significant hepatic disease. 
No dose a<fjUS!ment is needed in patients with mild renal impairment (creatinine clearance 
> 40 mUmin), but there are no data regarding ZllliROMAX usage in patients with more se.ere 
renal impairment Thus caution should be exercised before prescribing ZllliROMAX in ~ patients. 
The following adllene events have been reported with macrolide products: ventricular arrhythmias, 
including ventricular tachycardia and IC>IJOdrs ch pointn, in in<frviduals with prolonged QT intervals. 
Although these advene events have not been reported in clinical trials with azithromycin, one AIOS 
pa~t dosed at 7 50 mg to 1 g daily experienced prolonged QT interval and IC>IJOdrs ch paonia 
Use in Pregnancy: 
Animal studies have demonstrated that azithrornycin crosses the placenta. Safety ol ZITHROMAX 
for use in human pregnancy has not been established. 
Use In Nunlng Mothers: 
There are no data on secretion in breast milk. Safety ol ZfTHROMAX for use in human lactation has 
not been established. 
Use in Children: 
Acute Otitis Media: Safety and efficacy ol ZITHROMAX in the treatment ol children with acute otitis 
media (dosage regimen: 10 mg/kg on day 1 followed by 5 mg/kg on days 2-5) under 6 months ol 
age have not been established. 
Pharyngitis and tonsillitis: Safety and effocacy ol ZITHROMAX in the treatment ol children with 
pharyngitis and tonsillitis (dosage regimen: 12 mg/kg on days 1-5) under 2 years ol age have not 
been established. 
Studies evaluating the use of repeated courses of therapy have not been conducted. Safety 
data with the use of ZllliROMAX at doses higher than proposed and for durations longer 
than recommended are limited to a small number of immunocompromised children who 
underwent chronic treatment 
In animal studies, treatment with azithromycin is associated with accumulation in various tissues, 
including the extra<ranial neural ganglia (i.e., retina and sympathetic nervous system). TISSUe 
accumulation is both dose and time dependent. and is associated microscopically with the 
development ol phospholipidosis (intra-lysosomal drug phospholipid complexes). The only evidence 
in animals that azithromytin is associated with alterations ol intracellular phospholipid metabolism 
has been the documentation ol sman increases in phospholipid content after prolonged treatment 
(6 months) or exaggerated doses. Phospholipidosis has been observed at total cumula!M doses only 
2 multiples ol the clinical dose. One month after withdrawal ol treatment the concentra!Jon ol 
azithromytin and the presence ol phospholipidosis in tissue, including the retina, is at or near 
predose levels. 
No data exist in humans in regard to the extent ol accumulation, duration of exposure, metabolism 
or excretory mechanisms ol azithromycin in neural tissue such as the retina and the cochlea. 
Rare cases ol hearing loss have been reported (see ADVERSE REACTIONS section). 
No data are available on the metabofosm and pharmacokinetics ol azithrornycin in children with 
lysosomal lipid storage diseases (see WARNINGS section). 
Use in Elderly: 
In elderly subjects (age 65 to 85) the pharmacokinetics are substantially the same as in younger subjects 
and no dosage adjustment is necessary for elderly patients with normal renal and hepatic functions. 
Drug lnteraclions: 
Antacids 
Aluminum and magnesium containing antacids (Maalox") reduce the peak serum leYels but not the 
extent ol azithromycin absorption. These drugs should not be taken simultaneously. 
Clmetldine 
Administration ol dmetldine (800 mg) two hours prior to ZllliROMAX had no elfect on 
azithromycin absorption. 
Theophylline 
Concurrent use ol macrolides and theophylline has been assodated with increases in the serum 
concentrations ol theophylline. ZllliROMAX did not affect the pharmacokinetics ol theophylline 
administered either as a single intravenous infusion or multiple oral doses at a recommended dose 
ol 300 mg every 12 hours. There is one post-marl<eting report ol supraventricular tachycardia 
assodated with an elevated theophylline serum level that developed soon after initiation ol treatment 
with ZllliROMAX. Until further data are available, prudent medical practice dictates careful monitoring 
ol plasma theophylline leYels in patients receiving ZITHROMAX and theophylline concomitantly. 
Warfarin 
ZllliROMAX did not affect the prothrombin tlme response to a single dose of warfarin. 
However, prudent medical practice dictates careful monitoring ol prothrombin time in all pa~ts 
treated with ZllliROMAX and warfarin concomitantly. Concurrent use ol macrolides and warfarin 
in clinical practice has been assodated with increased anticoagulant effects. 
Carbamazepine 
In a pharmacokinetic interaction study in healthy volunteers, no significant effect was observed on 
the plasma levels of carbamazepine or its aciM metabolite in patients receiving concom1tant 
ZllliROMAX. 
Concomitant Therapy 
The following drug interactlons have not been reported in dinical trials with ZllliROMAX and 
no specific drug interaction studies have been performed to evaluate potential drug-drug 
interaclions. Nonetheless, they have been observed with macrolide products, and there have been 
rare spontaneously reported cases with ZllliROMAX and some ol these drugs, in postmarketing 
experience. Until further data are developed regarding drug interaclions, when ZJTHROMAX and 
these drugs are used concomitantly, careful monitoring ol patients is advised both during and for 
a short period following therapy: 
Digoxin: Elevation ol digoxin leYels. 
Disopyramide: Increase in pharmacological effects. 
&gotamine or dihydroergotamine: Acute ergot toxicity characterized by se.ere peripheral 
vasospasm and dysesthesia. 
Triazolam: Decreases in the clearance ol triazolam and increases in the pharmacologic elfect 
ol triazolam. 
Drugs metabolized by the cytochrome P450 system: Elevations ol serum cyclosporine, 
hexobarbital, dsapride, and phenytoin levels. 
Antihistamines: Prolongation ol QT intervals, palpitations or cardiac arrhythmias 
with concomitant administration ol astemizole or terfenadine. 
No data are available on the concomitant clinical use ol ZllliROMAX and gentamicin or other 
amphiphilic drugs which have been reported to alter intracellular lipid metabolism. 
ADVlRSE REACTIONS 
The majority ol side elfects observed in controlled clinical triab iiWO!ving pa~ts (adults and children) 
treated with ZITHROMAX (azithrornydn dihydrate) were of a mild and transient nature. 
Approximately 0.7% ol both adult patients (n:3812) and children (n:2878) who had multiple doses 
ol ZllliROMAX discontinued therapy because ol drug related side effects. Most ol the side elfects 
leading to discontinuation were related to the gastrointestinal tract. e.g., nausea, 110miting, diarrhea 
or abdominal pain. Rare but potentially serious side elfects were angioedema and cholestatic jaundice. 
Clinical: 
Multiple-<lose regimen (adults and chUdren): 
In adult patients, the most common side elfects in patients receiving the multiple-dose regimen ol 
ZllliROMAX were related to the gastrointestinal system with diarrhea (4.3'16), abdominal pain 
(2.6'16), 110miting (1 .3'16) and nausea (3.5'16). In children (n: 1944) enrolled in North American 
controlled clinical trials in acute otitis media and S. pyogenes pharyngitis, the type ol side effects was 
comparable to that seen in adults, with diarrhea/loose stools (5.3'16), 110miting (3.6%), abdominal 
pa1n (.l.b'lb), nausea (I.U'Ib), rasn (I .U'Ib) ana neaoacne (I .U"IO>J me most rrequenuy "'~"""'"· 
Different side elfect inddence rates for the two dosage regimens recommended in children 
were observed: 
Acute Otitis Media: For the recommended dosage regimen oil 0 mg/kg on day 1 followed by 
5 mg/kg on days 2-5, the most frequent side elfects were diarrhea/loose stools (2'16), abdominal 
pain (2'16), 110miting (1'16) and nausea (1'16). 
Pharyngitis/tonsillitis: For the recommended dosage regimen ol 12 mg/kg on days 1-5, the most 
frequent side effects were diarrhea/loose stools (6'16), 110miting (5'16), abdominal pain (3%), 
nausea (2'16) and heaclache (1 '16). Side elfects that occurred with a frequency ol 1% or less 1n 
patients included the following: 
Cardiovascular. palpitations, chest pain; 
Gastrointestinal: dyspepsia, flatulence, vomiting, melena, cholestatic jaundice, consbpation, 
anorexia and gastritis; 
Genitourinary: monilia, vaginitis and nephritis; 
Nervous System: dizziness, headache, vertigo, somnolence, agitation, nervousness, insomnia 
and hyperkinesia; 
General: fatigue, fever and malaise; 
Allergic rash, photosensitivity. angioedema, erythema multiforme, pruritus and urticaria 
Single 1-gram dose regimen (adults): 
In adult patients (n--904), side elfects that occurred on the single one-gram dosing regimen ol 
ZllliROMAX with a frequency greater than 1'16 included diarrhea (6.1'16), nausea (4.9'16), abdominal 
pain (4.9'16), vomiting (1.7%), vaginitis (1.3'16), loose stools (1.2'16) and dyspepsia (1.1%). 
Single 2-gram dose regimen (adults): 
Ove<all, the most common side elfects in patients receiving a single 2-gram dose ol ZllliROMAX 
were related to the gastrointestinal system. Side effects that occurred in patients in this stucly with 
a frequency ol a 1'16 or greater included nausea (18.2'16), diarrhea/loose stools (13.8'16), 
vomiting (6.7%), abdominal pain (6.7%), vaginitis (2.2'16), dyspepsia (1 .1%) and dizziness (1.3'16). 
The majority ol these complaints were mild in nature. 
The following adllene experiences have been reported in patients under conditions (e.g ., open trials, 
marketing experience) where a causal relationship is uncertain or in patients treated with significant· 
ly higher than the recommended doses for prolonged periods: 
Cardiovascular. cardiac arrhythmia; 
Gastrointestinal: pancreatitis, hepatic necrosis, drug induced hepatitis, 
pseudomembranous colitis; 
Genitourinary: interstitial nephritis, acute renal failure, nephrotic syndrome; 
Nervous System: hearing loss', seizure, loss ol taste, tinnitus; 
General: muscle pain; 
Allergic serum sickness, Stevens-johnson syndrome, anaphylaxis, toxic epidermal necrolysis, 
exfolia!M dermatitis, vasculitis. 
* Hearing loss has been reported rarely in adult and pediatric patients treated with ZllliROMAX. 
Hearing loss is generally reversible and associated with the use ol higher than recommended 
doses for prolonged periods. 
laboratory Abnormalities: 
Adults: 
Significant abnormalities (irrespective ol drug relationship) occurring during the clinical trials in 
patients were reported as follows: 
With an incidence oll -2'16, elevated serum creatine phosphokinase, potassium, AI.T (SGPT), GGT 
and A5T (SCOT). 
With an incidence olless than 1 %, leukopenia, neutropenia, decreased platelet count. elevated 
serum alkaline phosphatase, bilirubin, SUN, creatinine, blood glucose, LOH and phosphate. 
When folow-up was provided, changes in laboratory tests appeared to be reversible. 
In multiple-dose clinical trials involving more than 3000 patients, 3 patients discontinued therapy 
because ol treatment.felated liver enzyme abnormalities and 1 because ola renal function abnonnality. 
Children: 
Significant abnormalities (irrespective ol drug relationship) occurring during clinical trials were all 
reported at a frequency olless than 1 '16, but were similar in type to the adult pattern. 
In multiple-dose clinical trials iiWO!ving almost 3000 pediatric patients, no patients discontinued 
therapy because ol treatment-related abnormalities. 
OVlRD05AGE 
Symptoms: 
There are no data on overdosage. 
Treatment 
Gastric lavage and general supportive measures are indicated. 
Up to 15 grams cumula!M dose ol ZllliROMAX (azithrornydn dihydrate) over 10 days has been 
administered in clinical trials without apparent advene effect. 
DOSAGE AND ADMINISTRATION 
Adults: 
CAPSULES: ZITHROMAX (azithrornydn dihydrate) Capsules should be given as a single daily dose 
at least 1 hour before or 2 hours after a meal. 
TABLETS: ZITHROMAX Tablets can be taken with or without food. 
ONE GRAM SINGLE DOSE PACKET: ZITHROMAX powder for oral suspension as one gram single 
dose packet can be taken with or without food after reconstitution. 
Mixing Directlons: 
Directions for administration ol the powder for oral suspension as a one gram single dose packet 
The entire contents ol the one gram single dose packet should be mixed thoroughly with 60 ml 
(two ounces) ol water. Drink the entire contents immediately, add an additional 60 ml (two ounces) 
ol water, mix, and drink to assure complete consumption of dosage. 
For skln and skln structure infectlons, upper and lower respiratory tracl infectlons: The 
recommended dose ol ZllliROMAX for the treatment ol individuals 16 years ol age and older is 
500 mg as a single dose on the first day followed by 250 mg once daily on days 2 through 5 for 
a total dose ol 1.5 grams. 
Genitourinary: The recommended dose ol ZllliROMAX for the treatment ol genital ulcer disease 
due to Hoemophilus ducreyi (chancroid) and non-gonococcal urethritis and cervicitis due to 
C trochomotis is: a single 1 gram (1000 mg) oral dose ol ZllliROMAX. This dose can be administered 
as four 250 mg capsules, four 250 mg tablets, or as a one gram single dose packet 
The recommended dose ol ZllliROMAX for the treatment ol urethritis and cervicitis due to Neiuma 
gonorrho«Jr is: a single 2 gram (2000 mg) dose ol ZllliROMAX. This dose can be administered as 
eight 250 mg capsules, eight 250 mg tablets, or as two single dose packets (1 g each). 
In patients with mild to moderate hepatic impairment. there is no evidence ol a marl<ed change in 
serum pharmacokinetics ol ZllliROMAX compared to those with normal hepatic function. In these 
pa~ts urinary recCM!rY ol azithromycin appears to increase. Hence no dose adjustment is recom-
mended for pa~ts with mild to moderate hepatic impairment Nonetheless, since the liver is the 
principal route ol elimination for azithromycin, the use ol ZITHROMAX should be undertaken with 
caution in patients with signifiCant hepatic disease. 
Children: 
POWDER FOR ORAl SUSPENSION: ZfTHROMAX Powder for Oral Suspension should be given as a 
single daily dose at least 1 hour before or 2 hours after a meal. 
Mixing Directions: 
ZllliROMAX Powder for Oral Suspension: 
Tap bottle to loosen powder. Add the directed volume ol water. Shake well before each use. 
Oversized bottle provides shake space. Keep tightly closed. The table below indicates the volume ol 
water to be used for reconstitution: 
-
.. . .. .. ...... ................................. ..._ . .-.ou"""''''J.._., , ..._..,,,.._.._,,..., .,. .., .... ,, 
to be added reconstitution (azithromydn content) after reconstitution 
9 mL (300 mg bottle) 15 mL (300 mg bottle) 100 mg/5 mL 
9 ml (600 mg bottle) 15 mL (600 mg bottle) 200 mg/5 mL 
12 mL (900 mg bottle) 22.5 mL (900 mg bottle) 200 mg/5 mL 
For upper respiratory tract infections: 
Acute Otitis Media: 
The recommended dose of ZITHROMAX oral suspension for the treatment of children with acute 
otitis media is 1 0 mg/ kg as a single-dose on the first day (not to exceed 500 mg/day) followed by 
5 mg!kg on days 2 through 5 (not to exceed 250 mg/day), for a total dose of 30 mg/kg of 
ZITHROMAX (see chart below). 
PEDIATRIC DOSAGE GUIDEUNE5 FOR ACUTE OTITIS MEDIA 
(Age 6 months and above) 
Based on Body Weight 
ACUTE OTITIS MEDIA 
Dosing Cakulated on 1 0 mg/ kg on Day 1 dose, followed by 5 mg/kg on Days 2 to 5. 
Weight 100 mg/ 5 mL 200mg/5 mL Total mL Suspension Suspension per 
Treatment 
Kg lbs Day 1 Days 2-5 Day 1 Days 2-5 Course 
5 11 2.5 ml(1!, tsp) 1.25 mL (1/, tsp) 7.5 mL 
10 22 5 mL(1 tsp) 2.5 mL (1!, tsp) 15 ml 
20 44 5 ml (1 tsp) 2.5 mL (1/ 2 tsp) 15 ml 
30 66 7.5 mL (1 1!, tsp) 3.75 mL ('/, tsp) 22.5 mL 
40 88 10 ml (2 tsp) 5 mL (1 tsp) 30 mL 
Pharyngitis and Tonsillitis: 
The recommended dose for children with pharyngitis and tonsillitis is 12 mg/ kg once a day (not to 
exceed 500 mg/day) for 5 days for a total dose of 60 mg/ kg of ZJTHROMAX (see chart below). 
PEDIATRIC DOSAGE GUIDEUNE5 FOR PHARYNGITIS AND TONSILLITIS 
(Age 2 years and above) 
Based on Body Weight 
PHARYNGITIS AND TONSILLITIS 
Dosing Cakulated on 12 mg/kg once daily Days 1 to 5 . 
Weight 200 mg/ 5 mL Suspension Total mL per 
Kg lbs Day 1-5 Treatment Course 
8 18 2.5 ml (1!, tsp) 12.5 mL 
17 37 5 mL (1 tsp) 25 ml 
25 55 7.5 mL (1 1!, tsp) 37.5 mL 
33 73 10 mL (2 tsp) 50mL 
40 88 12.5 mL (2 1/ 2 tsp) 62.5 mL 
PHARMACEUTlCAL INFORMATION 
DRUG SUBSTANCE 
Trad e Name: 
Proper Name: 
Chemical Name: 
Structural Formula: 
Molecular Formula: 
Molecular Weight; 
Description: 
pKa: 
Composition: 
ZITHROMAX 
azithromycin dihydrate 
9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate. 
H,C\ 
H~~: 0~~ .:.~~~ ........ : .• • 0 2H,D ~ 
.l ' -~,.. ,~-
CH3 0 HO 
CH3 
H,c 
Azithromycin d ihydrate 
c38H76N2014 
785.0 
Azithromycin dihydrate is a white to off -white crystalline powder of 
uniform appearance. The aqueous solubility at pH 7.4 at 3TC is 
39 mg/mL The powder is non-hygroscopic. 
8.48 
ZITHROMAX (azithromyd n d ihydrate) Capsules contain the following 
non-medicinal ingredients: lactose; com starch; magnesium stearate and 
sodium Iaury! sulphate. The capsule shells contain gelatin, FD&C Red 1140 
and titanium dioxide. 
ZITHROMAX Tablets are supplied for oral administration as engraved, 
film-<eated, modified capsular-shaped tablets, containing azithromycin 
dihydrate equivalent to 250 mg azithromydn and the following inactive 
ingredients: pregelatinized starch, anhydrous calcium phosphate dibasic, 
sodium aoscarmellose, magnesium stearate, sodium Iaury! sulphate, 
hydroxypropyl methylcellulose, lactose, titanium dioxide, triacetin and 
D&C Red # 30 aluminum lake. 
ZITHROMAX Powder for Oral Suspension contains azithromycin 
dihydrate equivalent to: 300 mg; 600 mg; and 900 mg of azithromycin 
per bottle. The non-medicinal ingredients include: sucrose; sodium 
phosphate, tribasic hydroxypropyl cellulose; xanthan gum; FD&C Red 
#40 and artificial flavours. After reconstitution, the 300 mg strength 
contains 100 mg/5 mL and the 600 and 900 mg each contain 200 mg/5 
mL (see DOSAGE AND ADMINISTRATION, Mixing Directions section). 
ZlTHROMAX one gram single dose padcet contains azithromydn dihydrate 
equivalent to 1000 mg of azithromycin in a mixture of: sucrose, sodium 
pnospnate tnoaste, c:otlotOal sUtcon OIOXI<le, art1t1aa1 banana and artJttoal 
cherry flavou" (see DOSAGE AND ADMINISTRATION, Mixing 
Directions section). 
Storage Recommendations: 
Store ZITHROMAX (azithromycin dihydrate) Capsules, Film-Coated Tablets and the One gram 
single dose packet at controlled room temperature (15-30'Q . 
Powder for Oral Suspension: 
Dry powder: Store at controlled room temperature (15-30'Q . 
Reconstituted suspension: Store between 5' C and 30'C. Discard unused portion after 5 days. 
AVAILABIUTY OF DOSAGE FORMS 
CAPSULES: ZITHROMAX (azithromydn dihydrate) Capsules each contain azithromydn dihydrate 
equivalent to 250 mg of azithromycin. The red, No. 0 hard gelatin capsules imprinted with ' Pfizer" 
and ' ZITHROMAX' in black ink. are packaged in white plastic (high density polyethylene) bottles of 
30 and 100 or in a single treatment package (Z-PAK) of 6 blister packaged capsules per box. 
TABLETS: Each pink, film-coated, modified capsular-shaped ZITHROMAX tablet. engraved 'Pfizer" 
on the upper face, and scored on the lower face, contains azithromycin dihydrate equivalent to 
250 mg of azithromydn. The tablets are packaged in white plastic (high density polyethylene) 
bottles of 30 and 100 or in a single treatment package (Z-PAK) of 6 blister packaged tablets per box. 
POWDER FOR ORAL SUSPENSION: ZlTHROMAX Powder for Oral Suspension, after reconstitution, 
contains a cherry flavoured suspension. Each bottle (high density polyethylene) provides 
azithromycin dihydrate equivalent to: 300 mg per 15 mL (1 00 mg/5 mL); 600 mg per 
15 ml (200 mg/5 mL); 900 mg per 22.5 mL (200 mg/ 5 mL). Dropper is included in the package. 
ONE GRAM SINGLE DOSE PACKET: ZlTHROMAX powder for oral suspension as a one gram single 
dose packet contains azithromycin dihydrate equivalent to 1000 mg of azithromycin in a sealed, 
laminated aluminum foil and polyethylene pouch. 
Product Monograph Available Upon Request. 
t Product licensed from Pliva, Zagreb, Croatia. 
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BODYGUARD FOR HYPERTENSIVES 
Smooth 24-hour PLUS 
blood pressure control 
with one capsule, once dailyt,2t 
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n=36. mild essenoal hypertetlSIOil 
• Effective blood pressure control 
even during the last stages of the 
dosing period2 
More than 80% of patients 
respond to ~5 mg once daily 3 
' Altace is indicated in the treatment of essential 
hypertension, normally when beta-blockers and 
diuretics are inappropriate. Uke other ACE inhibitors, 
Altace is not recommended for pregnant or lactating 
women and should be used with caution in patients 
with renal insufficiency. 
Product monograph available to physicians and 
phannacists upon request. 
References: 1. Todd PA, Benfield P. Drugs 1990; 39: 
1-27. 2. Altace (ramipril) Product Monograph, 
Hoechst Marion Roussel Canada Inc. 3. Carre A, et 
al. ClinPhysio/Biochem 1992; 9: 105-112 . 
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• Hoechst 
Hoechst Marion Roussel 
The Pharmaceutical Company 
of Hoechst 
"Aegtstered trade marl< of Hoechst AG. Germany, used under hcence 
by Hoechst Manon Roussel Ganada Inc 
OUR PEOPLE 
The Astra Customer Relations Team is committed to providing 
the most responsive, comprehensive customer service in the 
pharmaceutical industry. 
SERVICES 
• Accurate information on all Astra products and services 
• Access to patient brochures and educational materials 
{video and audio cassettes) 
• Up-to-date provincial formulary listing information 
• Direct and voice messaging liaison to all Astra personnel 
• Account inquiries 
• Distribution inquiries 
• Order processing 
We follow up until your need is met. 
ACCESS 
1-800-668-6000 
Toronto area: (905) 566-4015 
Fax: 1-800-268-077 4 
Toronto area: (905) 896-4745 
The Astra Customer Relations Teom is readily available to help 
from 8 a.m. to 5 p.m. EST, Monday to Friday, with voice 
messaging outside of these hours. 
All voice messages and fax transmissions are retrieved by 
10 a .m. EST, the next business day. 
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